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Chapter 1. Introduction 
Antibiotics provided humanity resilience to the majority of bacterial 
infections. It thereby altered the natural course of most infectious diseases 
and saved millions of lives. One could argue that antibiotics are the most 
significant development in modern medicine. An important trade-off is how -
ever, the emergence of antimicrobial resistance, and a diminished and 
perturbed microbiota, resulting in an increased susceptibility for Clostridioides 
difficile infections and Western (lifestyle associated) diseases  [1 -3]. The World 
Health Organization (WHO) has declared antimicrobial resistance one of the 
greatest challenge to global public health today, compromising the treatment 
of common bacterial infections  [4]. More specifically, the Centers for Disease 
Control and Prevention (CDC) has outlined and prioritized the threats posed 
by specific multidrug Resistant Organisms (MDRO) of which drug resistant 
Neisseria gonorrhoeae, Candida auris, carbapenem resistant Enterobacterales 
and  C.  difficile were the most urgent  [5].  
To understand the role of the microbiota in defence against various 
infectious and non-infectious diseases, we need to define and measure the 
human microbiota by well accepted and standardized techniques, including 
methods to determine the function of the microbiota. This thesis focusses on 
the significance and possible interventions of the gut microbiota of patients 
colonized with antibiotic resistant bacteria or patients suffering from multiple 
recurrent Clostridioides difficile infection. This introduction summarizes the 
basic knowledge on the human microbiota of healthy and diseased individuals, 
the worldwide problem of increased antibiotic resistance and the threat of anti-
biotic-associated  C.  difficile infections.  
EXPLORING THE ROLE OF THE MICROBIOTA IN DEFENCE AGAINST CLOSTRIDIOIDES DIFFICILE  
AND MULTIDRUG RESISTANT GRAM-NEGATIVES
10
The microbiota 
The human gut microbiota 
The human body houses a diverse microbial ecosystem, consisting of bacteria, 
archaea, fungi, viruses and parasites, together called the ‘microbiota’. Because bacteria 
reach the highest density, the bacterial fraction of the microbiota is most studied. It is 
estimated that the ratio of bacterial to human cells in an adult body is 1:1  [6], and the 
collective bacterial genome contains 450-fold more genes than the human genome  [7]. 
Each body site (e.g. gut, skin, vagina, stomach, oral cavity) has a different microbiota 
composition. With 1010-1011 bacterial cells per gram feces, from approximately 1000 
different species, the colon contains the largest number of bacteria  [8]. The bacterial 
part of the gut microbiota is largely composed of two groups at the phylum level, the 
obligate anaerobic Bacteroidetes and Firmicutes [9]. In addition, the gut microbiota 
comprises of members of the Actinobacteria, Verrucomicrobia, Fusobacteria and 
Proteobacteria phyla  [9]. It is important to realize that classification to phylum level 
gives a rather simplistic view of an extremely complex ecosystem (Figure 1). Humans 
belong at phylum level to the Chordates, just like a Komodo dragon and a dolphin for 
example. Subsequently, the microbiota can be further subdivided at different levels; 
Phylum, Class, Order, Family, Genus and (sub) species (Figure 1).  
In general, it is believed that colonization, competition and engraftment of the human 
microbiota starts during labour. However, the “sterile womb” paradigm is currently 
challenged by several studies reporting bacterial communities in the intrauterine 
environ ment by next generation sequencing  [10]. Others have found that viable bacterial 
colonization is highly limited in the foetal intestine or placenta, however can contain 
potential pathogens  [11, 12]. Still, the consensus is that current scientific evidence does 
not support the existence of a foetal microbiota  [13], and that the finding of bacteria in 
the intrauterine environment is probably explained by contamination (e.g. of the kit, 
background DNA)  [14, 15]. Irrespective of the precise starting point of colonisation, birth 
gives microbiota development a boost. The human microbiota is acquired both vertically 
(via vaginal birth from mother) and horizontally (from the environment). Consequently, 
birth mode (vaginal or caesarean section) has significant effects on the microbiota 




influenced by, gestational age and breastfeeding. At two to three years of age, microbiota 
composition becomes more stable and adult-like.  [17, 18] The adult-like gut microbiota is 
functionally more complex and is structured to metabolize plant-derived poly-
saccharides from the diet  [19]. The primary determinant of the microbiota composition is 
body site or habitat [9, 20, 21]. Within habitats, the interpersonal variability is high, whereas 
individuals exhibit only minor temporal variability  [21]. Although the microbiota is 
constantly exposed to environmental stressors, its composition and function in an 
individual are relatively stable against most pertur ba tions  [22]. This resistance to change 
is described as resilience; the property of a microbial community that defines how fast, 
and to what extent, it will recover its initial functional or taxonomical composition follow-
ing a catastrophic perturbation  [22]. Still, minor changes in environmental factors such 
as diet, medicine use, season, travel or house-hold contact can affect the microbiota  [23 -
25]. A recent study showed for instance that a large percentage of non-antibiotic drugs 
can inhibit the growth of certain bacteria, or even complete bacterial classes  [24]. In fact, 
24 % of human drugs, amongst all therapeutic classes, inhibited bacterial growth of at 
least one bacterial strain  [24]. Surprisingly, the chemically diverse antipsychotics were 
overrepresented as microbiota effectors. One could even speculate that regular use of 
pharmaceuticals nowadays may contribute to the decrease in microbiota diversity of the 
modernized human populations  [26, 27].  
 
 
 Figure 1. Taxonomic classification of the most abundant bacterial phyla present in 
the gut.  
Subsequently, phyla can be further subdivided at different levels; Class, Order, 
Family, Genus and (sub) species. From each of the most dominant phyla present in 
Kingdom Bacteria
Phylum Firmicutes Bacteroidetes Actinobacteria Verrucomicrobia Fusobacteria Proteobacteria
Class Clostridia Bacteroidia Actinobacteria Verrucomicrobiae Fusobacteria Gammaproteobacteria
Order Clostridiales Bacteroidales Bifidobacterales Verrucomicrobiales Fusobacterales Enterobacterales
Family Ruminococcacae Bacteroidaceae Bifidobacteriaceae Akkermansiaceae Fusobacteriaceae Enterobacteriaceae
Genus Faecalibacterium Bacteroides Bifidobacterium Akkermansia Fusobacterium Escherichia
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the gut, an example of a bacterium from phylum to species level is depicted. For 
comparison also humans and a Komodo dragon, belonging to the same phylum, are 
displayed in the Animalia kingdom.  
Techniques to study the microbiota  
The microbiota can be studied by several techniques. In the past, researchers 
depended highly on culturing techniques. However, many bacteria are very difficult to 
culture. With recent innovations in the field of sequence technology and analysis, 
scientists are now able to determine and analyse these difficult to culture bacteria. In 
the 2010-2020 decade, sequencing of a small part (for instance the V4 region of about 
250 nucleotides) of the 16S ribosomal RNA gene, was most commonly used. The 16S 
rRNA gene consists of around 1500 nucleotides and contains regions conserved 
among all bacteria and archaea, interspersed with nine regions (V1 to V9) that are 
highly variable among bacterial phylotypes. Phylotypes are defined as a group of 16S 
sequences having 97-99 % sequence identity, and usually equals taxonomically to 
genus or sometimes species level. Because only a small part of the complete genome 
is sequenced, one can determine the composition and relative abundance of bacterial 
taxa present in a sample in a relatively fast and inexpensive way. Samples are generally 
compared using alpha-diversity (within-sample diversity; one value per sample, an 
example is a Shannon-diversity index) and beta-diversity (between-sample diversity; 
pair-wise values for all sample combinations, an example is Unifrac-distance or Bray-
Curtis-dissimilarity). Bacterial abundance and composition gives insight in ‘who is 
present’, which does not necessarily describe the functionality (“what are they doing”). 
To analyse the functional potential, metagenomic shotgun sequencing is more 
suitable  [28]. This technique shotgun sequences the total DNA of the microbiota. There -
fore the complete genomic make-up of the microbiota (which is called, the ‘meta genome’ 
or more frequently the ‘microbiome’) is assessed, and one can not only determine the 
composition, but also predict the potential functions of the microbiota. In Figure 2, 
a general overview of pipelines of 16S and metagenomic shotgun sequencing is depicted.  
While with 16S analysis only the 16S rRNA containing bacteria can be studied, 
metagenomics is not limited to sequencing bacteria, the microbiota including viruses, 




is challenging and relies on specialized and skilled bioinformatic experts. In addition, 
metagenomic sequencing is expensive, and one approach to lower the costs is mini-
misation of sequence depth or coverage. Coverage is the number of unique reads that 
include a given nucleotide (copy number) in the reconstructed sequence  [29]. (Ultra) 
deep  sequencing refers to the general concept of aiming for high copy number, which 
allows for detection of lowly abundant species or sequence variants in mixed 
populations. To reduce the amount of data and lower the costs, the sequence depth 
can be decreased. This is referred to as shallow sequencing  [30]. A complete overview 
of all techniques studying the microbiota with all advantages and limitations is shown 
in Table 1. 
 
Figure 2. 16S rRNA sequencing and metagenomics pipeline.  
Adopted from Milani and co-workers  [31]. 
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General overview of the bioinformatic pipelines for the 16S rRNA gene (amplicon) 
sequencing on the left and shotgun metagenomics on the right. First microbial DNA 
is extracted and subsequently sequenced. With 16S rRNA analysis, only (part of) 
the 16S rRNA is sequenced. Highly similar sequences are grouped into Operational 
Taxonomic Units (OTUs), which for identification can be compared to a 16S database. 
The microbiota community can be described in terms of which OTUs are present, 
their relative abundance, and/or their phylogenetic relationships. On the right, 
metagenomic shotgun sequencing of the microbiota is depicted, in which the total 
extracted and fragmented DNA is shotgun sequenced. The resulting DNA sequences 
are either pieced together using assembly algorithms or reference databases, or 
analysed in an unassembled manner to monitor whole-community functional 
capabilities. The phylogenetic origins of microorganisms and their functions can be 
determined by comparison with previously annotated genes in a database. 
 
A famous project trying to unravel the composition and function of the microbiota 
is the Human Microbiome Project (Figure 3). This project illustrates the value of the use 
of a combination of different techniques; the difference between ‘who is present’ is 
studies with 16S and ‘what can they do’ with metagenomics. The combination of both 
techniques revealed that healthy individuals can have a very different microbiota 
composition, while the relevant functions of those microbiota compositions for their 






Figure 3. Carriage of microbial taxa in the gut varies while predicted metabolic 
pathways remain stable within a healthy population.  
Adopted from the Human Microbiome Project  [32]. 
Vertical bars represent microbiome samples by body habitat in seven locations with both shotgun 
and 16S data; bars indicate relative abundances coloured by  microbial phyla from binned OTUs 
(a) and metabolic modules (b). Legend indicated most abundant phyla or pathways by average 
within one or more body habitats. OTU: operational taxonomical unit. 
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Measuring the functional capacity of the microbiota with metagenomics does 
not necessarily provide insight in what the bacteria are actually doing. The following 
– omics techniques each unravel different layers of information of the microbiota as 
complex ecosystem (Figure 4). The direct measurement of transcripts (mRNA) with 
(meta)transcriptomics or proteins with (meta)proteomics is at present increasingly 
used as complementary technique to metagenomics  [33]. The combination of 
metagenomics with metatranscriptomics enables the identification of gene repression 
or induction under specific conditions, and can additionally distinguish metabolically 
active from inert or dead micro-organisms  [34]. Not all transcripts are however trans-
lated into proteins. Therefore metaproteomics, in which the expressed proteins are 
measured with high resolution mass spectrometry, should provide more insight into 
gut microbial functionality as compared to metatranscriptomics. In addition, it 
determines proteins derived from the microbiota and their host, which is important 
when studying microbiota-host interactions. In the past this technique suffered from 
low measurement depth and lack of efficient bioinformatic tools  [35]. The availability 
of new metaproteomic data processing tools has enabled better characterization of the 
proteome. The fecal metabolome is often regarded as an endpoint read-out of 
biological processes originated from the gut microbiota and their host. To measure 
these metabolites, nuclear magnetic resonance (NMR) spectroscopy or mass 
spectrometry can be applied, known as metabolomics. Identified metabolites in faeces 
can include those derived from microbiota (e.g. Short Chain Fatty Acids, lipopoly-
saccharides) or the host (e.g. anti-microbial peptides (AMPs)). Integrating multi-omics 
data provides a comprehensive overview of microbiota composition, function and 
metabolomic activity, in relation to its host. Due to the increased complexity and 
diversity of multi-omics data, efficient bioinformatic tools, advanced statistical 
methods and machine-learning approaches are needed, which are at present only 
available in some microbiota expert teams. The multi-omics approach is of particular 
importance for translational research (microbiome analysis into clinical applications), 
because chronic human illnesses or diseases associated with a perturbed microbiota 







Figure 4. Multi-omics approach of microbiota analysis.  
Adopted from Xu Zhang and co-workers  [36]. 
The human gut consists of host and microbial cells, as well as secreted proteins, metabolites, and 
microparticles, all of which may interact with each other to impact human health. Different meta-
omic approaches each examine different aspects of this intestinal ecosystem at different levels 
with their own advantages and disadvantages.  
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Molecular techniques to study bacterial strains in depth 
To interpret the metagenomic (annotated) data, culturing is still essential. To deter -
mine the functions and phenotypes of unknown bacterial genes, culturing of the micro-
bial communities (culturomics) has revived and regained interest  [37, 38]. In addition, 
complete genetical and phenotypical characterisation of cultured isolates is essential to 
define microbiota interactions (between bacterial species or between bacteria and host) 
that are difficult or yet impossible to predict unless tested bio logically  [39].  
Once isolated, the complete DNA of a bacteria can be determined with whole 
genome analysis (WGS). The introduction of next-generation sequencing (NGS) 
machines had made WGS attainable in terms of costs and time. The generated WGS 
data can then be subjected to a variety of molecular analyses to characterise the 
bacterium in terms of antibiotic resistance, molecular epidemiology (e.g. typing) and 
virulence. Due to its high resolution and inter and intra-reproducibility, WGS is highly 
suitable as typing method. One means of exploiting WGS data is the identification of 
single nucleotide polymorphisms (SNPs) that vary among isolates. An alternative 
approach is multi locus sequence typing (MLST). With common MLST, a limited 
number of housekeeping genes is sequenced and every sequence variant of a house-
keeping gene (locus) is assigned as a distinct allele. For each isolate, the alleles at 
each of the loci define the allelic profile or sequence type (ST). To increase the 
resolution and to make optimal use of WGS, many more loci can be employed with 
core genome MLST (cgMLST) (for E. coli around 2500 of total 7700 genes) and whole 
genome MLST (wgMLST)  [40]. An advantage of MLST, cgMLST and wgMLST is that 
loci used in the schemes are readily conserved and shared among laboratories using 
online databases. In addition to online (commercial or free available) databases for 
typing, also many online databases exist to further characterize bacterial isolates 
with respect to genes or mutations in chromosomes or plasmids associated with 
resistance, serotypes, plasmids or specific gene functions. A new trend of micro bio -
logical characterization is the application of long read sequencing by rapid methods, 
such as the “MinION” nanopore. Analysis with longer read lengths will alleviate numer-
ous computational challenges surrounding genome assembly as short-read methods 
can miss some randomly-distributed segments of genomes present in phages, plas-
mids and virulence factors. Therefore long-read sequencing provides the tool to study 




Table 1. Techniques to study the microbiota, description, advantages and limitations. 







Relatively quick and easy  •
to manage and interpret 
Also suitable for low-biomass and •
highly host-contaminated samples 
Large, available public databases•
No discrimination between dead or alive bacteria •
Only determination to Operational Taxonomic Unit  •
(equivalent to genus or sometimes species level) 
Amplification bias because of targeted primer  •
(sensitivity and copy number among species differs) 




Determination and relative •
abundance of microbial functional 
genes, microbial taxonomic 
and phylogenetic identity to 
species and strain level 
(for known organisms) 
Captures the complete micro -•
biota (bacteria, phages, viruses, 
plasmids, microbial eukaryotes) 
Can be mined for novel  •
gene families 
Possibility to assemble  •
population-averaged 
microbial genomes
Relatively expensive, laborious and complex sample preparation •
and analysis. 
No discrimination between dead or alive bacteria •
Contamination from host-derived DNA and organelles •
may obscure microbial signatures. 
Significant proportion of data cannot be functionally assigned •
due to a lack of close matches in reference databases. In 
particular with viral data (where over 80% of sequence reads 
have no known match) 
Often difficult to assign function unambiguously based •
on sequence similarity alone  
Can be difficult to assemble genomes, particularly from less •
abundant members of the microbiota or when a community 
contains many closely related species. This means that, even 
if a function can be ascertained, it may be difficult to assign it 
to specific species within the whole community.  
Population-averages microbial genomes tend to be inaccurate •
owing to assembly artefacts
Meta transcriptomics Can estimate which micro -•
organisms in a community 
are actively transcribing  
(if paired to marker gene or 
metagenomic analysis) 
Can discriminate between active •
and alive versus dormant or dead 
microorganisms or extracellular DNA 
Captures dynamic intra-individual •
variation 
Directly evaluates microbial •
activity, including responses to 
intervention and event exposure 
Expensive, laborious and complex sample preparation •
and analysis 
Rely on obtaining sufficient high-quality RNA from the sample •
(challenging due to ubiquitous RNAses in host-derived samples) 
= fast processing is mandatory 
Saturated with less informative, highly abundant transcripts •
(i.e. ribosomal proteins, major outer membrane proteins) 
obscuring the detection of functionally important, but less 
abundant transcripts 
Requires paired DNA sequencing to decouple transcription •
rates from bacterial abundance changes
Metaproteomics Can measure which proteins •
are produced by active members 
of the microbiota 
Measures not only microbiota but •
also proteins of the host (essential 
for microbiota – host interactions)
Expensive and complex data analysis •
Lower depth of measurement compared to metagenomics •
and metatranscriptomics, and can only capture 10-20% of 
expressed protein. MS spectra can also be saturated with the 
highly abundant proteins from dominant species, issue likely 
to be resolved by increasing the speed of time of MS scanning.  
Lack of universal guidelines and protocols for proper •
performance and analysis of metaproteomic experiments 
Metabolomics Can measure which proteins •
are produced by active members 
of the microbiota 
Measures not only microbiota but •
also proteins of the host (essential 
for microbiota – host interactions)
Expensive and complex data analysis •
Difficulty to distinguish host- and microbiome-origin metabolites •
and directly link metabolites to specific taxa. Co-variations 
between metabolites and microbial species not yet known.
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Microbiota and colonization resistance 
In a healthy state, there is a symbiotic relationship between the host and the micro -
biota. The microbiota fulfils many functions which are of benefit for the host. Similarly, 
host factors are required to maintain a balanced microbiota. The gut microbiota 
contributes to host health by, amongst others degradation of carbohydrates (food), 
synthesis of bioactive substances (for example vitamins) and colonization resistance 
against pathogens  [43]. Colonization resistance is the mechanism whereby the micro -
biota protects against colonization of exogenous and often pathogenic micro-
organisms. The importance of a healthy indigenous intestinal microbiota for the 
presence of colonization resistance was first recognized in the 1950s, and it was 
initially referred to as “antibiotic associated susceptibility”  [44]. When pre-treated with 
streptomycin, a minimal infectious dose of only 10 instead of 106 Salmonella enterica 
bacteria was sufficient for mice to become infected  [45]. Together with the observation 
that the susceptibly decreased when mice were exposed to coprophagy with 
normal mouse feces led to the idea that antibiotics cause a perturbation of the gut 
microbiota  [45]. Colonisation resistance is the result of direct or indirect factors. 
Direct colonisation resistance refers to the direct suppression of intestinal pathogens 
by competitive exclusion (competition for nutritional niches or space) and by anti -
microbial activities like bacteriocins  [46]. For instance, Bacteroides thetaiotaomicron 
consumes carbohydrates used by Citrobacter rodentium, a gastro-enteritis pathogen in 
mice  [47]. Bacteroides thuringiensis secretes thuricin, a bacteriocin (small-spectrum anti-
biotic) that directly targets spore-forming Bacilli and Clostridia, including Clostridium 
difficile  [48]. In addition, commensal bacteria can also indirectly control invading 
pathogens by enhancing host immunity and mucus production in the intestines. 
The microbiota plays an important role in the development, training and maintaining 
of the immune system  [49]. An example of this has been observed with B. thetaiotao-
micron which can induce the host to produce antimicrobial C-type lectins that target 
Gram positive bacteria  [50]. 
Gut microbiota and disease 
The significance and role of many bacterial species in health and disease are poorly 




range of diseases. This perturbation in function and composition of the microbiota 
is called dysbiosis, which is still difficult to distinguish from homeostasis or 
healthy microbiota, because a healthy reference or core microbiota is not (yet) 
defined. Importantly, dysbiosis is not only associated with intestinal disorders, such as 
inflammatory bowel disease (IBD; morbus Crohn and ulcerative colitis)  [51 -53] and 
irritable bowel syndrome (IBS)  [54, 55], but also with a wide range of extra intestinal 
conditions, such as metabolic syndrome  [56 -58], (non)-alcoholic fatty liver disease 
(NAFLD)  [59 -62]. Neurological diseases like Parkinson’s disease and multiple sclerosis, 
and psychiatric disorders are also considered to be associated with intestinal dysbiosis 
via the so-called hypothetical gut-brain axis  [63 -66]. Whether the microbiota is truly 
involved in the pathogenesis of those disorders awaits to be seen, but for many 
diseases, a role in the development or course of the disease has been shown in animal 
models  [9]. Interestingly, the microbiota is not only involved in the pathogenesis, but 
also alters the pharmacokinetics or may mediate (side effects of) certain drugs direct 
or via CYP-like proteins  [67, 68]. The microbiota is therefore, of importance in drug 
discovery, risk assessment and dosing regiments for various infectious and non-
infectious diseases.  
It is foreseen that all above mentioned diseases have a disease-specific profile of 
dysbiosis, although a conclusive description of dysbiosis in specific disorders is still 
lacking. In general, dysbiosis is characterized by a reduced diversity of the microbiota, 
with a reduction of certain species of the normally abundant Firmicutes or 
Bacteroidetes phylum (such as Clostridium cluster IV an XIVa, Faecalibacterium 
prausnitzii, Akkermansia, Eubacterium halli) and a higher abundance of the normally less 
abundant (opportunistic) Proteobacteria (like Escherichia coli or Klebsiella species). 
Whether such a perturbed microbiota is involved (driving or maintaining) in the 
pathogenesis or an epiphenomena (a consequence of the disease) is not yet 
elucidated for many diseases. In this regard, Clostridioides difficile infection appears 
unique, as dysbiosis of the microbiota is mandatory. Infection with  C.  difficile represents 
the classic example of a disease that is caused by a dysbiotic microbiota, providing 
a model to study the dysbiotic microbiota and interventions targeting dysbiosis.  
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Clostridioides difficile infection  
as result of intestinal dysbiosis  
Introduction & pathogenesis 
Clostridioides difficile is a Gram-positive, spore forming, obligate anaerobic bacterium 
that was identified as part of the normal gut flora of healthy infants in 1935  [69]. The 
species name is derived from the initial difficulties to culture and identify  C.  difficile. The 
genus name was used for more than 80 years, but recently, based on phenotypic, 
chemotaxonomic and phylogenetic analyses, a novel genus Clostridioides gen. nov. has 
been proposed for Clostridium difficile as Clostridioides difficile  [70]. Fortunately, the 
abbreviation remained intact.  C.  difficile is considered as part of the gut commensal 
microbiota of both humans as well as animals and is transmitted by spores via the fecal-
oral route. Most vegetative  C.  difficile bacteria are killed in the stomach  [71].  C.  difficile 
spores are however acid resistant and will subsequently pass the stomach. After germi -
na tion of the spores in the small intestine under the influence of bile salts, vegetative 
bacteria enter the colon where they can remain inactive (asymptomatic colonization) 
or cause an infection (CDI,  C.  difficile infection) varying from self-limiting and mild 
diarrhoea to life-threatening pseudomembranous colitis (Figure 5)  [72]. Several virulence 
factors, including flagella and hydrolytic enzymes have been associated with disease  [73]. 
 
Figure 5. Healthy colon mucosa (left) versus Pseudomembranous colitis due to 
a Clostridioides difficile infection (right).  




The two most important virulence factors of  C.  difficile are the exotoxins that are 
produced, toxin A and B. Both toxins are cytotoxic for a number of different cell types, 
increase vascular permeability by opening tight junctions between cells, and cause 
apoptotic cell death  [72, 73]. In addition, the toxins induce an inflammatory response 
mediated by tumour necrosis factor-alpha (TNF-α) and pro-inflammatory cytokines 
which contribute to the characteristic formation of pseudo-membranes  [73]. 
Colonization versus infection  
 C.  difficile infection (CDI), previously described as C. difficile-associated diarrhoea 
(CDAD), is the most common cause of healthcare associated diarrhoea in Western 
countries  [75]. By shedding of spores from symptomatic patients,  C.  difficile can spread 
within healthcare facilities, which can subsequently result in new symptomatic patients 
and eventually clusters or outbreaks. Not all newly diagnosed CDI patients can be 
linked to other symptomatic CDI cases. Two studies using multi-locus sequence typing 
and whole genome sequencing with single-nucleotide typing respectively, could only 
link 25 %-40 % of CDI patients to a previously identified CDI patient  [76, 77]. Recent 
studies show that also asympto matically  C.  difficile colonized patients contribute to the 
spread of C.  difficile spores via healthcare workers or the environment  [78 -80]. Riggs 
showed that  C.  difficile spores were present on the skin of asymptomatic carriers and 
easily transferred to investigator’s hands and the environment  [80]. Although transmission 
events from asymptomatic carriers as index patient remains rare  [79], asymptomatic 
carriers may still importantly contribute to transmission, as they likely outnumber 
sympto matic CDI patients. In addition, the  C.  difficile carriers have themselves a higher risk 
of progression to CDI  [81 -83]. Approximately 5 % (0-15 %) of healthy individuals are 
asymptomatically colonized with  C.  difficile  [82]. The incidence increases during prolonged 
hospitalization to 4 - 21 %, and in nursing home residents colonization rates of 4 – 10 %, 
but up to 51  %, have been reported  [82]. These observations prompted to survey  C.  difficile 
colonization rates in the healthy population and amongst nursing home residents in the 
Netherlands. Asymptomatic carriership is usually undetected, as routine screening is not 
performed. Interestingly, in Canadian tertiary institution in Quebec City, isolation 
 pre cautions for colonized patients identified upon admission, decreased healthcare 
associated CDI  [84], suggesting that asymptomatic  C.  difficile carriers significantly 
contribute to spread of CDI.  
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Microbiological diagnosis of Clostridioides difficile  
The diagnosis of CDI is not always easy and straightforward. Because of the 
possibility of asymptomatic colonization and the potential presence of other causes 
for diarrhoea, detecting the presence of  C.  difficile in the feces does not necessarily 
defines disease. The main problem is absence of a fast and easy to perform test that 
differentiates between colonization and infection with high positive and negative 
predictive value. Of note, the presence of two gold standards, each with their own 
benefits and drawbacks also complicates the interpretation of research in this area. 
The cell cytotoxicity assay (CCNA) as gold standard test, detects the presence of 
free  C.  difficile toxin by a cytopathic effect in cell culture that is neutralized by the 
presence of antitoxin  [85]. Detection of free toxin in the stool correlates best with CDI 
symptoms  [86], however is labour intensive and non-standardized  [86]. Toxigenic 
culture (TC), the second gold standard, evaluates the potency of cultured isolates to 
produce toxins in vitro  [86, 87]. TC is considered the most sensitive of both assays, 
however in return less specific as asymptomatically colonized individuals are also 
tested positive. Given these drawbacks, one can question whether a true gold standard 
exists at all. Due to its labour intensiveness and required expertise, the availability of 
both tests in routine clinical microbiology laboratories is limited. Furthermore, the test 
results are only available after several days, often too late for clinical decision making. 
In Table 2, estimates of pooled sensitivity and specificity for different diagnostic CDI 
tests compared to the gold standard are shown. These were used to calculate positive 
and negative predictive values (PPV and NPV) for the different tests at varying hypo-
thetical CDI prevalence’s, depicted in Table 3. The most rapid, and easy to perform 
diagnostic tests are toxin enzyme immunoassays (EIAs), but it has become evident 
that these assays lack sensitivity to accurately diagnose CDI (Table 2), especially in 
a low prevalence disease setting ranging between 5-10 % (Table 3)  [88]. In contrast 
a glutamate dehydrogenase (GDH) EIA or toxin nucleic acid amplification test 
(NAATs) display high sensitivity, but also lack specificity. The European diagnostic 
guidance document advises therefore a two-stage algorithm, using a NAAT or GDH EIA 
as sensitive screening assay, in combination with tests to detect the presence of free 
toxins in stools as marker of disease activity  [88]. Using this guidance document, the 
European Center for Disease Prevention and Control (ECDC), formulated a practical 
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Table 4. Practical advice to apply the two-step algorithm by the ECDC 
 
 
CDI: Clostridium difficile infection 
ESCMID: European Society for Medical Microbiology and Infectious Diseases 
NAAT: Nucleic acid amplification test 
Toxin A/B EIA: enzyme immunoassay that test for both toxins A and B 
GDH: glutamate dehydrogenase 
N/A: not applicable 
* In this testing strategy, NAAT or toxigenic culture is an optional second test (there is no third test option) 
Gut microbiota & Clostridioides difficile infection 
The propensity of  C.  difficile spores to colonize the intestinal tract and subsequently 
outgrow and produce toxins, is highly influenced by the host microbiota and meta-
bolome. In healthy individuals, the immune system along with a complex interplay of 
the gut microbiota, by competition for food and place, excretion of metabolites and 
bacteriocins, suppresses the growth of  C.  difficile. This defence mechanism is also 
known as colonization resistance  [90]. Upon disruption of the microbiota due to exo -
genous factors such as antimicrobials or other medication as proton pump inhibitors 
or chemotherapy, colonization resistance decreases and  C.  difficile can proliferate, 
produce toxins and cause disease  [24, 91]. Of the antibiotics, clindamycin, fluor o qui -
nolones and cephalosporins, monobactams and carbapenems are in particular notori-
ous for serious microbiota disruption  [92]. By disrupting the microbiota, antibiotics have 
a selective effect on several key factors of the microbiota to suppress  C.  difficile. 
For example, microbiota changes can inhibit conversion of the primary bile acids 
with  C.  difficile spore-germinating capacity, to the  C.  difficile inhibiting secondary bile 
acids, enabling the outgrowth of  C.  difficile spores  [93, 94]. These disruptions of the 
micro biota and consequent vulnerability of disease progression are more common in 
the fragile elderly population. The precise microbes responsible for inhibition or 
progression from  C.  difficile colonisation to infection have not been identified. However, 
Categorization of CDI diagnosis CDI diagnostic algorithm




NAAT Toxin A/B EIA N/A
GDH EIA Toxin A/B EIA NAAT or toxigenic culture
GDH and Tox A/B EIA NAAT or toxigenic culture* N/A
Not recommended All other algorithms
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few suggestions have been made  [95]. For example, some bacteria, like for instance 
C. scindens, convert the  C.  difficile enhancing primary bile acids to the inhibiting 
secondary bile acids  [93, 94]. Moreover, several studies have reported the recovery of 
Bacteroidetes and members of the Firmicutes phylum; the families Lachnospiraceae 
(formerly known as Clostridium cluster XIVa) and Ruminococcaceae (formerly known 
as Clostridium cluster IV), including Faecalibacterium prausnitzii, Eubacterium rectale, 
Roseburia intestinalis and other known butyrate-producing bacteria along with success-
ful clinical recovery from CDI  [96 -99]. Additionally, the level of Bacilli and Proteo -
bacteria, generally found at high levels in patients with CDI, decreased after successful 
recovery  [98]. Those observations will guide the future development of bacterial 
mixtures to prevent and treat CDI. Finally, the involvement of host immunity in the gut 
microbiota-mediated colonization resistance to CDI is incompletely under stood but 
has recently been studied in mice, suggesting that IL-22-mediated host glycosylation 
stimulates the growth of commensal bacteria that compete with C.  difficile for the 
nutritional niche  [100].  
Treatment of Clostridioides difficile infection 
In 2014, the CDI treatment guideline of the European Society of Clinical Micro -
biology and Infectious Diseases (ESCMID) advised metronidazole, vancomycin and to 
a lesser extent fidaxomicin as the cornerstones of the CDI treatment  [101]. However, 
after publication of this guideline, a large multicentre RCT showed that metronidazole 
is inferior to vancomycin in the treatment of both severe and non-severe CDI  [102], with 
cure rates of respectively 81 % versus 73 %. The lower cure rate could be partly 
explained by the poor intestinal concentration of metronidazole in the lower gastro -
intestinal tract  [103]. As result, metronidazole is currently replaced by vancomycin in 
most guidelines as first line CDI therapy  [104]. Similarly, the IDSA guidance document 
recommended either vancomycin or fidaxomicin over metronidazole for an initial 
episode of CDI  [105]. After treatment of an initial episode of CDI, recurrence occurs 
within eight weeks in 15-25 %  [102, 106, 107]. For a patient with one or two recurrences, 
the risk of further recurrences is increased to 40-65 %  [106, 108]. Fidaxomicin seems 
evenly effective as vancomycin in curing the symptoms of a first CDI episode, though 
due to its small antibiotic spectrum, relapses occur significantly less, 25.3 % versus 




relapses occurred in the fidaxomicin treated versus a vancomycin treated group (19.7 % 
versus 35.5 %)  [107]. A variation of the 10 days fidaxomicin treatment is a so-called 
extended-pulsed fidaxomicin (200 mg oral tablets, twice daily on days 1-5, then once 
daily on alternate days on days 7-25). Extended-pulsed fidaxomicin was superior to 
standard-dose vancomycin for sustained cure of  C.  difficile infection with a cure rate of 
70 % versus 59 % at 30 days after end of treatment  [111]. Although the initial treatment 
costs of (extended-pulsed) fidaxomicin are very high (€ 1680,68 2dd200mg 10 days), it 
may be cost-effective as first line therapy in older patients, in comparison to vancomycin 
(€ 410.73 4dd250mg, 10 days), due its increased efficacy  [111, 112]. Nevertheless, due to 
the high costs, fidaxomicin is mainly prescribed for patients with recurrent CDI in the 
Netherlands. A new, interesting treatment strategy is provided by bezlotoxumab, an 
anti- C.  difficile monoclonal antibody, which can be prescribed as additive to standard 
antibiotic therapy. In a large phase 3 study, bezlotoxumab significantly lowered the rate 
of recurrence within 12 weeks in comparison to standard therapy (17 % versus 27 %)  [113]. 
As for fidaxomicin, the current price of bezlotoxumab in combination with the limited 
additional beneficial effects hampers its broad scale implementation in clinical practice. 
Despite high expectations, treatment approaches directed to bind or neutralize  C.  difficile 
toxin in the intestinal tract, were not successful. In most cases, the design of the studies 
was not optimal or insufficient number of patients were included. Tolevamer, a  C.  difficile 
toxin binding polymer, was inferior to antibiotic treatment in two RCTs comparing 
tolevamer with vancomycin or metronidazole  [102]. Unfortunately, tolevamer was not 
tested in combination with anti-CDI antibiotics. Several attempts have been made to 
develop immune whey with anti-CDI antibodies obtained by vaccination of cows. 
Though in vitro studies were promising, only one clinical trial was started but stopped 
due to bankrupt of the company  [114, 115].  
Despite of the above described treatment modalities, a subgroup of patients 
suffers from persisting CDI, with continuing relapses after cessation of antibiotics. 
Recurrent CDI is characterized by a permanently disturbed microbiota, enabling the 
out growth  C.  difficile spores once the anti-CDI antibiotic is stopped. Modifying the gut 
microbiota to break this cycle and prevents relapses to occur. Of all gut modifying 
therapies, Faecal microbiota transplantation (FMT) shows at present the best cure 
rates of over 85 %  [96, 116, 117]. In Table 5, FMT and other microbiota modifying therapies 
are discussed. 
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Table 5. Overview of gut microbiota modifying therapies for treatment of recurrent CDI 
 
CDAD: Clostridioides difficile-associated diarrhoea 
NNTB: number needed to treat to benefit one person 
RR: relative risk 
Gut modifying therapy Comment Evidence in CDI treatment
Prebiotics Dietary components that foster the 
growth of beneficial micro-organisms 
and stimulate a healthy microbiota.  
For instance, fibres of which Short Chain 
Fatty Acids (SCFA) are produced, which 
are healthy for the host.
An RCT with oligofructose amongst 132 patients 
showed that a relapse of diarrhoea occurred in 8.3% 
of oligofructose treated patients versus 34.3% of 
placebo treated patients [118]
Probiotics A live microbial feed supplement 
which could be of benefit for the host. 
Limited efficacy. One bacterial mix 
beneficial for all conditions seems too 
simple. Generalizability of the results is 
challenging due to varied probiotic 
preparations in the research. Examples 
of studied probiotics: Saccharomyces 
boulardii, Lactobacillus plantarum, 
non-toxigenic C. difficile strain, a multi-
strain preparation of Lactobacilli and 
Bifidobacteria.
Systematic review of RCTs: Two studies have 
found benefit to probiotics in prevention of rCDI: 
S. boulardii [119, 120] and a non-toxigenic 
C. difficile strain M3 [121] when compared to placebo. 
Cochrane systematic review (n=8672, 31 RCTs). 
Moderate certainty evidence: probiotics effective to 
prevent CDAD (NNTB = 42 patients, 95% CI 32-58). 
Post hoc subgroup analysis: probiotics effective with 
CDAD baseline risk >5% (NNTB = 12), but when 
baseline risk ≤5%. When probiotics administered 
together with non-CDI antibiotics RR reduction of 0.4 
in acquiring CDI (1.5 vs 4%), NNT 40 [122].
Synbiotics Combination of pre- and probiotics, 





Bacterial mix of healthy bacteria Poof of principal Phase I study with bacterial spores 
(approximately 50, SER-109), effective in subset of 
patients [123]. However, failure to treat rCDI in phase 
II study. 
Multiple studies with rational selected bacterial 
consortia (VE303, Vedanta) underway.
Phage therapy Transfer of bacteriophages Proof-of-principle: Faecal filtrate (including meta -
bolites/bacteriocins) was proved to cure (n=5) CDI 
patients [124].  
In addition, FMTs with increased bacteriophage 




Transfer of complete healthy microbiota 
ecosystem to diseased microbiota, 
containing living bacteria, bacteriophages, 
metabolites and bacteriocins. 
Established to prevent relapses in multiple, 
recurrent CDI. 
Metabolites (postbiotics) Transfer of beneficial microbial products 
that prevent germination, colonization 
and/or toxin production of C. difficile. 
Without risk of permanent engraftment of 
potential microorganism with risk, 
although question whether response 
permanent and chronic therapy needed.
Ursodeoxycholic acid (UDCA) prevented rCDI in 




Faecal microbiota transplantation, a highly effective microbiota 
modulating therapy 
Recurrent CDI is associated with an impaired immune response to  C.  difficile toxins 
and more importantly, with a persistent and severely perturbed colonic microbiota  [127]. 
16S rRNA gene sequence analysis of patients with recurrent disease showed a highly 
variable bacterial composition in comparison with the normal predominance of 
Bacteroidetes and Firmicutes in healthy individuals  [98, 127]. Furthermore, patients with 
rCDI showed lower species richness compared with patients with an initial CDI 
episode or control subjects  [97, 127]. This perturbed and diminished microbiota is essen-
tial in maintaining the disease, which is supported by the observation that replenishing 
the microbiota by Faecal Microbiota Transplantation (FMT) results in prompt 
resolution of rCDI.  
The use of human stool as therapy for (mainly) gastrointestinal disorders, such as 
food poisoning and diarrhoea, was first reported in ancient China  [128]. In the fourth 
century, Ge Hong orally administered faecal suspensions to treat severe diarrhoea, 
later referred to such suspensions as ‘yellow soup”  [128]. In 1958, Western literature 
described the first patients with severe antibiotic-induced colitis who were successfully 
treated with donor stool containing enemas  [42]. With the increased CDI incidence in 
the 21st century, this ‘ancient’ therapy regained interest. In 2013, the first randomized 
trial using FMT to treat recurrent CDI demonstrated a remarkable efficacy in 
comparison to vancomycin  [96]. FMT was successful in 81 % of rCDI patients after just 
one FMT infusion, 94 % after multiple infusions, while vancomycin was successful in 
only 31 % of patients  [96]. This high efficacy was confirmed in many independent 
studies that followed  [116, 117, 129], and FMT is now advised in guidelines for treatment 
or recurrent CDI  [104, 105]. A meta-analysis by Quraishi, including seven RCTs and 30 
case series, showed that FMT was more effective than vancomycin in resolving 
recurrent and refractory CDI with a relative risk of 0.23 and a clinical resolution of 
92 %  [116]. The second meta-analysis by Moayyedi, included ten RCTs with a total of 
657 patients with  C.  difficile-associated diarrhoea and demonstrated that FMT was 
significantly more effective compared with placebo or vancomycin treatment, with 
a relative risk of 0.41  [117]. After FMT, patients show an increase in microbiota diversity, 
reaching levels that are observed in healthy donors  [96, 98]. In conclusion, FMT is 
a highly effective treatment for patients suffering from multiple recurrent CDI  [105].  
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Large heterogeneity exists among the included studies with respect to donor faeces 
volume, FMT preparations, route of administration, pre-treatment and numbers of 
FMTs  [116, 117, 130]. This underlines the need for standardization of FMT to facilitate FMT, 
and increase the safety of this new treatment modality, stool banks such as the 
Netherlands Donor Feces Bank (NDFB) are emerging to standardize and centralize the 
process of donor selection and screening and to provide ready-to-use donor faeces 
suspensions to treating physicians. In addition, initiatives are undertaken to further 
standardize the process of FMT in Europe. 
For now, CDI remains the prime disease for which there is a consistent body of 
evidence supporting treatment by FMT. However our growing understanding of the gut 
microbiota in health and disease suggests FMT, or more precisely; the concept of 
modulating the gut microbiota, could have great potential in treating other diseases 
than CDI  [131, 132] (see Table 6).  
 
 
Colonisation with multidrug resistant organisms; 
unknown association with intestinal dysbiosis  
Antibiotic resistance - Introduction 
Antibiotic resistance, the ability of a bacterium to resist the action of one or more 
antibiotics, threatens effective prevention and treatment of infections, and is 
considered a major threat to public health worldwide  [4, 168]. Bacterial resistance of 
several antibiotic classes is nowadays also becoming increasingly more common in 
the Netherlands  [169, 170]. Infections with multidrug resistant organisms (MDROs) are 
not only more difficult to treat, but are accompanied with a rise in health care costs, 
patient morbidity and mortality  [171]. Data based on the European Antimicrobial 
Resistance Surveillance Network (EARS-Net) show that each year, more than 670,000 
infections occur in the European Union with antibiotic resistant bacteria, of which 
64 % health care associated. Over 33,000 patients die annually as a direct 
consequence thereof  [172]. The related cost to the healthcare system is around 1.1 
billion Euro’s  [173].  
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The Centers for Disease Control and Prevention (CDC) has outlined and prioritized 
the threats posed by specific MDROs of which drug resistant Neisseria gonorrhoeae, 
carbapenem resistant Enterobacterales (CRE) and  C.  difficile were the most urgent  [5]. 
Although resistance is considerably more common in the Netherlands than 20 years 
ago, resistance rates are much lower compared to many other European countries  [169]. 
This is partly because of the limited antibiotic use, both in the community as well as 
in the hospital  [1]. Nevertheless, much effort is put in maintaining this low prevalence 
rate of MDRO. Low prevalence rates give the opportunity to combat resistance, for 
example with an active search-and-destroy (decolonisation) policy regarding 
“Methicillin Resistant Staphylococcus Aureus (MRSA)”. With support of medical micro -
biologists, infection prevention workers and infectious disease specialists, only 1.2 % of 
Staphylo coccus aureus isolates cultured from infections was resistant against 
methicillin in the Netherlands in 2018  [169]. In contrast, infections with Extended 
Spectrum β-lactamase-producing (ESBL) Enterobacterales (previously known as 
Enterobacteriaceae  [174]) are much more frequently encountered, both in healthcare 
facilities and in the community  [175] (Figure 6). In the Netherlands, Enterobacterales 
resistant to both fluoroquinolones and aminoglycosides, are also considered a MDRO, 
 
Figure 6. Trend in ESBL producing E. coli (left) and K. pneumoniae (right) in the 
Netherlands in different patient populations (from left to right 2015 to 2019). Isolates of patients 
attending the general practitioner are depicted in yellow, the outer patient clinic in green, the 
hospitalised patients (minus intensive care) in light blue and intensive care in dark blue. 




Antibiotic resistance - General mechanism of action  
Antimicrobial resistance is ancient and is the result of a million years of microbial 
co-evolution  [179]. Most antimicrobial compounds are (derived) from microorganisms. 
The co-resident target microorganisms have therefore evolved mechanisms to over-
come the antimicrobial action, referred to as ‘intrinsic resistance’. Intrinsically resistant 
bacteria are however not the focus of the resistance problem. In contrast to ‘acquired 
resistance’, in which a bacterium that was originally susceptible to the antimicrobial 
compound, gained resistance. There are several major resistance mechanisms, namely 
1. Destruction or modification of antibiotic molecule (for instance β-lactamases) 2. 
Modifications of antimicrobial target and/or binding place (for instance, alteration of 
Penicillin Binding Protein) 3. Prevention to reach the antimicrobial target by actively 
extruding by efflux-pumps or decreasing penetration (for instance by porins) or 
upregulation of the target 4. By-pass of target molecule by microorganism by change 
in metabolic pathway (for instance some sulphonamide resistant bacteria switch to 
using preformed folic acid)  [180]. Development of acquired resistance can occur ‘de 
novo’ or by acquisition of exogeneous resistance genes. Bacteria acquire external 
DNA through three strategies 1. Transformation (incorporation of naked DNA), 
2. Transduction (phage mediated) and 3. Conjugation (bacterial sex). Emergence of 
resistance in the hospital environment often involves conjugation, a very efficient 
method of gene transfer that involves cell-to-cell contact and is likely to occur at high 
rates in the gut microbiota under antibiotic treatment  [181]. This is referred to as 
horizontal spread. Conjugation makes use of mobile genetic elements as vehicles to 
share valuable genetic information. The most important mobile elements are plasmids 
and transposons  [181].  
 
as these antibiotics are important antibiotics used in hospital settings  [170, 176]. Of 
infections with Enterobacterales, urinary tract infections constitute the main clinical 
syndrome, followed by bloodstream infections with often a urinary or biliary tract 
origin. On the other hand, similar as  C.  difficile, also MDR Enterobacterales can 
asympto matically reside in the gut. The intestinal tract is considered as an important 
reservoir of human Enterobacterales colonization and infections  [177, 178].  
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Antibiotic resistance to cephalosporins by 
“Extended Spectrum β-lactamases (ESBLs)” 
β-lactam agents such as penicillin’s, cephalosporins, monobactams and carba -
penems, are the most frequently prescribed antibiotics. β-lactamases are bacterial 
enzymes that inactivate β-lactam antibiotics by hydrolysis and are the predominant 
mechanism of resistance in Gram-negative bacteria  [180]. Extended-spectrum 
β-lactamase-(ESBL) producing bacteria have the ability to hydrolyse oxyimino-
cephalosporins, and monobactams, but not cephamycin’s or carbapenems. ESBLs 
were first described in 1983 and emerged especially in Klebsiella pneumoniae and 
Escherichia coli  [182]. The genes encoding ESBL resistance, are frequently located on 
plasmids. Large plasmids carrying both ESBLs and several other resistance genes (e.g. 
aminoglycosides and fluoroquinolones) are frequently present in the Enterobacterales 
family  [183]. Plasmid-mediated spread of ESBL and other antibiotic resistance genes 
(ARGs) contributes to the global spread of resistance against many frequently used 
antibiotics. The global pooled prevalence of ESBL colonization in the intestinal tract 
of asymptomatic individuals is 14 %, with an increasing trend of 5.4 % annually  [2]. 
Driving factors for this rise are the globalization and the pandemic spread of CTX-M 
as most dominant ESBL enzyme  [184], both in the hospital as well as in the com -
munity  [2, 175]. CTX-M originated from chromosomal β-lactamases genes from different 
Kluyvera species  [185]. Kluyvera spp. are ubiquitous found in the environ ment  [186], and 
the probable environmental reservoir of the resistance genes. These β-lactamases 
genes were captured and mobilized on a variety of mobile genetic elements mediating 
rapid dissemination  [187]. In the Netherlands, approximately 4.5-8.6 % of the healthy 
individuals is asymptomatically colonized with ESBL-producing Enterobacterales  [188-
191]. The prevalence of ESBL colonization varies largely per population; geographically 
as well as in diseased versus healthy individuals. Travel, kitchen hygiene (for instance 
not changing the kitchen towel each day) and antibiotic use are important risk factors 
for carriership of ESBL producing E. coli or K. pneumoniae in healthy individuals  [192-
194]. Carriership showed even a seasonal variation, that could not be explained by 
travel and antibiotic use  [193]. Spontaneous clearance of the ESBL varies per bacterial 
species and per ESBL enzyme. One study reports a long duration of carriage in 
patients with a clinical infection, since 43 % remained ESBL positive after 1 year  [195]. 




for >8 months in 32.9 %  [193]. However, a study amongst 633 Dutch travellers who 
acquired ESBL during travel, concluded that the median duration of colonisation after 
travel was 30 days, and only 14.3 % and 11.3 % remained colonized at 6 and 12 months 
after return, respectively  [190]. A second large community survey showed that the 
average duration of carriage was 0.35 years (4.2 months) amongst 4177 Dutch 
community-dwelling subjects  [192]. Spontaneous clearance of certain subclones 
appears to be more difficult, as colonization of E. coli subtype (ST) ST131 is associated 
with a longer duration of carriage in a long-term care facility residents, with a half-life 
of 13 months versus 2- to 3- months for other STs  [196]. Of particular interest is the 
recognition of individuals with a higher risk of asymptomatic carriage and potential 
spread to the healthcare facility or community of MDROs. Nursing home residents as 
well as patients attending the hospital have multiple risk factors for colonization and 
infection with MDRO and  C.  difficile  [178, 197-203]. They are thought to be a potential 
reservoir for spread and transmission in the hospital  [80, 204, 205]. Frequent contact 
between residents due to communal living, high frequency of healthcare contact and 
presence of factors that facilitate MDRO spread such as incontinence present 
additional opportunities for transmission  [206].  
Resistance to polymixins and carbapenems 
Infections with MDROs resulted in an increasing demand to use carbapenems. 
Subsequently, carbapenem resistance developed  [207]. Carbapenemases can be 
produced by Enterobacterales and non-fermenters, and are classified into three 
classes according to Ambler classification; class A, B and D. Of the genes conferring 
carbapenem resistance, the carbapenemases pose the most threat, because of the 
possibility of horizontal gene transfer by plasmids or other mobile genetic elements. 
Carbapenemases are still sporadically observed in the Netherlands, both in the 
hospital  [169] as well as in the community  [194]. However, national surveillance 
detected a small cluster of eight closely related New Delhi metallo-beta-lactamase 
producing K. pneumoniae in patients without epidemiological link, indicating unnoticed 
spread  [208]. Due to the rise of carbapenemase producing MDRO’s, some of the older 
antibiotics such as polymyxins (colistin and polymyxin B) regained interest for 
patients’ treatment. Colistin, also known as polymyxin E, is bactericidal and demon-
strates activity against most Gram negative bacteria  [209]. However, its nephrotoxicity 
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and neurotoxicity has prevented the use of colistin in regular patient treatment  [210]. 
Therefore, colistin usage was mainly limited to veterinary medicine for treatment of 
gastrointestinal infections in food producing animals  [211]. In the Netherlands, poly-
myxin B is frequently used for selective gut decontamination in Intensive Care Units 
and stem cell transplantation patients  [212, 213]. The polymyxins are cationic peptides 
with fatty acid tails. Electrostatic interaction occurs between the positively charged 
groups on the polymyxin and the negatively charged groups of the lipid A component 
of the lipopolysaccharide (LPS). The fatty acids interact with the lipid components of 
the outer membrane. These interactions result in a change in the permeability of the 
outer membrane, and the polymyxins gain access to the cytoplasmic membrane. The 
breach in the permeability barriers, result in leakage of intracellular contents and 
subsequently cell death  [209]. Some important Gram-negative bacteria, such as Serratia 
marcescens, Burkholderia and Proteus species, are intrinsically resistant to the action of 
polymyxins. Colistin resistance in Gram-negative bacteria is primarily due to post-trans-
lational modification of the lipopolysaccharide (LPS) molecules  [214]. Sub stituents 
(such as 4-amino-L-arabinose, phosphoethanolamine and/or galacto samine) which 
are positively charged reduce the negative charge of the outer membrane, resulting in 
less binding between the bacterial LPS and the colistin  [214]. While the genes necessary 
for most of these additions are chromosomally encoded, the identification of a plasmid 
harbouring a novel colistin resistance gene, mcr-1 in November 2015, is of concern 
as it threatens to increase the rate of colistin resistance  [215]. Since the discovery of 
the mcr-1 gene, ten mcr genes types (mcr-1 to mcr-10) have been detected in Entero -
bacte rales isolates of human, animal and environmental origin with worldwide 
 distri u tion  [216, 217]. The emergence of colistin resistance is currently analysed in a large 
European survey coordinated by ECDC and preliminary data indicate that its 
prevalence in the Netherlands amongst clinical isolates of E. coli and K. pneumoniae is 
higher than expected (March 2020, source RIVM).  
Multidrug resistant organisms;  
rationale for microbiota modifying therapies 
Most infections with ESBL producing Enterobacterales have high morbidity and 
mortality and are preceded by intestinal colonization  [171, 177, 178]. Prevention and 




interest. Since spontaneous decolonization occurs infrequently, innovative strategies 
for decolonization of MDR bacteria are needed. A published guidance document 
by the ESCMID could not recommend an antimicrobial intervention strategy for 
decolonization [218]. However, Millan et al., observed that FMT for treatment of patients 
with multiple recurrent CDI decreased the number and diversity of antimicrobial 
resistance genes  [219]. This observation was followed by various case-reports of 
patients colonized with ESBL producing Enterobacterales who were successfully 
decolonized by FMT  [156-159, 220-225]. However, only one RCT was performed 
which assessed decolonization of MDRO Enterobacterales by treatment of oral non-
 absorbable antibiotics or by FMT. Unfortunately, no statistically significant advantage 
of FMT was found, though the trial suffered from inclusion of insufficient number of 
patients  [160, 226]. 
 
 
Outline of this thesis 
This thesis, entitled “Exploring the role of the microbiota in defence against 
Clostridium difficile and multidrug resistant Gram negatives”, reports on the micro bio -
logical, epidemiological and clinical aspects of Clostridioides difficile and multidrug 
resistant organisms (MDROs). Part I of this thesis focusses on the epidemiology and 
diagnostic practices of asymptomatically colonized individuals, whereas part II 
focusses on eradication and/or treatment of these micro-organisms by restoring 
a healthy microbiota with “Faecal Microbiota Transplantation”.  
Chapter 1 is a general introduction on the gut microbiota in relation to colonization 
and infection with  C.  difficile and MDRO, and Fecal Microbiota Transplantation. 
 
Part I: New insights in the epidemiology of Clostridioides difficile and 
multidrug resistant organisms. 
 
Chapter 2 evaluates the performance of several diagnostic  C.  difficile tests compared 
to the gold standard toxigenic culture of asymptomatically colonized patients at 
admission to three large hospitals in the Netherlands. 
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Chapter 3 reports on the prevalence of plasmid mediated colistin resistance genes; 
mcr-1,2  [215, 227], in faecal samples of patients attending a tertiary care hospital in the 
Netherlands. Furthermore, it describes the genetic mechanism of phenotypically 
colistin susceptible mcr-1 containing E. coli. 
Chapter 4 determines the prevalence, risk factors and transmission within the nurs-
ing home of  C.  difficile and MDRO in asymptomatic nursing home residents in a high 
(Ireland) and low (the Netherlands) endemic country. Transmission of MDROs was 
studied with whole genome sequence analysis.  
 
Part II: The initiation of the Netherlands Donor Feces Bank to facilitate 
quality assured faecal microbiota transplantation 
 
Chapter 5 describes the establishment of the Netherlands Donor Feces Bank 
(NDFB), a national operating non-profit stool bank facilitating FMT in the Netherlands. 
It addresses the current practice of donor recruitment and screening, preparation of 
the faecal suspension, logistics and transport of the faecal microbiota suspension to 
treating physicians in the local hospitals, and the follow-up of the outcome and safety 
of FMT in patients treated with FMT suspensions provided by the NDFB. 
In Chapter 6 the four years results of extensive donor screening and the outcome 
of FMT with suspensions provided by the NDFB are reported. In addition, the 
additional benefit of expert consultation, as provided by the working group of the 
NDFB is described. An attempt was made to understand the failures (post-FMT 
recurrence), and to identify donor and faeces suspension specific factors for optimal 
rCDI treatment. 
Chapter 7 is an analysis of the effect of transmission of Blastocystis species from 
donors to patients by FMT, using a combination of PCR and subtyping techniques. 
Chapter 8 describes an attempt of MDRO decolonisation from the intestinal tract 
with FMT in a patient suffering from recurrent urinary tract infections with a VIM-
positive Pseudomonas aeruginosa. Microbiota analysis using 16S analysis was 
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Detection of Clostridium difficile 
in feces of asymptomatic patients 
admitted to the hospital  
Diagnostics in asymptomatic C. difficile carriers
Chapter 
Chapter 2. Detection of Clostridium difficile 
in feces of asymptomatic patients admitted 
to the hospital 
Abstract  
Recent evidence shows that patients asymptomatically colonized with 
Clostridium difficile may contribute to the transmission of  C.  difficile in 
 healthcare facilities. Additionally, these patients may have a higher risk of 
developing  C.  difficile infection. The aim of this study was to compare 
a commercially available PCR directed to both toxin A as B (artus  C.  difficile 
QS-RGQ Kit CE, QIAGEN), an Enzyme Linked Fluorescent Assay to Glutamate 
Dehydrogenase (GDH ELFA, VIDAS, bioMérieux), and an in-house developed 
PCR to TcdB, with (toxigenic) culture of  C.  difficile as gold standard to detect 
asymptomatic colonization. Test performances were evaluated in a collection 
of 765 stool samples obtained from asymptomatic patients at admission to the 
hospital. The  C.  difficile prevalence in this collection was 5.1 %, 3.1 % contained 
a toxigenic  C.  difficile. Compared to  C.  difficile culture, the sensitivity, specificity, 
positive predictive value (PPV), and negative predictive value (NPV) of 
C.  difficile GDH ELFA were 87.2 %, 91.2 %, 34.7 % and 99.3 %. Compared with 
results of toxigenic culture, the sensitivity, specificity, PPV and NPV of the 
commercially available PCR and the in-house PCR were 95.8 %, 93.4 %, 31.9 %, 
99.9 %, and 87.5 %, 98.8 %, 70 % and 99.6 %, respectively. We conclude that in 
a low prevalence setting of asymptomatically colonized patients, both GDH 
ELFA and a Nucleic Acid Amplification Test can be applied as a first screening 
test as they both display a high NPV. However, the low PPV of the tests 
hinders the use of these assays as stand-alone tests. 
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Introduction  
Clostridium difficile infection (CDI) is a leading cause of hospital-acquired diarrhea. 
The transmission of spores from symptomatic patients can spread  C.  difficile within 
healthcare facilities with subsequent development of more symptomatic patients, and 
eventually clusters and outbreaks. However, recent data suggests that patients 
asymptomatically colonized with  C.  difficile also contribute to spread of  C.  difficile spores 
to the environment and to other patients  [1 -3]. Asymptomatic carriers shed spores into 
the environment to a lesser extent than CDI patients  [3, 4], but by outnumbering the 
CDI patients they can still play an important role in the transmission of the disease. 
This hypothesis has recently been supported in a Canadian study, where isolation 
of  C.  difficile colonized patients significantly reduced the incidence of hospital-acquired 
CDI  [5]. A second new insight in the significance of asymptomatic colonization is 
that it may increase the risk of subsequent clinical disease in some colonized 
patients  [6-10]. Progression from colonization to CDI can be provoked by alterations of 
the microbiota and a subsequent decrease of secondary bile acids, which normally 
inhibit spore germination  [11 -13]. But other factors like pre-existing antitoxin antibodies 
may also play a role, in protection from progression to CDI, although their exact role 
needs to be clarified.  
Thus, recognition of asymptomatically colonized patients may be clinically 
relevant to reduce nosocomial transmission and for protection from progression to 
symptomatic disease. Asymptomatic colonization of  C.  difficile varies widely between 
various patient populations studied. Approximately five to 15 % of newly hospital 
admitted patients carry  C.  difficile in their feces  [4, 5, 14-17]. Carriage rates of residents in 
long-term care facilities varies from 4-51 %, but in general tends to be higher than in 
hospitalized patients  [3, 14, 18]. Asymptomatic colonization of  C.  difficile in the pediatric 
populations is very high, approximately 37 % of children are asymptomatic carriers in 
their first year of life, decreasing to 15 % for children between one and eight years of 
age  [19].  
A recently published European guidance document advises a two-stage algorithm 
to diagnose CDI using a toxin Nucleic Acid Amplification Test (NAAT) or GDH Enzyme 
Immuno Assay (EIA) as sensitive screening assay in combination with tests to detect 
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the presence of free toxins in stools as a marker of disease activity  [20]. Samples without 
free toxins detected will largely represent asymptomatic carriers. However, this guideline 
addresses diagnostics of CDI in diarrheal patients and reviewed the literature of 
symptomatic patients with CDI. The optimal diagnostic test to detect  C.  difficile in 
asymptomatically colonized patients with normally formed stool is unknown. There fore, 
the aim of this study was to compare the performances of a commercially available 
glutamate dehydrogenase (GDH) EIA with a primary gold standard, a con ven tional 
culture of  C.  difficile in asymptomatically colonized patients at admission to three large 
hospitals in the Netherlands. Moreover a commercially available PCR for TcdA and TcdB, 
and in-house developed PCR for detection of TcdB, was compared with a secondary gold 
standard; toxigenic  C.  difficile culture (TC). 
 
Material and methods 
Study design 
A multi-center study was performed on feces samples obtained between Novem -
ber 2014 and December 2015 in the Leiden University Medical Center, Leiden (623 
samples), Amphia hospital, Breda (72 samples), and Erasmus Medical Center, Rotterdam 
(70 samples) in the Netherlands. The study was designed to determine risk factors for 
asymptomatic  C.  difficile colonization at admission to the hospital  [ZonMW 50-52200-98-
035]. The institutional review board judged that ethical approval was not required. Feces 
samples were obtained from patients on admittance to internal  medicine and surgical 
wards, and from patients attending the kidney transplant outpatient clinic. If a patient 
was admitted twice in the study period, the patient remained eligible for this study.  
Culture and characterization of  C.  difficile 
The samples were processed for  C.  difficile culture and TC within 72 hours of arrival at 
the laboratory and were subsequently stored at -20°C, without addition of glycerol. Feces 
was inoculated on  C.  difficile selective agar (CLO-medium; bioMérieux, Marcy  l’Etoile, 
France) and CNA- (colistin and naladixic acid containing agar, bioMérieux) medium with 
and without ethanol shock pretreatment  [21]. The media were incubated for five days in 
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an anaerobic atmosphere at ± 35ºC. Gray-brown colonies with the characteristic horse 
manure odor were further tested by an in-house GDH PCR  [22].  C.  difficile isolates were 
tested for the presence of toxin genes by PCR for toxin A (TcdA), toxin B (TcdB) and 
binary toxin (CdtA, CdtB)  [22]. Capillary gel-based electrophoresis PCR ribotyping was 
performed to characterize the isolates  [23].  
Diagnostic  C.  difficile tests 
After thawing the stored feces samples, the GDH EIA and both NAATs were per-
formed in bulk testing. The targets of the applied detection assays are depicted 
in Table 1. The GDH EIA was performed on an enzyme-linked fluorescent immuno -
assay (ELFA) platform (VIDAS; bioMérieux, Marcy-l’Etiole, France) as previously 
described  [24]. A relative fluorescent value of ≥ 0.1 was regarded positive. Both GDH 
ELFA and artus PCR were performed according to manufacturer’s instructions. As 
both assays are not registered for use in formed stools of asympto matic patients, 
instructions were modified for off-label use, in consultation with the manufacturer. 
For both tests approximately the size of half a pea of feces (approximately 0.3 to 
0.4 gram), instead of 200 μl of liquid feces, as this is routine practice in our laboratory 
for isolation of DNA of formed feces. For the artus PCR (artus  C.  difficile QS-RGQ Kit 
CE, QIAGEN, the Netherlands) feces was transferred into a test tube with 1500 μl tissue 
lysis buffer (ATL), vortexed and centrifuged for a short period. The tubes were then 
inserted into the QiaSymphony supplied with the artus  C.  difficile AS software, which 
regulates DNA isolation and preparation of PCR mix. The PCR mix was manually 
transferred to the Rotor Gene Q MDx. Samples with invalid artus PCR results were 
retested until the result was valid, with a maximum of three testing rounds. For the in-
house PCR, DNA extraction was performed using the MagnaPure96 system (Roche 
Diagnostics, Almere, the Netherlands). In short, approximately half a pea size of feces 
was resuspended in 1 ml S.T.A.R. buffer (Roche, Diagnostics), supplemented with 
Precellys beads (Bertin Technology, France), mixed thoroughly by shaking on a Vibrax 
shaker (5 min, 2200 rpm) and centrifuged for 1 min at 14000 rpm. Of the supernatant, 
200 µl was used for nucleic acid (NA) extraction using the MP96 DNA and Viral NA 
Small volume kit yielding a final eluate of 100 µl. The in-house developed real-time 
PCR for the specific detection of the TcdB gene was tested in a multiplex assay with 
Phocine herpes virus as internal control as described previously  [25]. Samples with 
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a quantification cycle (Cq) value higher than 40 were considered negative. In addition, 
samples with an internal control Cq value that deviated more than 3.3 Cq values 
compared to the internal control Cq value of the negative control were considered 
inhibited. Due to a change in workflow of adding BSA to all our in-house PCRs 
with feces as sample material to decrease the inhibition rate, the last 142 samples 
were tested with addition of 5 mg/mL of the PCR enhancer bovine serum albumin 
(BSA)  [26].  
 
Table 1.   C.  difficile detection assays included in this this study 
 
 
GDH: Glutamate Dehydrogenase, tcdA: toxin A, tcdB: toxin B, cdtA and cdtB: binary toxin 
Discrepancy analysis 
Samples with discordant results were retested, except for positive results of the GDH 
ELFA because of an expected low specificity. An enriched TC was performed 
when three diagnostic tests were positive and the TC was negative. For enriched TC, 
half a pea size of feces was suspended in a cycloserin-cefoxitin-mannitol broth with 
taurocholate, lysozyme and cysteine (CCMB-TAL, Anaerobe Systems, Morgan Hill, 
CA). The enrichment broth was subcultured on CLO and CNA agar as described 
above, on day two and five. 
 
Assay type Assay Target(s) Supplier
Anaerobic culture C. difficile culture Identification by PCR with GDH  
as target
In-house [22]
Toxigenic culture C. difficile culture and  
PCR for toxin genes
Multiplex PCR with TcdA, TcdB, 
cdtA and cdtB (binary toxin) 
In-house [22]
Automated immunoassay Vidas GDH GDH Biomerieux, France
Nucleic acid amplification test Artus C. difficile QS-RGQ Kit CE TcdA and TcdB QIAGEN, Germany
Nucleic acid amplification test In-house C. difficile PCR TcdB In-house [25]
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Statistical analysis 
A GDH positive result was considered true positive or true negative, if the stool 
culture was positive or negative for  C.  difficile, irrespective of its toxin production. For 
both PCRs a positive result was considered true positive or true negative if the stool 
culture was positive or negative for toxigenic  C.  difficile. False positive and false negative 
test results were defined as discrepant results compared to the gold standard. 
Sensitivity and specificity of the tests were determined by the proportion positive, or 
negative respectively, correctly identified. The difference in both sensitivity and 
specificity between the toxin PCRs was determined using McNemar’s test for paired 
proportions. The sensitivity and specificity data were used to calculate the positive 
predictive value (PPV) and negative predictive value (NPV). Cq values of false positive 
results were compared with Cq values of true positive results using an independent 
student t-test. ROC curves were constructed for all index tests. Analyses were per-
formed using SPSS 23.0 and STATA version 12.1 statistical software.  
 
Results 
In total, 765 feces samples of 581 unique patients were included in the evaluation, of 
which 39 (5.1 %, 95 % CI: 3.8-6.9) were positive for the presence of  C.  difficile by culture; 
24 (3.1 %, 95 % CI: 2.1-4.6) contained toxigenic  C.  difficile. All 765 samples were tested by 
toxigenic culture, GDH ELFA and in-house PCR, but due to insufficient sample volume 
of one sample, 764 samples were tested with the artus PCR. Sensitivity, specificity, PPV 
and NPV data of the various tests are depicted in Table 2. The artus PCR had the highest 
sensitivity of 95.8 %. The mean Cq value in true positive samples was 27.5 for TcdA and 
28.4 for TcdB. The in-house PCR showed an sensitivity of 87.5 %, with a mean TcdB Cq 
value of 29.3 in true positive samples. The difference in sensitivity between artus PCR 
and the in-house PCR was not significant (p=0.5). The GDH ELFA had a sensitivity of 
87.2 %. The mean relative fluorescent unit (RFU) of the GDH ELFA in true positives was 
11.7 (SD 8.11). Specificities were 98.8 %, 93.4 % and 91.2 % for the in-house PCR, artus 
PCR and GDH test, respectively. The specificity of the in-house PCR was significantly 
higher than the artus PCR (p<0.000001). The NPV was in general very high and ranged 
from 99.3 % to 99.9 % for all assays. The PPV, on the other hand, was only 31.9 % for the 
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artus PCR and 34.7 % for the GDH ELFA. In comparison to these former two tests, the 
in-house PCR had a higher PPV of 70.0 % (Table 2). Receiver operating characteristics 
(ROC) curves were made for the performances of the individual tests. For GDH ELFA, 
artus PCR and in-house PCR, the diagnostic accuracy as given by the area under the 
curve was 0.8918, 0.9467 and 0.9314, respectively (supplemented Figure 1).  
 
Table 2. Comparison of various  C.  difficile detection assays in comparison with 
culture of toxigenic and non-toxigenic  C.  difficile as gold standards. The sensitivity 
and specificity are given as percentages, and the 95 % confidence interval (95 % CI) 
values are shown in parentheses. 
 
 
1   GDH ELFA was compared with  C.  difficile culture, Artus and in-house PCR were compared with toxigenic culture.  
2   Four of false negative samples were positive in all tests (GDH, Artus, in-house PCR) 
Of 623 samples tested with the in-house PCR without the addition of BSA, 61 
(9.8 %) showed inhibition which disappeared at a 1:10 dilution of the sample. Of 142 
samples tested by the in-house PCR with addition of BSA, no inhibition was observed. 
Of 764 samples tested by artus, 40 (5.2 %) showed inhibition which disappeared with 
repeated testing. Additionally, 26 (3.4 %) invalid artus results were obtained due to TcdA 
Cq value above accepted range (n = 4), a TcdB Cq value above accepted range (n = 16), 
TcdA uncertain (n = 3) or TcdB uncertain (n = 3). 
A discrepancy analysis was performed on discordant results and is displayed in 
Table 3. Four of 741 TC negative samples tested positive with all three assays (GDH 
ELFA, in-house PCR and artus PCR), suggesting a false negative result of the TC. One 
of these 4 feces samples was positive for culture of toxigenic  C.  difficile using the 
enriched TC method, suggesting that a very low number of  C.  difficile was present. Two 
(Toxigenic) 
Culture 1
Assay Pos Neg Sensitivity (%) (95% CI) Specificity (%) (95% CI) PPV (%) NPV (%)
GDH positive 34 642 87.2 (72.6-95.7) 91.2 (88.9-93.1) 34.7 99.3
GDH negative 5 662
Artus positive 23 49 2 95.8 (78.9-99.9) 93.4 (91.3-95.1) 31.9 99.9
Artus negative 1 691
In-house positive 21 9 2 87.5 (67.6-97.3) 98.8 (97.7-99.4) 70 99.6
In-house negative 3 732
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Table 3. Results of first and second tests  
After resolving of the four TC negative/other tests positive samples, results were as 
follows: two false positive in-house PCR results retested positive (Cq values 28 
and 31.6 respectively), while three false positive in-house PCR results could not 
be confirmed with retesting. All 45 false positive artus samples retested negative. 
All remaining 60 GDH false positive samples were not retested. Two out of three 
false-negative in-house PCR results retested positive. One in-house PCR and artus 
false negative sample remained negative upon retesting by both PCRs, while both 
in-house and artus PCR on the cultured strain were positive. Two GDH ELFA negative 
sample retested positive, while two remained negative. 
 
The green color indicates a false (positive or negative) result  
ND: not detected 




First tests Second test(s)
GDH in-house artus culture TC GDH in-house artus enriched TC
617 – – – – – ND ND ND ND
56 + – – – – ND ND ND ND
40 – – + – – ND ND – ND
19 + + + + + ND ND ND ND
12 + – – + – ND ND ND ND
4 + – + – – ND ND – ND
2 – ++ – – – ND – ND ND
2 – + – – – ND + ND ND
2 – – – + – + ND ND ND
1 – + + + + + ND ND ND
1 – + + + + – ND ND ND
1 – – + + + – + ND ND
1 + – + + + ND + ND ND
2 + + + – – ND ND ND ND
1 + + + – – ND ND ND +
1 + + + – – ND + + –
1 + + + + – ND – – –
1 + – – + + ND –* –* +
1 – – ND – – ND ND ND ND
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other TC negative results could be explained by vancomycin treatment at time of feces 
sampling, which inhibits the growth of  C.  difficile. No clear explanation was found for the 
remaining false negative TC feces sample. All 45 false positive artus samples tested 
negative with retesting. The artus PCR flags a result as real positive when one or both of 
the toxin genes are below a certain Cq value. Of these 45 TC negative but positive 
flagged artus results 21 were positive only for TcdA, and seven only for TcdB, whereas 17 
were both TcdA and TcdB positive. The mean Cq values of the false positives were higher 
(TcdA 33.1, TcdB 33.4) than the Cq values of artus true positives (TcdA 27.8, TcdB 28.4). No 
discrepancy analysis was performed on the remaining 60 GDH false positive samples 
(Table 2; 60 minus four as mentioned above) due to the expected low specificity. One 
feces sample tested negative by in-house PCR as well as the artus PCR and remained 
negative with retesting. However, the toxigenic cultured strain was positive tested by both 
PCRs, suggesting that a very low number of  C.  difficile was present in the feces. After the 
discrepancy analysis the sensitivity, specificity, PPV and NPV were 96.6 %, 100 %, 100 %, 
99.9 % and 96.9 %, 99.7 %, 93.3 % and 99.7 % of artus and in-house PCR respectively.  
The distribution of PCR ribotypes isolated from asymptomatic patients in this 
cohort is displayed in Figure 1. Five strains could not be ribotyped since the profiles of 
the corresponding strains were not present in the National Reference Laboratory of the 
Netherlands. 
 
Figure 1. Distribution of  C.  difficile ribotypes isolated from asymptomatic patients 
displayed in a pie chart. Indicated in red (arched) are the toxigenic strains, in blue (dotted) the 
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Discussion 
The aim of this study was to compare two molecular assays (artus  C.  difficile PCR, 
in-house TcdB PCR) and  C.  difficile GDH ELFA with (toxigenic) culture of  C.  difficile as 
gold standards to detect asymptomatic colonization.  
In this study, 5.1 % of the patients attending a tertiary care hospital was positive 
with  C.  difficile and 3.1 % contained a toxigenic  C.  difficile. Other studies testing feces 
samples for the presence of asymptomatic colonization of  C.  difficile at admission (or 
collected feces within 72 hours after attending the hospital), reported a higher 
prevalence of 7.5 %-15.7 % toxigenic  C.  difficile  [1, 2, 10, 27-30]. The lower prevalence rate in 
our study is probably related to the overall low prevalence of  C.  difficile and CDI in the 
Netherlands. A recently completed cross-sectional study among 2,494 healthy adults 
in the Netherlands revealed a prevalence of toxigenic  C.  difficile of 1.2 % in the 
community (submitted).  
The sensitivity and specificity of the automated VIDAS GDH ELFA in comparison 
to  C.  difficile culture were 87.2 % and 91.2 %, respectively. Davies et al, studied the 
 performance of the same GDH ELFA in diarrheal samples submitted for  C.  difficile 
testing, and reported a higher sensitivity of 95.8 % and a similar specificity of 91 % [31]. 
The lower sensitivity found in our study could be due to presence of lower numbers 
of  C.  difficile in feces samples of asymptomatically colonized patients than in patients 
with CDI  [18]. However, we don’t exclude the possibility that the percentages change 
when larger number of feces samples are tested. An alternative explanation for the 
lower sensitivity rates in our study are the formed feces samples that we included, 
instead of diarrheal samples.  
The artus PCR and the in-house PCR were compared with TC and revealed 
sensitivities of 95.8 % and 87.5 % respectively, though this difference in sensitivity rate 
was not significant. In contrast, the artus PCR was statistically less specific in 
comparison with the in-house PCR (93.8 % versus 98.8 %). Since the artus PCR 
positive, TC negative samples could not be confirmed by retesting, the results indicate 
false positivity. This was supported by the considerably higher Cq values of TcdA and 
TcdB for the false positive test results than for true positives. A hypothetical algorithm 
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to enhance the specificity of artus is considering the artus PCR result only positive 
when TcdA as well as TcdB are positive. This, resulted in a specificity of 97 %, and 
a subsequent PPV of 51 %, while remaining the high sensitivity of 95.8 %. However, in 
the rare event a patient is colonized with a toxin A negative, toxin B positive  C.  difficile 
strain  [32, 33], the new strategy will not identify this strain. The test results of artus 
showed less inhibition rates than the in-house PCR, 8 % versus 5.3 %, however 
inhibition of the in-house PCR was overcome by adding the PCR enhancer BSA  [26]. 
An additional 3.5 % of artus tested samples gave invalid test results, largely because of 
Cq values above the accepted range. Because of invalid or inhibited results, 8.7 % of 
the feces samples needed retesting by the artus PCR. The performance of the artus 
PCR in this study resembled the results in loose stool samples submitted for CDI 
testing as reported by Jazmati et al  [34]. In a collection of 201 stools specimens all 28 
positive TC samples were detected by the artus PCR (sensitivity 100 %), but the 
specificity, similar to this study, was relatively low (89.5 %)  [34]. They stated that the 
lower specificity could largely be explained by a higher sensitivity of the artus PCR than 
TC. However, we did not share this observation. Our hypothesis is that the false positive 
results were based on DNA contamination, as none of the other diagnostic tests were 
positive in these samples. The contamination route can be explained by the manual 
handling of the tubes containing the isolated DNA and PCR mix to the Rotor Gene, 
which required placing caps on tiny tubes, arranged very close to each other. The 
sensitivity of both PCR’s and specificity of the in-house PCR are in agreement with 
the NAAT test performance in symptomatic  C.  difficile patients, as mentioned in the 
recently published ESCMID guidance document with an overall sensitivity of 95 % and 
specificity of 98 % in comparison with TC  [20]. A discrepancy analysis was performed, 
mainly to clarify why conflicting test results were obtained. The test characteristics that 
were calculated after resolving discrepant results could thereby be biased in favor of 
the index tests and should be considered with caution.  
For CDI diagnosis, the use of a two-step algorithm is recommended [20]. After 
a first sensitive test which reliably classifies non-diseased patients, a more specific 
test is applied as a second test to discern true positives from false positives. For 
diagnosis of colonized patients, a similar approach could be used. All three assays 
that we analyzed in this study had high NPV and would therefore be useful as a first 
screening test. Thereafter, confirmation of positive samples by a specific test could be 
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recommended. This specific test could be a NAAT or toxigenic culture when GDH was 
used as a first screening test. A second algorithm could be screening by NAAT and 
confirmation by TC. 
The ribotypes of asymptomatic carriers found in this study, do not differ from 
the ribotypes found among CDI patients  [35]. This supports the hypothesis that 
asymptomatic carriers and CDI patients share a common source, or transfer  C.  difficile 
to each other irrespective of the PCR ribotype. Furthermore only one of 24  C.  difficile 
strains belonged to the epidemic ribotype 078 and no 027 strains were detected. Other 
studies confirm this finding  [36 -38], supporting the hypothesis that epidemic strains 
seldom lead to asymptomatic colonization.  
Many studies report on the performance of  C.  difficile diagnostic assays in patients 
with presumed CDI, but only a few report on the application of diagnostic tests in 
patients with asymptomatic  C.  difficile colonization  [1, 2, 15, 27, 28]. The studies in asympto -
matically colonized patients vary greatly in patient inclusion criteria, tested material 
and applied diagnostic and gold standard tests. For instance, a great number of the 
studies only test rectum swabs, or use a combination of stool samples and rectum 
swabs  [4, 8, 18, 27, 28, 36, 39]. Guererro et al. showed that asymptomatic carriers have lower 
numbers of  C.  difficile in their rectal swab than CDI patients, indicating that stool 
samples should be preferred  [4]. Furthermore, a mix of diagnostic screening tests have 
been applied to detect  C.  difficile, frequently subdivided into assays to recognize toxi-
genic or non-toxigenic strains  [20]. However, a comparison of various diagnostic tests 
with a reference method to detect asymptomatic colonization of  C.  difficile has not been 
studied before.  
Our study has a few limitations. An important limitation is the low prevalence rate 
of asymptomatic  C.  difficile colonization, which resulted in a low PPV of 31.9 to 70 % for 
the different tests. However, this prevalence rate provides the most precise information 
on the performance of the test in our patient population. All tests would have better 
PPVs in a population with higher prevalence rates of  C.  difficile colonization, or when 
a selection of samples is tested when a predictive model for  C.  difficile colonization 
becomes available. A second limitation may be the freeze-thaw step which presumably 
can lower the sensitivity, though we performed all tests immediately after thawing, 
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except for the discrepancy analysis. In addition, no published reports indicate that free-
thawing affect the performances of diagnostic PCRs for bacterial pathogens.  
In conclusion, this study is the first which evaluates the use of three different assays 
for detection of asymptomatic  C.  difficile colonization in stool samples and compares 
it to their gold standards. In our low endemic setting of asymptomatically colonized 
patients all three assays (i.e. GDH ELFA, artus PCR and in-house PCR) can be applied 
as a first screening test as they display a very high NPV. The positive predictive values 
of these tests were suboptimal and therefore these assays are not suitable as stand-
alone tests in a low prevalence setting.  
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Supplementary Figure 1. Receiver operating characteristics (ROC) curves were for 
the performances of the individual tests.  
For GDH ELFA (top), artus PCR (middle) and in-house PCR (bottom), the diagnostic accuracy 
as given by the area under the curve was 0.8918, 0.9467 and 0.9314, respectively. 
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Abstract 
The emergence of the plasmid-mediated mcr colistin resistance gene in the 
community poses a potential threat for treatment of patients, especially when 
hospitalized. The aim of this study was to determine the prevalence of all 
currently known mcr mediated colistin resistance gene in fecal samples of 
patients attending a tertiary care hospital. From November 2014 until July 
2015, fecal samples of patients attending the Leiden University Medical Center 
were collected and screened for presence of mcr using real-time PCR. Two of 
576 patients were positive for mcr-1, resulting in a prevalence of 0.35 %, 
whereas no mcr-2 was found. One of these samples was culture negative, the 
second sample contained a blaCMY-2 and mcr-1 containing E. coli. This strain 
belonged to Sequence Type 359 and serotype O177:H21. The mcr-1 containing 
E. coli was phenotypically susceptible to colistin with a MIC of ≤ 0.25mg/l, due 
to a 1329bp transposon IS10R inserted into the mcr-1 gene as identified by 
WGS. This prevalence study shows that mcr-1 is present in low levels patients 
out of the community attending a hospital. Furthermore the study underlines 
the importance of phenotypical confirmation of molecular detection of a mcr-1 
gene. 
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Introduction  
Colistin, also known as polymyxin E, is highly active against most Gram-negative 
bacteria  [1]. However, its nephrotoxicity and neurotoxicity has prevented the use of 
colistin in regular patient treatment  [2]. Therefore, colistin usage was mainly limited to 
veterinary medicine for treatment of gastrointestinal infections in food producing 
animals  [3]. In the Netherlands, colistin is frequently used for selective gut deconta -
mination in Intensive Care Unit (ICU) and stem cell transplantation patients  [4, 5]. 
Colistin regained new worldwide interest after the emergence of multidrug resistant 
(MDR) Enterobacteriaceae and is nowadays used as a last resort antibiotic for infections 
caused by MDR Enterobacteriaceae. The recent finding of a plasmid harbouring a novel 
colistin resistance gene, mcr-1 and mcr-2, is therefore of concern  [6, 7]. 
The mcr-1 colistin resistance gene is predominantly found in Enterobacteriaceae, and 
results in a moderate level of resistance, with MIC values varying from 4 to 16 mg/l  [8, 9]. 
The prevalence of mcr-1 varies considerably and ranges from 0.02 % to 20.6 % in live-
stock, 1.3 % to 19 % in retail meat and 0.08 % to 2 % in hospitalized patients  [10 -14]. The 
worldwide distribution of the mcr-1 gene and a relatively high prevalence of mcr-1 
mediated colistin resistance in livestock and retail meat suggests food animals as 
reservoir for transmission to humans  [8]. Until now, almost exclusively Extended 
Spectrum Beta-Lactamase (ESBL) producing or colistin resistant isolates have been 
screened for the presence of mcr-1. A number of reports of mcr-1 in the United States 
of clinical and ESBL-negative strains indicate that the true extent of mcr-1 prevalence 
amongst unselected Gram-negatives may be highly underestimated  [15, 16]. The mcr-2 
colistin resistance gene had 76.7 % nucleotide identity to mcr-1 and had so far only 
been found in colistin-resistant E. coli isolates identified from porcine and bovine  [7]. 
Studies about human fecal carriership of mcr-1 in the community are limited, 
and so far only been described in China; in healthy volunteers (prevalence of 19 of 
2923 = 0.65 %), in a public bacterial metagenome dataset before 2010 (prevalence of 
3/1267 = 0.24 %)  [17, 18], and in Dutch travellers returning from Asia, South America or 
Africa (prevalence of 0.95 % - 4.9 %)  [19, 20]. Recently, no mcr genes could be detected 
in the stool of 1091 healthy Swiss individuals  [21]. Epidemiological data on the 
prevalence of mcr-1 in the community attending a hospital are lacking and the risk of 
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colonized patients to spread mcr-1 positive bacteria is unknown. Therefore, the aim of 
this study was to determine the prevalence of mcr mediated colistin resistance gene in 
fecal samples of patients attending a tertiary care hospital.  
Material and methods 
Patients and specimens 
Between November 2014 and July 2015, fecal samples were obtained from patients 
on admittance to internal medicine and surgical wards, and from patients attending 
the kidney transplant outpatient clinic of the Leiden University Medical Center 
(LUMC) in the Netherlands. These wards were selected for their relative high patient 
turn-over, enabling more rapid inclusion of sufficient patients attending our hospital. 
The fecal samples were originally used for a study to define the role of Clostridium 
difficile in asymptomatic colonised patients at admittance to the hospital. The samples 
were processed within 72 hours of arrival at the laboratory and were subsequently 
stored at -20°C, without addition of glycerol. These samples obtained for  C.  difficile 
screening were also used for screening of the mcr gene. The medical ethical committee 
“Medisch Ethische Toetsings Commissie” of the LUMC waived the need for consent for 
the additional analysis on these fecal samples. 
DNA extraction and real-time PCR 
After thawing the stored fecal samples, DNA extraction was performed using the 
MagnaPure96 system (Roche Diagnostics, Almere, Netherlands). In short, approxi -
mately 0.3 to 0.4 gram (half a pea) feces was resuspended in 1 mL S.T.A.R. buffer 
(Roche Diagnostics, Almere, The Netherlands), supplemented with Precellys beads 
(Bertin Technology, France), mixed thoroughly by shaking on a Vibrax shaker (5 min, 
2200 rpm) and centrifuged for 1min at 14000 rpm. Of the supernatant, 200µl was used 
for nucleic acid (NA) extraction using the MP96 system and Viral NA Small volume 
kit (Roche Diagnostics) yielding a final eluate of 100µl. To monitor the NA extraction 
process and the presence of potential PCR inhibitors in the eluate, an universal inter-
nal control Phocine Herpes Virus (PhHV) was used  [22]. Initially real-time PCR for the 
specific detection of the mcr-1 gene was tested in a multiplex assay with PhHV as 
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described previously  [23]. After the report of Xavier et al., describing mcr-2, a generic mcr 
real-time PCR assay for the detection of both mcr-1 and mcr-2 was developed and 
used to screen for the presence of additional mcr-2 containing samples (Table 1)  [7]. 
 
Table 1. Primers and probe used to screen for the presence of mcr-genes 
 
 
Culture and colistin susceptibility testing 
To further characterize mcr containing isolates, mcr positive fecal samples were 
cultured on commercially available sheep blood-, CNA- (colistin and naladixic acid 
containing agar) and CLED- (cysteine lactose electrolyte deficient) medium (Bio -
Mérieux, Marcy l’Etiole, France) both directly and after enrichment in a Tryptic Soy Broth 
with and without colistin (2 mg/l). All morphological different aerobic  Gram-negative 
bacteria were identified by MALDI-TOF MS (Microflex, Bruker Daltonics, Bremen, 
Germany) and tested for the presence of mcr-1 by real-time PCR as described earlier. All 
bacterial isolates were also tested for colistin resistance with VITEK2 (card N199, 
BioMérieux, Marcy l’Etiole, France) and Sensititre colistin microdilution assay (Sensititre, 
TREK Diagnostic Systems, Inc., Cleveland, OK), using EUCAST breakpoints for Entero -
bacteriaceae, which interprets a MIC of ≤ 2 mg/l as susceptible and > 2mg/l as resistant. 
Whole Genome Sequence analysis  
Whole Genome Sequence analysis of mcr-1 containing isolates was performed to 
further characterize the E. coli strain including the plasmid carrying the mcr-1 gene and 
other genes associated with antimicrobial resistance  [6]. The genome sequence of the 
mcr-1 containing isolate was determined using the Pacific Biosciences RSII system from 
DNA prepared by the Qiagen Genomic Tip 500/G kit (Qiagen, Hilden, Germany) follow-
ing the manufacturer’s recommendations. De novo assembly was performed using 
SMRT®Analysis v2.3.0 (PacBio’s bioinformatics software suite) with expected genome 
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size of 5 Mbp and coverage of 30. The assembled sequence was analysed using 
Geneious software V8.0.5 (Biomatters, Auckland, New Zealand) and the online tools 
Resfinder, MLST, SeroTypeFinder and Plasmidfinder (http://genomicepidemiology.org/). The 
plasmid sequence was analysed in DNA plotter to generate a circular DNA map.  
Results 
Mcr prevalence and culture of mcr containing isolates 
A total of 621 fecal samples of 576 unique patients were screened for presence of 
the mcr genes by real-time PCR. The median age of patients at submission of their 
stool was 62 years (range 18-93). Two samples of two different patients (0.35 %) were 
positive for mcr-1 in real-time PCR with quantification cycle (Cq) values of 31 and 17, 
respectively (S1, Table). Additional testing with the mcr-generic real-time PCR assay 
confirmed this finding and did not find extra positive samples. A mcr-1 containing E. coli 
isolate was cultured from the second fecal sample (Cq 17) only, in subcultures of the 
enrichment broth without colistin. Remarkably, despite the presence of mcr-1 gene 
sequences, this E. coli isolate tested colistin susceptible (MIC <0.25 mg/l), which was 
confirmed in triplicate by both VITEK2 and the Sensititre assay. The antimicrobial 
susceptibility results and the corresponding genes coding for resistance are depicted 
in Table 2. Because of the decreased susceptibility to cephalosporins, the production 
of ESBL was tested phenotypically using the combination disk diffusion test, with 
a negative result. Subsequent testing for an AmpC β-lactamase gene by an in-house 
developed real-time PCR assay showed the presence of the blaCIT gene. 
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Table 2. Antibiotic phenotype with the corresponding molecular resistance of 
cultured mcr-1 containing E. coli 
The phenotype was tested with VITEK2 and a colistin microdilution assay, using EUCAST breakpoints. Molecular resistance 
determined with whole genome sequencing. 
 
 
Whole Genome Sequence analysis  
WGS analysis showed that the mcr-1 gene found in the colistin susceptible E. coli 
isolate had a homology of 100 % with the first published mcr-1 gene sequence  [6]. 
However, the reading frame was disrupted by a 1329bp long IS10R transposon 
(Figure 1). WGS analysis of the E. coli resulted into six contigs with a total length of 
~5.5 Mbp (accession numbers: CP016546-CP016551, S2 Table). The largest contig was 
~5.1 Mbp, covering the expected E. coli genome size, whereas analysis of the remaining 
five contigs (length between ~7.3 kb and ~126 kb) with PlasmidFinder 1.3 indicated the 
presence of plasmids IncX4 (~50 kb), IncI2 (~86 kb) , IncB/O/K/Z (~91 kb) and IncY 
(~126 kb). WGS analysis also revealed the presence of two identical IS10R containing 
mcr-1 genes located on the same IncX4 plasmid. Multi Locus Sequence Typing 
(MLST) and serotype analysis showed that the E. coli belonged to Sequence Type (ST) 
Antibiotic MIC (mg/l) Interpretation Encoding resistance genes
Ampicillin ≥ 32 R blaTEM-1B
Amoxicillin/ Clavulanic acid ≥ 32 R blaTEM-1B
Cefuroxime 32 R blaCMY-2
Cefotaxime 4 R blaCMY-2 
Cefoxitin ≥ 32 R blaCMY-2
Ceftazidime 16 R blaCMY-2 
Cefepime ≤ 1 S
Ciprofloxacin ≥ 4 R
Colistin ≤ 0.25 S Mcr-1 inserted by IS10R transposon
Gentamicin ≤ 1 S aph(3’)-lc, strB, strA, aadA5
Meropenem ≤ 0.25 S
Nitrofurantoin ≥ 320 S
Piperacillin/Tazobactam ≤ 4 S
Tetracycline 128 R tetB
Tobramycin ≤ 1 S aph(3’)-lc, strB, strA, aadA5
Trimethoprim/Sulfamethoxazole ≥ 4 R sul1, sul2, dfraA17
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359 and serotype O177:H21. With ResFinder, the AmpC belonging to the CIT-group, as 
detected by the in-house AmpC real-time PCR, was confirmed to be present as 
blaCMY-2, located on the plasmid designated as IncB/O/K/Z. Additional genes 
associated with antimicrobial resistance detected in the sequence with their resulting 
antimicrobial phenotype are depicted in Table 2.  
 
Figure 1. Circular presentation of the mcr-1 containing IncX4 plasmid in the 
colistin susceptible E. coli 
In green the mcr-1 sequence. In red the IS10R insertion sequence, interrupting the mcr-1 gene at 
position 572. Arrows indicate open reading frames (ORFs), dark blue ORFs with annotation, light 
blue ORFs without annotation (hypothetical protein). Numbers indicate nucleotide positions. 
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Patient characteristics 
Both mcr-1 positive patients were kidney transplant patients. The mcr-1 positive stool 
sample from which no mcr-1 containing isolate could be cultured belonged to a patient 
admitted to the acute care ward due to bacteremia with a colistin resistant Salmonella 
enterica serotype Dublin (MIC ≥4 mg/l). The S. enterica isolate tested negative with the 
specific mcr-1 PCR. The feces with the colistin susceptible mcr-1 E. coli belonged to 
a patient attending the kidney transplant outpatient clinic. No epidemiologic link could 
be established between the two patients. The patients did not have a history of recent 
travelling and had not been treated with colistin recently. Also, none of the patients 
had developed an infection with a mcr-1 containing isolate.  
Discussion 
To assess the risk of mcr introduction into our academic tertiary care hospital, the 
prevalence of mcr in fecal samples obtained from patients attending our hospital 
was investigated and found to be 0.35 % (n=2) of the 576 tested patients for mcr-1, 
whereas no mcr-2 was found. This low prevalence is in accordance with earlier studies 
performed in asymptomatic carriers in the European community, ranging from 0 % to 
0.92 %  [19 -21]. However, studies on mcr-1 prevalence in asymptomatic carriers attending 
a hospital are lacking. Infections in hospitalized patients with mcr-1 positive isolates 
have been reported in a number of countries, ranging from 0.24 % to 1.4 % depending 
on the used denominator  [6, 10, 24]. In line with earlier studies, no mcr-2 containing 
samples were detected in this study  [21, 25]. 
One of the mcr-1 positive fecal samples from the current study could not be 
confirmed by culture, most likely due to the fecal storage without glycerol at -20°C for 
one year which reduces the viability of Gram-negative bacteria. The fecal sample of 
the second patient contained a mcr-1 positive E. coli with a colistin MIC of <0.25 mg/l. 
WGS analysis of the isolate revealed the presence of IS10R, encoding for an active 
 transposon commonly found in Enterobacteriaceae  [26]. Introduction of this IS10R into 
the mcr-1 gene resulted in a non-functional mcr-1 gene. Interestingly, two identical mcr-
1 genes with IS10R duplicates were located on IncX4, a plasmid that has been 
frequently observed in combination with mcr-1  [10, 12, 27, 28]. The mcr-1 containing E. coli 
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belonged to ST359, this ST with a very similar antimicrobial resistance pattern is earlier 
described on chicken retail meat in Denmark  [10]. Though we tested all morphological 
different Gram negative Enterobacteriaceae for the presence of mcr-1, we cannot exclude 
the possibly that more than one mcr-1 containing bacterial species was present in the 
positive tested feces samples.  
Pham Thanh et al. reported the first mcr-1 positive but colistin susceptible isolate, 
a Shigella sonnei, that was based on a truncated mcr-1 gene caused by a 22bp dupli -
cation  [29]. A colistin susceptible mcr-1 containing E. coli isolate with unknown cause 
of the susceptibility was reported in August 2016 by Liassine et al.  [25]. Although the 
altered mcr-1 gene of the Shigella sonnei could be re-activated by conjugation experi-
ments resulting in a colistin resistant phenotype, the mcr-1 gene interrupted with IS10R 
containing E. coli of this study cannot be re-activated, as upon removal of an IS trans-
poson two remaining nucleotides would disrupt the reading frame of the gene  [30]. 
These studies underline the importance of phenotypical confirmation after molecular 
screening, as respectively the E. coli and Shigella sonnei isolate showed colistin 
suscepti bility despite the presence of mcr-1 gene sequences that had been detected 
by PCR amplification.  
The mcr-1 positive E. coli isolate showed resistance to third generation cephalo-
sporins due to the presence of a AmpC β-lactamase gene, blaCMY-2, as has previously 
been found by Prim et al.  [24]. As almost all earlier studies only screened for the 
presence of mcr-1 in ESBL producing isolates, the true extent of the mcr-1 prevalence 
may be underestimated  [10, 11, 14, 19, 31, 32].  
Most likely, the kidney transplant patients acquired the mcr-1 gene in the community, 
for instance by consumption of mcr-1 containing retail meat  [6, 10, 12, 13, 32]. Spread of the 
mcr-1 gene in the community and successively in the hospital would pose a threat to 
patients developing an infection with mcr-1 containing multidrug resistant isolates. 
Enterobacteriaceae resistant to both carbapenems and colistin by the presence of 
plasmid mediated mcr-1 have already been reported  [17, 31, 33-35]. Therefore, screening for 
and isolation of mcr-1 containing patients should be considered. Prudence and close 
monitoring is necessary, especially when selective gut decontamination with colistin for 
ICU and hematological stem cell patients is common practice.  
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In conclusion, the current prevalence of mcr-1 suggests that spread from the 
community into the hospital environment is low, but cannot be excluded. Furthermore 
the finding of a colistin susceptible, mcr-1 containing E. coli underlines the importance 
of phenotypical confirmation after molecular screening. 
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Spread of ESBL-producing 
Escherichia coli in nursing home 
residents in Ireland and 
the Netherlands may reflect 
infrastructural differences  
Low MDRO rate in nursing home residents
Chapter 
Chapter 4. Spread of ESBL-producing 
Escherichia coli in nursing home residents 
in Ireland and the Netherlands may reflect 
infrastructural differences 
Abstract  
A prevalence study in two nursing homes (the Netherlands and Ireland) 
found four (11 %) Dutch and six (9 %) Irish residents colonised with 11 
extended-spectrum B-lactamase (ESBL)-producing Escherichia coli, ten 
containing CTX-M-15. Four Dutch isolates, from three residents of the same 
ward belonged to E. coli O25:H4, sequence type (ST) 131 and were part of the 
same cluster type by whole genome sequencing. Four Irish residents on 
three different wards were colonised with an identical E. coli O89:H9, ST131, 
complex type 1478. Cross-transmission between three Irish wards may reflect 
differences in nursing home infrastructure specifically communal areas and 
multi-bedded resident rooms. 
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Introduction  
Nursing home residents have multiple risk factors for colonisation with multidrug 
resistant organisms (MDRO), and are potential reservoirs for transmission  [1]. Frequent 
contact between residents due to communal living, high frequency of healthcare contact 
and factors that facilitate MDRO spread such as incontinence present additional 
opportunities for transmission. MDRO prevalence varies considerably in nursing homes 
from 55 % colonisation with extended spectrum beta-lactamase (ESBL)-producing 
Escherichia coli and 3 % vancomycin resistant enterococci (VRE) colonisation in 
Ireland  [2], to 4.2 % ESBL-producing E. coli colonisation in the Netherlands  [3]. 
Clostridioides difficile colonisation in nursing home residents also varies from 4 – 51 %  [4]. 
We conducted a prevalence study of  C.  difficile and MDRO colonisation (specifically, 
VRE, ESBL and carbapenemase-producing Entero bacteriaceae (CPE)) in two nursing 
homes, one in the Netherlands and the other in Ireland to identify characteristics 
associated with carriage and risk factors for cross-transmission. 
Materials and methods 
Full time residents of two nursing homes under the governance of the investigators 
hospitals and in the investigators catchment area, one in the Netherlands and one in 
Ireland, were invited to participate. Written informed consent by the resident or his/her 
proxy was required. The nursing homes were similar to previously studied nursing 
homes in terms of infrastructure and resident demographics  [5]. The Dutch nursing 
home consisted of 131 beds in eight wards varying in size (12 – 35 beds) that consisted 
of single en-suite rooms, except for three double rooms for couples. All wards had 
a separate dining area and the nursing home had a large communal recreation and 
physiotherapy area. The Irish nursing home consisted of 100 beds in four, identical 
25-bed wards with one common recreation and dining area. Each ward consisted of 
a mixture of single (n=17), double (n=2) and four-bed (n=1) en-suite rooms.  
Demographic and MDRO risk factor data (care load indicators, hospitalisation, anti-
biotics, urinary catheter use, wounds, pressure sores, previous MDRO or CDI) were 
collected on each consenting resident using standardized definitions  [5] in February 
2017 (6-17 February in the Netherlands, 6-10 February in Ireland). A corresponding 
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faecal specimen was also collected, stored at 4°C, processed for multidrug-resistant 
Enterobacteriaceae, VRE and  C.  difficile within 72 hours of arrival to the laboratory and 
subsequently stored at -20°C.  
Ethical approval was granted by the medical ethical committee “Medisch Ethische 
Toetsings Commissie” of Leiden University Medical Center (no. P16.039) and the 
Beaumont Hospital Ethics (Medical research) committee.  
Following national recommendations, Dutch faeces samples were enriched in 15ml 
of Tryptic Soy Broth and incubated for 18 hours at 35oC prior to plating on ChromID 
ESBL, VRE agar and MacConkey tobramycin agar (bioMérieux, Marcy l’Etiole, France) 
for 48 hours at 35oC. In Ireland, faeces were directly inoculated on identical agar plates. 
Isolates were identified by the BD Bruker MALDI-TOF Biotyper (Microflex, Bruker 
Daltonics, Bremen, Germany). Antibiotic susceptibility testing was performed by 
VITEK2 (The Netherlands; card N199, bioMérieux) or BD PhoenixTM automated AST 
system (Ireland; BD Diagnostics), using the European Committee of Antimicrobial 
Susceptibility Testing breakpoints. ESBL production was confirmed by a double disk 
method. Specimens were screened for the presence of CPE and isolates with 
a meropenem minimum inhibitory concentration >0.25 mg/L (Etest, bioMérieux) 
investi gated by an in-house multiplex PCR to detect KPC, VIM, NDM, OXA-48 and 
IMP.  C.  difficile was detected as previously described  [6], and suspected colonies tested 
by MaldiTOF (Ireland) or an in-house GDH PCR (the Netherlands)  [6].  
Whole genome sequence analysis (WGS) analysis was performed to further 
characterize ESBL-producing E. coli isolates from both nursing homes at GenomeScan 
(Leiden, the Netherlands). Genome sequences were determined using the Illumina 
HiSeq 4000 platform (Illumina, San Diego, CA) from DNA prepared by the 
QIAsymphony DSP Virus/Pathogen Midi kit (Qiagen, Hilden, Germany) following 
the manufacturer’s recommendations. Sequence libraries were prepared using 
NEBNext® Ultra™ II DNA Library Prep Kit for a 150 bp paired-end sequencing. All raw 
sequencing data was submitted to the European Nucleotide Archive (ENA) under 
accession numbers ERR3151305 - ERR3151315. Core-genome Multi Locus Sequence 
Typing (cgMLST) was performed using SeqSphere+ software version 5.1.0 (Ridom 
GmbH). The number of targets for E. coli is 2513 with a Cluster-Alert distance of 10. 
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A minimum spanning tree based on the generated complex types was created in 
SeqSphere and expanded by uploading seven known complete genomes of E. coli 
ST131 (accession numbers: CP021179, CP021454, NC022648, CP014316, CP006784, 
CP010876, HG941718). The web-based tools ResFinder and RGI/CARD were used to 
determine antibiotic resistance genes. 
 
Statistical analysis was performed using SPSS 23.0 and STATA SE version 15.1 
(StataCorp, Texas, US). Numerical data were compared with an unpaired t-test. For 
categorical data, an odds ratio (OR) was calculated using logistic regression and 
presented with a 95 % confidence interval (95 % CI). For statistical comparisons, 
a p- value below 0.05 was considered significant. 
Results  
Data and a corresponding faeces specimen was collected from 37/64 (57.8 %) 
Dutch and 67/86 (77.9 %) Irish residents. (Table 1). One Dutch resident had previous 
VRE colonisation, whereas 27 Irish residents were previously MDRO colonised (17 
methicillin resistant Staphylococcus aureus, seven VRE, three ESBL-producing E. coli). 
Dutch residents were less likely to have received an antibiotic and be hospitalised in 
the previous six months (OR 0.31, CI 0.14-0.73 and OR 0.19, CI 0.04-0.92 respectively) 
(Table 1).  
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Table 1. Socio-demographics and risk factors for multidrug resistant organism 
(MDRO) and  C.  difficile colonisation and infection of residents in the Dutch (NL) 
and Irish (IR) nursing homes.  
 
a    Significance is indicated in bold. The risk factor analysis was only performed for the residents of which faeces was collected. 
b    For age and length of stay of the residents, differences between the two countries was calculated with an unpaired t-test. 
Instead of an odds ratio, the p- value is shown.  
c    In the previous six months 











Odds Ratio a 
(95% CI) 
(NL vs IR)
Mean no. of beds/room 
    Room type: Single 
    Room type: Double 














5.92 (1.64 – 21.39) 
0.65 (0.16 – 2.61) 
-




2.6 years 0.036 b




84.2 years 0.771 b













1.25 (0.54 – 2.87) 
1.17 (0.52 – 2.69) 
-
Disorientated 25 (67.6%) 53 (79.1%) 78 (75.0%) 0.55 (0.22 – 1.36)
Recentc hospitalisation 2 (5.4%) 15 (22.4%) 17 (16.3%) 0.19 (0.04 – 0.92)
Current antibiotic use 3 (8.1%) 8 (11.9%) 11 (10.6%) 0.65 (0.16 – 2.61)
Recentc antibiotic use 14 (37.8%) 44 (65.7%) 58 (55.8%) 0.31 (0.14 – 0.73)
Urinary catheter in situ 3 (8.1%) 17 (25.4%) 20 (19.2%) 0.26 (0.07 – 0.95)
Pressure sore 5 (13.5%) 2 (3.0%) 7 (6.7%) 5.08 (0.93 – 27.62)













1.21 (0.52 – 2.82) 
0.11 (0.08 – 0.55) 
0.21 (0.82 – 4.50)
Proton pump inhibitor use 26 (70.3%) 37 (55.2%) 63 (60.6%) 1.91 (0.82 – 4.50)
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Four (11 %) Dutch and six (9 %) Irish residents were colonised with eleven ESBL-
producing E. coli. One Dutch resident was colonised with two different isolates. Of the 
Dutch isolates, four derived from three residents on ward R, were phenotypically similar 
on antibiotic susceptibility testing including resistance against tobramycin and cipro-
floxacin. The fifth isolate from a resident on a different ward (ward L), was also resistant 
to gentamicin and trimethoprim/sulfamethoxazole (TMP/SMX) with intermediate 
resistance to tobramycin and ciprofloxacin. Of the six Irish isolates, residents were 
located on three different wards (wards B, C, H); five isolates were also resistant to 
ciprofloxacin and TMP/SMX and one resistant to gentamicin. Ten (five Dutch and five 
Irish) of the eleven MDRO isolates harboured CTX-M-15. No residents were colonised 
with CPE or  C.  difficile. No Dutch residents were colonised with VRE, in contrast to one 
Irish resident.  
The four Dutch ESBL-producing E. coli isolates from ward R were typed as E. coli 
serotype O25:H4, sequence type 131. Core genome (cg) MLST analysis showed that 
two isolates (from two residents) had identical complex types (CT) 1172, two isolates 
from a third resident were closely related (CT 1480 and 1479) and belonged to the 
same cluster type (Fig 1). The fifth Dutch isolate from a different ward (L), was distinct 
(CT 1483). All six Irish isolates were typed as E. coli serotype O25:H4, sequence type 131. 
Four isolates from residents on three different wards (wards B, C, H) were closely 
related and belonged to CT 1478 and the same cluster type (Irish cluster, Figure 1). The 
two other Irish isolates, CT 2923 and CT 1487 were unrelated. Four of the seven 
epidemiologic unrelated E. coli ST131 from Europe (Denmark (two isolates), Germany, 
Austria), United States (Minneapolis two isolates), and Australia, with complex type 
3100 clustered together in one cluster type (Figure 1). 
None of the following were significantly different for ESBL-colonised (n=10) versus 
ESBL-negative (n=94) residents; age (OR1.04, 95 % CI 0.93 – 1.15), mean length of 
residence (OR 0.90 95 % CI 0.61 – 1.33), previous MDRO (OR1.60 95 % CI 0.18 – 15.09), 
residence in a single room (OR 0.46, 95 % CI 0.12-1.77), recent hospitalisation or anti-
biotic use (OR: 0.54 95 % CI 0.06 – 4.55 and OR 1.21 95 % CI 0.32 – 4.58 respectively), 
disorientation, faecal incontinence, urinary catheter, pressure sore or other wounds 
(OR 0.76, 95 % CI  [0.18, 3.16], OR 2.55, 95 % CI  [0.62, 10.49], OR 1.06, 95 % CI  [0.21, 5.4], 
OR 4.45, 95 % CI  [0.74, 26.71], and OR 1.70, 95 % CI  [0.32, 9.02], respectively.  
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Figure 1. Minimum spanning tree of core genome MLST data of 11 ESBL-producing 
E. coli isolates  
Circles: represent a core genome (cg) MLST complex type. A larger size circles represents two 
MDRO isolates (Complex Type 1172 and 3100), the smaller circles one isolate each. The circles are 
connected to the closest relative; the numbers on the connecting lines give the number of genes 
containing SNPs.  
Colours: represent MDRO isolates from different wards in both nursing homes and the unrelated 
ST131 isolates. In Ireland; ward B in red, ward C in yellow, ward H in green. In the Netherlands; ward 
R in pink and ward L in turquoise. The unrelated ST131 isolates are coloured in blueberry blue.  
Zones around the circles indicate the presence of closely related isolates belonging to the same 
cluster type (cluster alert distance: 10).  
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Discussion  
The prevalence of ESBL producing E. coli, in Ireland (9 %), was lower than previously 
reported  [2], whereas in the Netherland the 11 % prevalence is in line with previous 
reports  [3, 7]. No resident was colonised with CPE or  C.  difficile in either country, and 
only one (Irish) resident was VRE colonised. Antibiotic use prevalence in both nursing 
homes were similar to that previously reported  [5]. No association of MDRO carriage 
with investigated risk factors was found, which reflects the low numbers of MDRO 
colonised residents.  
Nine of the eleven (82 %) ESBL-producing E. coli isolates belonged to the MLST 
ST131 with CTX-M-15 as most common ESBL. The predominance of ST131 is not 
surprising as it is associated with and older age  [8], and is frequently observed in 
European nursing homes  [2, 7]. Of the seven epidemiologically unrelated E. coli ST131 
NCBI strains from Europe, the US and Australia, four clustered together with cgMLST 
in one cluster type. This further underlines the clonality of this pandemic strain.  
WGS of E. coli isolates shows possible small-scale spread between three wards in 
the Irish nursing home and within one ward in the Dutch facility. There may have been 
more opportunities for cross-transmission in Ireland because of multi-bedded rooms 
and communal dining in contrast to predominance of single rooms and ward-based 
dining in the Netherlands. Transmission of ESBL-producing Enterobacteriaceae was 
higher within households than in hospitals (23 % versus 4.5 for ESBL E. coli, p< 0.01) 
emphasising faecal-oral transmission in ESBL epidemiology  [9]. Likewise, a recent 
Dutch study reported co-carriage between preschool children and their parents within 
the same household with identical extended-spectrum cephalosporin-resistant 
Enterobacteriaceae, suggesting clonal transmission between children and parents 
within the household  [10]. If transmission dynamics in nursing homes are reflective of 
household contact MDRO transmission, then the consequences of colonisation and 
initial small-scale MDRO spread could be significant. This would be compounded 
in nursing homes by faecal incontinence (e.g., 64 % Irish versus 19 % Dutch residents 
in this study) communal areas and multi-bedded resident rooms. In addition, a 
simulation study of MDRO transmission noted that while the daily probability of trans-
mission in nursing homes was less than the acute hospital setting, the longer length 
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of resident stay (e.g. mean 2.6 years in our study) can facilitate cross- transmission, 
hence, hospital-based control efforts may not be effective in preventing nationwide 
outbreaks  [1].  
In this study, no residents were colonised with CPE or  C.  difficile, and only one Irish 
resident was colonised with VRE, which is in line with previous reports  [2, 4], although 
higher  C.  difficile colonisation prevalence was reported in Ireland (10 %), albeit in a 
single nursing home study.  
Limitations of this study include its cross-sectional design, which was chosen for 
pragmatic reasons, potential selection bias from inclusion of only one nursing home 
per country, and low resident consent and specimen collection specifically in the 
Netherlands, reflecting local challenges in acquiring informed consent but limiting 
the generalisability of findings. Specifically, the analysis of MDRO risk factors and 
association with MDRO colonisation was underpowered because of low numbers and 
the cross-sectional design limited analysis of epidemiological risk factors for 
colonisation, beyond associations with ward location. As data collection was based on 
previous European nursing home prevalence studies  [5], additional data such as scores 
for resident independency that could impact on social contact with other residents 
were not collected. However, data on mobility (ambulant, wheelchair, bed-ridden) was 
collected as an indicator of care load with little difference between both sites. 
Strengths include the use of robust definitions, a standardized shared protocol, and 
the extensive molecular analysis. The study protocol was based on that from previous 
European studies  [5], and similar protocols for faeces collection and laboratory 
processing were employed. The only difference was the use of an MDRO enrichment 
broth in the Netherlands, which may have resulted in a higher recovery rate. However, 
both countries applied the national recommended culture methods enabling 
a national comparison and previous Irish studies did not use an enrichment step 
enabling comparison  [2]. 
In conclusion, in a nursing home prevalence study, the high abundance of risk 
factors did not lead to high MDRO prevalence. Core genome MLST analysis showed 
small-scale MDRO spread between residents of the same ward in the Netherlands and 
on different wards in Ireland. This may reflect differences in nursing home infra-
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structure, specifically communal areas and multi-bedded resident rooms in the Irish 
nursing home which were not present in the Netherlands.  
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How to: Establish and run 
a stool bank  
Development of the Netherlands Donor Feces Bank
Chapter 
Chapter 5. How to: Establish and run a stool bank 
Abstract 
Since 2013, several stool banks have been developed following publications 
reporting on clinical success of “Fecal Microbiota Transplantation” (FMT) for 
recurrent Clostridium difficile infections (CDI). However, protocols for donor 
screening, fecal suspension preparation and transfer of the fecal suspension 
differ between various countries and institutions. Moreover, no European con -
sensus exists regarding the legislative aspects of the fecal suspension product. 
Internationally standardized recommendations about the above mentioned 
aspects have not yet been established. In 2015, the Netherlands Donor Feces 
Bank (NDFB) was founded with the primary aim to provide a standardized 
product for the treatment of patients with recurrent CDI in the Netherlands. 
Standard operation procedures for donor recruitment, donor selection, donor 
screening, and production, storage and distribution of frozen fecal suspensions 
for FMT were formulated. Our experience summarized in this review addresses 
current donor recruitment and screening, preparation of the fecal suspension, 
transfer of the fecal microbiota suspension and the experiences and follow-up 
of the patients treated with donor feces of the NDFB. 
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Background  
Clostridium difficile, recently reclassified as Clostridioides difficile  [1] is capable of 
inducing diarrheal disease ( C.  difficile infection, CDI) due to the production of secreted 
toxins  [2]. After CDI treatment, the risk of a recurrence within eight weeks is 15–25 %, 
which rises to 40-65 % in patients with multiple recurrences  [2, 3]. Recurrences are 
associated with clinically severe diarrhoea and persistent disturbance of the colonic 
microbiota  [4]. Fecal Microbiota Transplantation (FMT) is therefore a very effective 
treatment for recurrent CDI, with cure rates close to around 85 %  [5, 6]. Large scale 
implementation of FMT in daily clinical practice is hampered by lack of easily available 
donor feces and safety concerns. A centralized stool bank can overcome these hurdles.  
Aim and structure of a non-profit stool bank  
The overall and primary aim of a stool bank is to provide on a (inter) national or 
regional level, ready to use, high-quality donor feces solutions to treat patients with 
recurrent or refractory CDI. Secondly, a central stool bank should enable careful 
monitoring of treatment outcome, side effects and long term effects of FMT. There fore, 
the stool bank should preferably be facilitated by a well-equipped biobank to store 
an aliquot of the donor feces, and samples of all delivered fecal suspensions, to 
guarantee traceability in case of adverse events. A stool bank is ideally entwined with 
a clinical microbiological department as the expertise and equipment to perform both 
various screening tests, and to process fecal suspensions is already present. Since FMT 
is not yet an approved, treatment modality by the European Medicines Agency (EMA) 
or US Food and Drug Administration (FDA), commercial stool banks are not the 
preferred suppliers. A stool bank working group should consist of experts in the fields 
of Microbiology, Infectious Diseases, Gastroenterology, Biobanking, Methodology, and 
if donor feces is considered as a drug; Pharmacology. An overview of the currently 
existing donor feces banks is depicted in Table 1. Similar as to the NDFB, most of the 
donor banks are non-profit and primarily use FMT for treatment of patients with 
recurrent CDI. 
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Legislation of a donor feces bank  
There is still considerable confusion about the regulatory aspects of FMT  [7-10]. The 
FDA dictates that adequate informed consent must be obtained before use of FMT 
products  [11]. In the European Union (EU), a standardized policy is lacking and each 
member state is allowed to have its own policy. In the Netherlands, FMT is currently 
regarded as an unclassified treatment approach, which is allowed (if applied safely), 
for patients with recurrent CDI, or in the context of an approved investigational study 
protocol.  
Although FMT appears a typical transplantation product to most experts in the 
field  [12], it does not fulfil the criteria for guidance by the EU tissue and cell trans-
plantation act, because the cellular component of FMT appears not to be the active 
substance. Furthermore, human excretions are excluded by the US act for tissue and 
cell transplantations. As a consequence, several European countries are considering 
donor feces as a drug (Table 1), which has major regulatory implications negatively 
influencing future availability and pricing of donor stool solutions for FMT. Application 
as a drug has the consequence that the proposed drug would have to be identical in 
active ingredient, dosage form, route of administration, quality, and performance 
characteristics. However, the complexity of the microbial community in stool and the 
variability across stool samples makes it impossible to guarantee the contents from 
batch to batch. Furthermore, it would have the consequence of putting fecal material 
for use in FMT under the jurisdiction of hospital pharmacies, requiring storage of the 
fecal product in the pharmacy itself. In this regard, common sense and consultation 
of the experts in the field may hopefully result in adjustment of the EU law in concord-
ance with the rapid scientific developments, enabling a future status of donor feces as 
transplantation product. 
How to recruit donors?  
Historically, FMT donors were conveniently selected among close relatives and 
friends of patients with the underlying idea that they would have at least a partially 
shared microbiome, increasing the chances of success  [13], and limiting the risk of 
pathogen transmission  [13, 14]. However, later evidence showed that FMT with donor 
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feces from unrelated donors was as effective  [5, 15]. This finding provided an opportunity 
for a better standardized, safer, faster and cheaper method of donor selection, screening 
and fecal suspension preparation. 
The NDFB acquired many potentially interested donors after announcing the 
opening of the first Dutch stool bank via local and national media (e.g. paper, national 
news). One of several options for recruitment of feces donors are amongst established 
blood donors, as this has the advantage of previously screened, healthy and motivated 
volunteers. An important difference in the donor recruitment in the Netherlands and 
most other European countries (except Germany) compared to the USA is that it is 
prohibited to offer a paid reimbursement for blood (or stool) donations. This prohi bi -
tion, is in line with the blood donating advice of the World Health Organization which 
states that the safest blood donors are voluntary, non-remunerated donors  [16]. As it is 
important to limit the time between defecation and delivery of the feces, to preserve 
as much anaerobes, donors should be recruited in the near proximity of stool banks, 
such as non-health care workers of the hospital and personnel of companies in the 
neighbourhood. 
Donor screening by questionnaire and interview  
All potential donors are extensively screened by a questionnaire and a personal 
interview concerning risk factors for transmissible diseases and factors influencing the 
intestinal microbiota (Table 2). The NDFB has applied an arbitrary age limit of 18 to 50 
years, assuming that above the age of 50 years a significant increase of comorbidities 
with a less stable microbiota can be present  [17]. A body mass index (BMI) > 25 kg/m2 
is also an exclusion criterion, since obesity may also be associated with a specific 
microbiota composition  [18]. Moreover, one case-report, and an experimental animal 
study suggesting new-onset obesity after infusion of donor feces of an overweight 
donor has been reported  [19, 20]. Any other gastrointestinal disorder (e.g. irritable bowel 
syndrome (IBS), Crohn’s disease and ulcerative colitis) also qualifies as an exclusion 
criterion of donation  [21]. Other exclusion criteria that have been shown to be related 
to aberrant microbiota composition are depicted in box 1  [22]. The list of exclusion 
criteria will probably expand in the future when other conditions are found to be 
associated with an altered microbiota composition.  
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Box 1. Aim and exclusion criteria of the donor screening by questionnaire. 
 
 
Donor screening by laboratory tests  
An extensive laboratory analysis should be performed to identify potential patho -
gens transmissible by fecal transfusion. An overview of all tests performed by the 
NDFB is shown in Table 2. The pathogens included in the blood-screening program 
correspond with the screening protocols for blood donors and are generally agreed 
upon between the different stool banks  [14, 15, 35-39]. However, screening protocols for 
detection of specific microorganisms in the intestinal tract differ between stool banks, 
and evolve with time and new insights, since there is no consensus guideline. This 
applies for example to the screening for the presence of multidrug resistant (MDR) 
organisms, including ESBL- and carbapenemase-producing bacteria, vancomycin-
resistant enterococci and methicillin-resistant Staphylococcus aureus. Screening for 
the (asymptomatic) presence of rotavirus is not routinely performed by stool banks, 
but since rotavirus is frequently found in asymptomatic donors, especially in winter, 
we included this in our protocol  [38, 40]. Adenovirus type 40/41, Sapovirus and 
Astrovirus are associated with mild gastro-intestinal diarrhoea and are therefore 
also screened  [41]. Enterovirus and Parechovirus are usually asymptomatic but can 
cause skin disease (and-foot-and-mouth disease), pleurodynia, myocarditis and 
menin gitis  [42, 43]. Adenovirus non-40/41 can cause myocarditis  [44]. In addition, feces 
is screened for Hepatitis E, which is frequently found in asymptomatic (blood) 
Aim:  
Risk assessment of fecal- and/or blood transmitted diseases and illnesses 
associated with a disturbed microbiota.
Exclusion criteria:  
Age <18 or ≥ 50, BMI <18.5 or > 25 [19, 20], high risk fecal- and or blood 
transmittable diseases, recent antibiotic use (<6 months) [23, 24], gastrointestinal 
complaints (for example diarrhoea, obstipation or irritable bowel like 
symptoms) [25-27], recent travel to endemic areas of gastrointestinal pathogens, 
(first degree relative with) inflammatory bowel disease [28], GI malignancy [29], 
first degree relative with a GI malignancy < 60 years, substantial comorbidity, 
various medication, autism [22, 30, 31], auto-immune disorders [32], neurological 
disease [33, 34]
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donors  [45]. To prevent transmission and development of systemic infections, potential 
donors are screened with PCRs for all the above mentioned viruses (see also Table 2 
for the total list of pathogens). 
 
Table 2. Donor screening by laboratory screening of feces and serum.  
When donors pass the questionnaire, feces is first screened for the presence of Dientamoeba fragilis and Blastocystis hominis. 
When negative, other pathogens are investigated, after which screening of serum is performed. 
 
a   If travel history to Middle and South America, Africa or Asia 
 
 
The significance of Dientamoeba fragilis and Blastocystis hominis as enteropathogens 
is less clear  [47 -50]. D. fragilis and B. hominis are commonly found in fecal samples of 
both symptomatic and asymptomatic individuals  [50, 51]. Prevalence varies consider-
ably depending on geographic location, the group studied, and diagnostic methods 
used  [47]. The cell wall of B. hominis is fragile and disrupts easily; storage of micro-
scopically positive stool samples in 10 % glycerol at -80°C results in complete lysis and 
negative microscopy after the samples are thawed and reinvestigated (unpublished 
observation). Despite the uncertainty of B. hominis and D. fragilis pathogenicity, coloni -
sation may be considered an indicator of a suboptimal microbiota compo si tion  [52]. 
Therefore, positive individuals are excluded from donorship for NDFB.  
Laboratory screening serum• Laboratory screening feces
Hepatitis A (IgM + IgG) •
Hepatitis B (HBsAg + anti-Hbcore) •
Hepatitis C (anti-HCV) •
Hepatitis E (IgM + IgG) •
HIV (anti-HIV, type 1 and 2) •
Lues; Treponema pallidum (Ig) •
Cytomegalovirus (IgM + IgG)  •
Epstein Barr Virus (IgM + IgG •
Strongyloïdes (IgG1/IgG4) a•
Clostridium difficile (PCR) •
Helicobacter pylori (antigen test)  •
Bacterial gastro-enteritis: (PCR, followed by culture)): Salmonella spp. Campylobacter •
spp., Campylobacter jejuni, C. coli, Shigella spp., Yersinia enterocolitica and 
Y. pseudotuberculosis, Aeromonas spp., Plesiomonas shigelloides, and Shiga Toxin 
producing E.coli  
Antibiotic resistant bacteria (culture); ESBL and/or carbapenemase producing •
bacteria, vancomycin resistant enterococci and methicillin resistant Staphylococcus 
aureus 
Viral pathogens (PCR): Norovirus serotype I+II, Astrovirus, Sapovirus, Rotavirus, •
Adenovirus 40/41, Adenovirus non-40/41, Enterovirus, Parechovirus, Hepatitis E 
Parasites (PCR): Giardia lamblia, Entamoeba histolytica, Cryptosporidium parvum and •
C. hominis, Microsporidium spp, Strongyloïdes a 
Microscopy for ova, cysts and larvae [46]: for example: Blastocystis hominis•
Questionnaire: One day before donation of feces 
Stool frequency/pattern, general health, use of antibiotics, travel history, sexual behaviour
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The serostatus of the donor is determined for Epstein-Barr virus (EBV) and Cyto -
megalo virus (CMV). Immunocompromised patients will be matched accordingly for 
safety reasons. However, the risk of transmission is not established and we await the 
results of ongoing study regarding the risk of CMV transmission due to FMT (TRANS-
DECMV Clin Trial Gov: NCT02694484).  
Approximately two months after the initial screening, a new donor sample of feces 
and blood are screened again, using similar tests as applied at entry of the program 
(see Table 2), except for CMV and EBV which are repeated once a year (in case of 
a negative serostatus. After a successful second screening, the donor fecal sus -
pensions collected until two weeks prior to the second screening are released for 
patient treatment. This quarantine period minimizes the risk for transmissible diseases. 
Collection, preparation and storage of 
donor feces suspensions 
It is generally believed that a high viability of bacteria in stools increases the chance 
of successful FMT. Since the majority of fecal bacteria are anaerobic, feces needs to 
be processed within six hours after defecation  [5, 6]. To prevent environmental conta -
mi nation, feces is collected by the donor in a fecal container (for instance Feco -
tainer™). For suspension, approximately 60 gram of donor feces is used based on the 
data of a systematic review suggesting a decreased cure rate with < 50 gram  [53]. The 
feces is homogenized with saline using a mortar and pestle, whereas some laboratories 
use a commercial blender  [15, 37]. Disadvantages of blenders are difficulties with 
appropriate sterilisation and aerosolization of the feces. A metal sieve (mesh 300µm) 
is used to remove undigested food fragments. The fecal suspension is then concen -
trated by centrifugation (15 minutes, 6000g)  [37] and glycerol is added as cryo-
protectant to a final concentration of 10 % in a total end volume of 200 ml. A recent 
study showed that frozen fecal suspension is equally effective as a fresh fecal 
suspension for the treatment of CDI  [54]. This allows stool samples to be stored at -
80°C for a longer period of time until the donor has been retested prior to actual use 
of the donor feces. Clinical success of frozen suspensions is reported until five to six 
months of storage at -80°C, but could be much longer, in theory. Like OpenBiome, the 
NDFB uses a storing period of two years.  
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How to apply safety measures and 
include quality controls  
At the Leiden University Medical Center (LUMC), storage of the FMT suspensions 
is accommodated by the certified centralized biobanking facility in a specific -80°C 
freezer with connected alarm notification to guarantee a continuous registration of the 
storage. In addition, the biobanking facility uses a dedicated biobanking information 
and management system (BIMS SampleNavigator®) for coding, registration, tracking 
and tracing of the bio samples. FMT suspensions, in combination with a small 
portion of the original feces and a 2 cc portion of the FMT suspension, are stored 
under a unique donor code with a successive suffix number for donation time and date 
for retrospective quality assessment. Information on the FMT suspension labels 
includes donor code, suspension number, production and expiration date, volume, and 
storage temperature instruction. Distribution of the FMT upon granted request by the 
NDFB is provided by dry-ice shipment through a certified Biologistic Courier service. 
Registration in a BIMS-related database for the shipped FMT suspensions, including 
recipient institution and requestor information, is provided in order to be able to 
perform biovigilance tracing in cases of adverse events.  
An important aim of the NDFB is to recognize complications of FMT. Therefore, 
systematic follow-up of both patients and donors is performed with signed informed 
consents. The NDFB collects recipients’ feces and clinical data on the day of FMT and 
approximately three weeks after the procedure. Furthermore, clinical information 
including abdominal complaints, development of diarrhea and adverse events (e.g. 
nausea, bloating, abdominal pain, belching, vomiting) is collected. No systematic long-
term follow-up has been scheduled yet to register development of auto-immune 
diseases, malignancies and other potentially microbiome-associated syndromes both 
in donors and patients. However, all feces and serum samples have been stored in the 
biobank and remain available for analysis.  
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How to determine eligibility of patients with 
recurrent Clostridium difficile infection for FMT  
Since the effectiveness of FMT has only been recognized by the authorities for 
recurrent CDI, it is extremely important to diagnose recurrent CDI both with the 
presence of clinical symptoms, and positive microbiological tests. Therefore, written 
requests for FMT treatment with a standardized form are evaluated by at least two 
clinical members of the NDFB board to determine eligibility of the patient. It is required 
that patients have a laboratory documented episode of recurrent CDI following at least 
one course of adequate CDI antibiotic therapy (≥ 10 days 125 mg vancomycin QID; 
≥ 10 days metronidazole 500 mg TID; 10 days 200 mg fidaxomicin BID). Recurrent 
CDI is defined as the re-appearance of diarrhoea (≥ 3 unformed stools per 24 hours 
for two consecutive days; or ≥ 8 unformed stools per 48 hours) within eight weeks 
after cessation of antibiotic therapy in combination with a positive diagnostic test 
for  C.  difficile. We strongly recommend a two-stage testing algorithm, as recently 
advised by the  C.  difficile ESCMID diagnostic guideline  [55]. In particular, a positive test 
for the presence free toxins in feces samples (e.g. by EIA) is a prerequisite, especially 
for patients with comorbidity of the intestinal tract, such as inflammatory bowel disease 
(IBD). If laboratories only use a PCR to detect toxin genes of  C.  difficile, we advise to 
send a fresh feces sample to a reference laboratory for toxin detection, since  C.  difficile 
(spores) can persist after successful treatment and may reflect colonisation.  
For a first recurrence of CDI, it is advised to first treat the patient with another course 
of antibiotics. Fidaxomicin could be considered because of potentially relapse reduc-
ing effect due to its narrow antibiotic spectrum  [56]. In general, FMT is advised in 
patients with multiple recurrences. However, in some cases of severe, therapy 
refractory CDI, FMT could be considered for a first recurrence  [39, 57]. A recently 
completed study suggests that intravenously administered humanised monoclonal 
antibodies against  C.  difficile toxin B (bezlotoxumab) protects against (multiple) 
recurrent CDI. However, it is yet unclear which patients really benefit from this very 
expensive treatment strategy  [58].  
Pregnancy, severe food allergy, and antibiotic usage other than for  C.  difficile at the 
day of expected infusion are exclusion criteria for FMT treatment. Although, recently, 
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the first case report of successful and safe FMT in a pregnant patient has been 
published  [59]. All potential risks, benefits, logistics, and procedural details are 
discussed with the patient by the treating physician.  
What is the procedure of FMT?  
If the patient is eligible for treatment with FMT, donor feces suspension is trans-
ported to the referring hospital on dry ice. Prior to transplantation, the feces suspension 
is thawed (overnight in a 4°C refrigerator or during five hours at room temperature), 
based on literature and our expert opinion  [15, 54, 60]. The donor feces suspension 
may be kept at room temperature for up to three hours or refrigerated at 4°C for up to 
six hours. Samples should never to be re-frozen, because freeze-thaw cycles may 
compromise stability and efficacy of the sample, possibly due to loss of viability. 
To eradicate vegetative cells of  C.  difficile, prior to FMT (until one day before the 
procedure), patients receive vancomycin (125-250 mg QID) for a minimum of four 
days, followed by two litres of bowel lavage one day prior to FMT  [5]. Whether bowel 
lavage can be excluded from the protocol is currently a matter of discussion, since 
recent reports have shown similar efficacy for FMT without bowel lavage  [61 -63]. The 
treating physician is advised to avoid antibiotics in FMT patients during the first 
month after FMT unless strictly necessary, and preferably as small as possible. FMT 
is generally performed by infusion of a donor feces solution through a gastric or 
duodenal tube  [5], colonoscope  [6], or enema  [54]. All infusion routes have advantages 
and disadvantages, and in every patient the ideal method should be evaluated. The 
FMT procedure can be performed by the treating physician and does not justify 
standard referral to a specialised centre. Physicians are instructed how to perform 
FMT, and if necessary, FMT training sessions are offered. In the Netherlands, FMT 
via duodenal tube is preferred because it is generally well tolerated by patients, and is 
less invasive compared to colonoscopy, especially in an inflamed bowel as with 
severe CDI  [5, 64, 65]. On the day of FMT treatment, a duodenal tube is placed through 
duodenoscopy, radiological guided, or with use of an electromagnetic imaging system 
(e.g. Cortrak TM). The thawed feces solution of approximately 200 ml is slowly infused 
through the duodenal tube with a 50 cc syringe, at a rate of 10cc/minute, after which 
the tube is flushed with 50 ml tap water. Thirty minutes after FMT, the duodenal tube is 
removed and patients are monitored for two hours. If FMT through a duodenal tube is 
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contra-indicated (i.e. due to a hampered bowel passage or higher risk of aspiration), 
FMT is performed via colonoscopy. We generally do not advice enemas, because of 
the need of repeated FMT’s to achieve a high cure rate with enemas  [66]. 
NDFB experience during May-January 2017 
In March 2016, the opening of NDFB was reported in various local and national 
newspapers and broadcasted in radio and television programs, accompanied by an 
invitation for volunteers to register as donor. Subsequently, 165 volunteers registered 
and informed by email about the procedure and were requested to complete an online 
questionnaire. After this evaluation only 21 potential donors (12.7 %) were screened for 
the presence of transmissible diseases (Table 3). Nine (5.5 % of initial responders) 
volunteers passed the screening and were invited to donate. This percentage is low, 
though in line with earlier reports on donor screening  [40, 67-69]. The fecal suspensions 
were quarantined for two months after which the donors were re-screened. Two volun-
teers had to temporarily stop donating for three months because of an episode of 
acute diarrhoea. Four donors did not pass a re-screening: two carried B. hominis, one 
an ESBL positive E. coli (exclusion for at least 6 months) and one donor a rotavirus 
(indication for re-screening of the previous donated samples and exclusion for 2 
weeks); this underlines the importance of a quarantine period. As a substantial portion 
of donors only donates temporarily, donor recruitment is a continuous process. 
In May 2016, the first FMT with a donor feces suspension of the NDFB was 
performed. In the first nine months after its opening, 31 feces suspensions to 18 
different hospitals throughout the Netherlands have been distributed for treatment with 
FMT. We noticed a cure rate of 84 %, which is in line with the earlier reported 
randomized controlled trails  [5, 6].  
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Table 3.  Experiences of the NDFB with donor screening 
 
a Some volunteers have multiple exclusion criteria 
b 1 minus cumulative proportion of excluded donors 
c Higher risk of temporary carriership of pathogens 
d Antibiotic use in the previous six months 
e Close relative with colon carcinoma, onset below age of 60 
f Treated, included as donor six months later 
Business plan  
In the Netherlands, disease entities are reimbursed regardless of the given treatment 
(e.g. for recurrent CDI; vancomycin or fidaxomicin or FMT) when the patient is treated 
in daycare. A business case to calculate the break-even point of producing safe feces 
samples for FMT was determined for the NDFB. We differentiated between (i) recruit-
ment, screening and selecting of suitable donors (ii) donation of feces by donors and 
periodic rescreening, (iii) assessment of eligibility of patients’ demand for FMT (iv) 
supply of a safe fecal suspension, and (v) post-treatment monitoring. The costs cover-
ing involved hospital staff (medical, technical, administrative, advisory), laboratory 
Potential 





165 Request of 
information by 
email
62% age > 50 years, 26% unable to deliver feces < 2 hour after 
defecation, 6% BMI > 25, 6% other
94 (57%) 71 (43%)
71 Extended 
questionnaire
17.2% age > 50 years, 27.1% BMI > 25, 14.3% (history of) 
depression, 8.5% comorbidity/medicine use, 7.1% profession of 
health care worker c, 7.1% inability to deliver feces < 2 hour, 
7.1% (close relative with) IBD, 4.3% anorexia, 2.9% recent use of 
antibiotics d, 2.9% autism, 2.9% (risk factors for) colon 
carcinoma e, 2.9% profession with frequent travelling, 
2.9% abundant flatulence
50 (70.4%) 21 (12.7%)
21 First feces 
screening
42.9% D. fragilis, 4.8% D. fragilis and B. hominis,  
4.8% D. fragilis and C. jejuni, 4.8% E. histolytica f
11 (52.3%) 10 (6.1%)
10 Serum screening None 0 (0%) 10 (6.1%)
10 Repeated feces  
screening 
20% B. hominis, 10% ESBL E.coli, 30% donor withdrawal (after 0, 
2 and 6 months) 
Temporarily excluded: acute diarrhoea (for 3 months), rotavirus 
carriership (for 2 weeks)  
6 (60%) 4 (2.4%)
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tests, storage and bio-banking amounts to a unit cost per patient to be treated 
(including 10 % re-treatment in case of initial non-response) of €899 in case of 
100 patients yearly, dropping to €785 in case of 400 patients yearly to account for 
economies of scale. 
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Chapter 6. Feces microbiota transplantation 
for Clostridioides difficile infection: 
four years’ experience of the Netherlands Donor 
Feces Bank 
Abstract 
Background: The Netherlands Donor Feces Bank (NDFB) provides standard-
ized ready-to-use donor fecal suspensions for fecal microbiota transplantation 
(FMT) treatment of patients with recurrent Clostridioides difficile infection 
(rCDI).  
Objective: Evaluation of safety, feasibility and outcome of FMT facilitated by 
a national stool bank. 
Methods: Observational cohort study of donors and recipients of fecal sus -
pensions; assessment of donor screening and patient selection performed by an 
expert panel of medical microbiologists, gastroenterologists and infectious 
disease specialists; and patient outcome evaluated at different timepoints 
post-FMT. 
Results: Donors: Of 871 volunteers who registered as potential feces donor, 16 
(2 %) became active donors. Nine donors stopped or were excluded after a mean 
donation period of 5.7 months. Patients: Between May 2016 and August 2019, 47 
(27 %) of the 176 requested FMTs were deemed not indicated by the expert panel. 
In total, 129 rCDI patients were treated with 143 FMTs in 40 different hospitals 
across the Netherlands. The cure rate at two months after a single infusion was 
89 % (107/120). Of 84 patients, long-term follow-up (median 42 weeks) was avail-
able and sustained cure was achieved in 61 (73 %). Early CDI relapses (within two 
months after FMT) and late recurrences (after more than two months) occurred 
more frequently in patients who received non-CDI antibiotics within three weeks 
post-FMT and in moderately to severely immunocompromised patients. Of 21 
patients with post-FMT CDI, 14 were cured with anti-CDI antibiotics and seven 
with a second FMT. No FMT-related serious adverse events were observed, but 
gastrointestinal complaints (nausea, abdominal pain or diarrhoea) persisted in 
32 % of the treated patients at long-term follow-up. 
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Conclusion: Fecal suspensions provided by a centralized stool bank, sup -
ported by a multidisciplinary expert team, resulted in effective, appropriate and 





Fecal microbiota transplantation (FMT) is a very effective treatment for recurrent 
Clostridioides difficile infection (rCDI). In recent years it has been implemented world-
wide as effective rescue therapy with cure rates of approximately 85 % [1-4]. Transplanting 
fecal microbiota of a healthy donor with the aim to restore a patient’s perturbed 
microbiota appears also promising for several other disorders, such as ulcerative colitis 
and hepatic encephalopathy [5, 6]. Careful donor screening is required, minimizing the 
risk of pathogen transfer or an impaired microbiota composition potentially predisposing 
Established knowledge  
on this subject 
 
» Fecal microbiota transplantation 
(FMT) is an established therapy 
for multiple recurrent Clostridioides 
difficile infection (rCDI). 
 
» Only a small percentage of potential 
donors is eligible after careful 
selection and screening. 
 
» Centralized stool banks provide an 
opportunity for quality improvement 
of FMT 
Significant and/or new findings 
of this study? 
 
» FMT that is facilitated by a national 
stool bank, is efficacious, safe and 
appropriately used. 
 
» Consultation by 
a multidisciplinary FMT-expert team 
results in appropriate use of FMT. 
 
» Post-FMT CDI relapse can be treated 
with antibiotics directed against CDI, 
even if these were ineffective prior to 
FMT in those patients. 
 
» Feacal suspensions for rCDI treat -
ment can be stored at -80°C for 
up to two years, without loss of 
effectivity.
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for disease. With the emergence of FMT as a new treatment approach, stool banks are 
needed to provide ready-to-use donor fecal suspensions that are produced in a 
standardized way [7]. Significant advantages of centralized donor screening and pro -
duction of donor fecal suspensions are the possibilities to provide quality assurance, and 
appropriate monitoring of potential yet unknown adverse events [7].  
At present, stool banks operating at an institutional level exists in several countries, 
and national operating stool banks are active in the US, the Netherlands and England 
[8-12]. In 2015, the Netherlands donor feces bank (NDFB) was founded as a non-profit 
national stool bank. In addition to providing fecal suspensions, the NDFB provides 
advice on the diagnosis, treatment and follow-up of recurrent or severe CDI by an 
FMT-expert panel of medical microbiologists, gastroenterologists and infectious 
disease specialists. The NDFB expert panel evaluates each request for FMT [10].  
The aim of the current evaluation report was to describe the results of donor screen-
ing and the outcome of FMT performed for rCDI facilitated by the NDFB, and under 
guidance of its expert panel. In addition, donor-, patient- and fecal suspension-specific 
factors underlying FMT treatment failure are addressed. 
 
Material and methods  
Study design 
This is a prospective, observational cohort study describing the results of feces 
donor screening and patient outcome after FMT from the first performed donor screen-
ing in January 2016, and FMT in May 2016, until August 2019.  
Screening & selection of donors 
The NDFB recruits healthy, unrelated volunteers who can supply stool to the to the 
microbiology laboratory within two hours after defecation. The procedure of donor 
recruitment, screening by questionnaire, interview and laboratory testing was described 
before [10], and is summarized in supplementary Table S1.  
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Processing and storage of fecal suspensions 
The NDFB uses standardized procedures for collection, preparation and storage of 
donor fecal suspensions [10]. In short, sixty grams of donor feces is used for the 
preparation of one fecal suspension. Storage at -80°C is accommodated by a certified 
biobanking facility. At the NDFB, the maximum shelf-life has been (arbitrarily) 
determined as two years. 
FMT consultation and treatment 
Requests for fecal suspensions are submitted to the NDFB by treating physi -
cians using a standardized form (www.ndfb.nl). The request is evaluated by at least 
three medical specialists (a gastroenterologist, medical microbiologist and infectious 
disease specialist) of the NDFB expert panel. The indication for FMT is assessed, the 
diagnosis of rCDI is verified, and the feasibility and safety of FMT  for the individual 
patient is considered. Patients with at least two recurrent CDI episodes or severe and 
therapy refractory CDI are eligible. CDI is defined as diarrhoea (≥ 3 unformed stools 
per 24 hours for two consecutive days; or ≥ 8 unformed stools per 48 hours), in 
combination with a positive diagnostic test for C. difficile and absence of another more 
likely cause of diarrhoea. To differentiate between infection and asymptomatic 
colonization, a two-stage testing algorithm is recommended [13]. In particular, presence 
of free C. difficile toxins is a prerequisite for patients with gastro-intestinal comorbidity. 
Severe CDI is defined by the presence of severe colitis or a complicated course, with 
systemic toxin effects and shock that may result in ICU admission or colectomy [14].  
If a patient is eligible for FMT, a donor fecal suspension is transported to the 
requesting hospital on dry ice and thawed according precise instructions [10]. In 
general, prior to FMT, patients receive vancomycin (125-250 mg QID) for a minimum 
of four days until 24 hours pre-FMT. For duodenal delivery, two litres of KleanPrep 
(bowel lavage) is prescribed one day prior to FMT [10]. Treating physicians are 
instructed how to perform FMT. The thawed fecal suspension is infused through a 
duodenal tube, at an advised rate of 10cc/minute. If FMT through a duodenal tube is 
considered unsafe or contra-indicated (i.e. due to a hampered bowel passage or 
increased aspiration risk), infusion via colonoscopy is advised. After infusion of 
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the donor feces, patients are monitored for two hours [1, 10]. Antibiotic stewardship 
to protect the microbiota post-FMT is advocated to prevent a relapse of CDI after 
FMT [10, 15, 16].  
Follow-up 
At each FMT treatment, the patient and treating physician receive information on 
potential adverse events and are advised to contact the NDFB if such an event occurs. 
Treating physicians are advised to plan a routine follow-up visit at three weeks post-
FMT and patients are requested to complete a questionnaire. Patients are routinely 
approached by an NDFB employee by telephone two months after FMT, and for the 
present evaluation report also at a later time-point between January 2019 and 
August 2019 (19 to 143 weeks) post-FMT for long-term follow-up. Information about 
recurrence, hospital admission, possible FMT-related adverse events and antibiotic use 
is collected. We defined early relapse as a CDI episode within two months following 
FMT [14], whereas a CDI episode after two months post-FMT was regarded as late 
recurrence. We defined cure as resolution of all CDI symptoms, and no CDI relapse 
within three weeks (primary cure), two months (cure at two months) or long-term 
follow-up (sustained cure). We categorized the relationship between adverse events 
and FMT as follows: definitely related, probably related, possibly related and unrelated 
to FMT [17]. 
Statistical analysis 
The statistical analysis was performed using SPSS 23.0 statistical software. 
Continuous data are presented as mean (range), or median in case of a skewed 
distribution. Possible associations between FMT treatment outcome and patient, fecal 
suspension or donor characteristics were tested by a Pearson’s Chi-squared test, or 
Fisher’s exact test where appropriate. An odds ratio was calculated using logistic 
regression and presented with a 95 % confidence interval [95 % CI]. For ordinal data, a 
linear-by-linear association test was used. Kaplan-Meier curves and log-rank tests were 
performed to assess CDI-free survival. A two-tailed significance level of p<0.05 was 
considered statistically significant. Missing data and patients lost-to follow-up were 
mentioned but data was not corrected for this. 
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Results  
Donor selection & screening 
Since the initiation of the NDFB, 871 volunteers registered as potential feces donor. 
After receiving information about donor requirements, 603 withdrew and 268 
completed an online questionnaire (Table 1). Based on the questionnaire, 83 (31 %) 
donors were invited for an interview, followed by microbiological testing. After 
 evaluation of the interviews, screening and rescreening of feces and serum, only 
16 volunteers were eligible as feces donor, which is 6 % of volunteers completing the 
questionnaire and 2 % of all initially interested individuals (Table 1). Of these 16 active 
donors, 10 (63 %) were female, the mean age was 33 (range 24-57) years, and the 
mean BMI was 22.4 (range 19.6-24.8) kg/m2. Asymptomatic, transient carriage of 
potential pathogens was occasionally found at re-screening (multidrug resistant 
organism (MDRO): n=4, norovirus: n=2, rotavirus: n=1, sapovirus: n=1, parechovirus: 
n=1, Salmonella species: n=1, or Dientamoeba fragilis: n=1). Nearly all active donors experi-
enced one or more transient episodes with upper respiratory complaints, diarrhoea, 
temporary change of defecation pattern, or antibiotic use, for which donations were 
temporarily stopped. Nine of the 16 (56 %) donors stopped or were excluded after 
a mean period of 5.7 months (range 1-14 months). Reasons for discontinuation were 
persistent carriage of potential pathogens during repeated testing (Blastocystis species: 
n=2, MDRO: n=1, or D. fragilis n=1) or a too heavy burden of required time and logistics 
(n=5).  
 
CHAPTER 6. FECES MICROBIOTA TRANSPLANTATION FOR CLOSTRIDIOIDES DIFFICILE INFECTION
141
6
Table 1. Results of the donor selection and screening process 
 
 
Abbreviations: MDRO: multidrug resistant organism, IBS: Irritable Bowel Syndrome 
† Some volunteers had multiple exclusion criteria, exclusion is displayed as the percentage of total excluded donors as result of 
a particular screening step.  
‡ From September 2018 changed to 55 years, or 60 years with negative colon carcinoma screening.  
§ Higher risk of temporary carriership of pathogens 
¶ Close relative with colon carcinoma with an onset below the age of 50 
¥ Screening algorithm used: first screening includes: Dientamoeba fragilis, microscopy for Blastocystis sp., MDRO and 
Helicobacter pylori screening, if negative, then additional tests are performed (Table S1) 
∫ 3 donors were excluded at first screening, successfully decolonized of MDRO, D. fragilis or E. histolytica, and they subsequently 
continued the donor screening program. 
Donors (%) Action Excluded (%) Exclusion reasons †
871 Request for 
more information 
by donor
603  (69%) 52% (n=311) withdrawal after reading additional information 
22% (n=132) unable to deliver feces < 2 hrs after defecation 
20% (n=121) age > 50 years ‡ 
8% (n=49) increased risk disturbed microbiota (bowel complains, 











185   (69%) 22% (n=41) comorbidity/medication use 
22% (n=40) BMI < 18.5 or > 25 m2/kg 
18% (n=33) (history of) depression 
15% (n=28) profession of health care worker § 
14% (n=25) age > 50 years‡ 
14% (n=25) bowel complaints 
12% (n=22) inability to deliver feces < 2 hours 
10% (n=19) withdrawal after completing questionnaire 
6% (n=12) (close relative with) IBD 
5% (n=9) frequent travelling 
4% (n=7) risk factor for colon carcinoma ¶ 
3% (n=6) high risk sexual behaviour 
7% (n=13) other 
83 (31%) 
↓
Interview 17    (20%) 65% (n=11) donors withdrawal or failure to deliver feces <2h once a week 
35% (n=6) donors excluded based on interview (IBS complaints, 
comorbidity, psychological evaluation, patient contact, atopy)
66 (25%) 
↓
 Feces¥ screening 47    (71%) 89% (n=42) Dientamoeba fragilis 
15% (n=7) MDRO 
9% (n=4) Blastocystis sp. 
4% (n=2) Helicobacter pylori 
2% (n=1) Campylobacter jejuni 
2% (n=1) Entamoeba histolytica
22�  (8%) 
↓
Serum screening 0        (0%) None








6      (27%) Exclusion of quarantined donor suspensions:  
83% (n=5) difficulty to implement donation in daily practice,  
17% (n=1) MDRO and refusal to perform rescreening 
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FMT consultation  
Since May 2016, 176 FMT requests for treatment of (r)CDI patients were reviewed by 
the expert panel. Of these requests, 47 (27 %) were deemed not indicated. The most 
frequent reason for rejection was  C.  difficile carriership in combination with diarrhoea 
due to inflammatory bowel disease (IBD) or another, unknown cause. Detailed results 
of the evaluation of FMT requests are listed in Table 2. 
 
Table 2. Results of the evaluation of FMT requests by the multidisciplinary FMT 
expert panel 
 
Abbreviations: CDI: Clostridioides difficile infection, IBD: Inflammatory Bowel Disease 
† 143 FMTs performed in 129 patients. Ten patients received multiple FMTs; 9 patients for treatment of a post-FMT CDI relapse 
(7 patients cured with a single repeat FMT, 1 patients cured with 2 repeat FMTs, 1 patient cured with antibiotics after a repeat 
FMT) and 1 patient received sequential FMT treatment for severe, therapy refractory CDI (in total 6 FMTs; 3 FMTs for a first 
episode and 3 FMTs for the relapse). 
FMT treatment  
In total, 129 patients with CDI were treated with 143 FMTs in 40 different hospitals 
throughout the Netherlands. Suspensions obtained from 12 of the 16 approved donors 
were used. The mean age of the patients was 69.9 years (range 2-96), and 60 % were 
female. Patients suffered from a mean of 4.2 (range 1-10) CDI episodes before FMT 
FMT decision Number of requests
FMT request rejected by NDFB expert panel 47/176 (27%)
Reasons of rejection of the 47 FMT requests: 
C. difficile carriership & diarrhoea due to other cause; 
      »  Diarrhoea with unknown cause 
      »  Diarrhoea due to IBD 
 
Anti-CDI antibiotics advised instead of FMT; 
      »  First, mild recurrence 
      »  New CDI infection (too long interval between CDI episodes) 
 
Long-term antibiotic use/elective operation 




















Request for FMT approved by NDFB expert panel 129/176 (73%)
FMT indication† 
      »  Multiple recurrent CDI 
      »  Severe, therapy refractory CDI 









Number of patients at risk for CDI after FMT:  
 
Figure 1. Kaplan Meier curve of the Clostridioides difficile infection  
(FMT failure, early relapse or late recurrence)-free survival post-FMT.  
Time (weeks) 0 3 8 20 40 60 80 100 120 140
Patients (number) 129 119 105 70 37 31 23 14 11 1
was considered. Most patients had rCDI (Table 2). Four patients received an FMT for 
a first episode of severe, therapy-refractory CDI, of whom one received multiple FMTs 
(six in total). The majority of FMTs (127/143, 89 %) were infused through a duodenal 
tube. FMT via the lower gastrointestinal route was performed by colonoscopy because 
of motility disorders (n=4), an already planned colonoscopy to rule out IBD (n=8); or 
sigmoidoscopy because of an ileus due to severe CDI (n=4).  
Outcome of FMT treatment  
Follow-up data were available for 128 of 129 patients at three weeks, and 120 
patients at two months after FMT. Three patients (2 %) died within three weeks due to 
causes unrelated to the FMT. The primary cure rate at three weeks after a single FMT 
infusion was 91 % (117/128). Cure at two months post-FMT was 89 % (107/120). Thirteen 
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patients suffered from an early relapse at a median of 1 week (range 0-5 weeks) post-
FMT. Of the 129 FMT treated patients; 11 (9 %) were deceased by the time of long-term 
follow-up, 34 (26 %) were lost to follow-up. From 84 (65 %) patients, long-term 
follow-up was available with a median of 42 weeks (range 19-143 weeks, interquartile 
range 26-97 weeks). Ten patients developed a late CDI recurrence after a median of 17 
weeks (9-57 weeks) post-FMT. Thus, sustained cure was achieved in 61 of 84 (73 %) 
patients still alive at long-term follow-up. Figure 1 shows the CDI free survival over time. 
The 23 patients suffering from post-FMT CDI had symptoms of diarrhoea, either in 
combination with a positive toxin EIA (14/23, 61 %), PCR (5/23, 22 %), or were 
 diagnosed with unclear methods but with clinical response to vancomycin treatment 
(4/23, 18 %). Most patients  experiencing CDI post-FMT eventually successfully cured 
(21/23), either by antibiotics alone (14/21, 67 %; received fidaxomicin, 4 vancomycin, 
1 metronidazole, and 1 fidaxomicin), or by a second FMT (7/21, 33 %; of whom one 
patient needed a third FMT). In two patients CDI treatment was not initiated, the 
patients died of an underlying disease with concurrent development of CDI.  
Risk factors for post-FMT CDI 
Patients with an early CDI relapse post-FMT had more often received non-CDI anti-
biotics during the first three weeks after FMT compared to patients without relapse 
(39 % versus 15 %) (Table 3). Antibiotic use preceded a late CDI recurrence in 80 % of 
patients. Nonetheless, antibiotic use shortly after FMT was still a significant predictor 
of all CDI episodes post-FMT (both early AND late) (40 % (8/20) compared to 15 % 
(14/95), p- value 0.001, Figure S1). In addition, early CDI relapses were observed more 
frequently in patients who were moderately (3/23) to severely (2/3) immuno-
compromised (Table 3). A trend was observed towards more CDI (early relapse or late 
recurrence) post-FMT in immunocompromised (31 %, 8/26) versus immunocompetent 
patients (15 %, 15/101) (p- value 0.054, Figure S2). No other patient or fecal suspension 
characteristic significantly differed between those who relapsed and those cured 
(Table 3). Importantly, a longer processing time of fecal suspensions (mean 168 
minutes, range 65–355 minutes) or longer storage time at -80°C (mean 269 days, range 
34–730 days, 30/129 were stored > 1 year) did not negatively influence the success rate 
of FMT. Donor selection did not influence the outcome of FMT; no differences 
between donors could be detected (p- value 0.10, individual donor data in Table S2). 
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Table 3. Patient, donor and fecal suspension risk factors for CDI relapse within two 
months after FMT  
 
Abbreviations: CDI: Clostridioides difficile infection, FMT: Fecal Microbiota Transplantation, PPI: proton pump inhibitor, IBD: 
Inflammatory Bowel Disease, OR: Odds ratio, rUTI: recurrent urinary tract infection, rCDI: recurrent Clostridioides difficile infection  
†     Immunocompromised classified as: not, moderate or severe. Patients are regarded as severely immunocompromised when: 
neutropenic, (scheduled or received last 100 days) an allogenic stem cell transplantation, active Graft-versus-host-disease 
requiring immunosuppressive agents, and moderately immunocompromised when: having <200 CD4 T-cells/µl, prolonged use 
of corticosteroids at a mean dose of 0.3mg/kg/d of prednisone equivalent for >3 weeks, treatment with other recognized T-cell 
immunosuppressants during the last 90 days or have an inherited severe immunodeficiency.  
‡    Hypervirulent clade RT027 (016, 019, 0247, 036, 075, 111, 112, 153, 156, 176, 208, 273) and clade RT078 (033, 045, 066, 078, 126, 127). 
¶   In the first 3 weeks post-FMT. 
Characteristic Patients with relapse  
within two months  
post-FMT 
Patients cured  




(OR [95% CI], p-value)
Patient sex (female) 77% (10/13) 58% (67/116) OR 2.4 [0.6-9.3], p-value 0.24
Donor sex (female) 54% (7/13) 50% (58/116) OR 1.2 [0.4-3.7], p-value 0.79
Donor – patient sex mismatch 39% (5/13) 47% (54/116) OR 0.7 [0.2-2.3], p-value 0.58 
Patient’s age (at FMT) 69 years (41-96) 70 years (2-92) p-value 0.76
Donor’s age (at donation) 36 years (24 – 46) 35 years (24-46) p-value 0.82
Lower gastro-intestinal infusion of 
FMT (sigmo- or colonoscopy)
23% (3/13) 8% (9/116) OR 3.6 [0.8-15.3], p-value 0.10
Mean processing time of the fecal 
suspension (defecation to freezer)
163 minutes 168 minutes p-value 0.73
Mean storage time of the fecal 
suspension (at -80°C) 
214 days 275 days p-value 0.27
Severe CDI as indication for FMT 8% (1/13) 2% (2/116) OR 4.8 [0.4-56.3], p-value 0.28
Prior CDI relapses,  
before FMT is performed
2.6 (13) 2.8 (114) p-value 0.69
PPI use 61% (8/13) 51% (55/108) OR 1.5 [0.5-5.0], p-value 0.47
Comorbidity of IBD 8% (1/13) 11% (13/114) OR 0.7 [0.1-5.4], p-value 1.0
Severe kidney comorbidity:  
dialysis or kidney transplantation
8% (1/13) 9% (24/112) OR 1.0 [0.1-8.2], p-value 1.0
rUTI in medical history 0% (0/13) 8% (9/113) p-value 0.60a
Use of non-CDI antibiotics in 
between the prior CDI episodes 















Hypervirulent clade‡ 25% (2/8) 20% (13/65) OR 1.3 [0.2-7.4], p-value 0.66
Post-FMT hospitalization  
for non-CDI indications post-FMT ¶  
23% (3/13) 14% (14/102) OR 1.9 [0.5-7.7], p-value 0.41
Post-FMT infection  
(other than CDI) ¶
15% (2/13) 17% (17/102) OR 0.9 [0.2-4.5], p-value 1.00
Post-FMT antibiotic use  
(non-CDI indications) ¶  
39% (5/13) 15% (15/102) OR 3.6 [1.0-12.6], p-value 0.03
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Patients: Follow-up of adverse events 
On the day of FMT, 66 % (62/94) of patients had mild, transient gastro-intestinal 
complaints (Table 4). At three weeks and at long-term follow-up, a subset of patients 
still reported abdominal pain (both 21 %) and diarrhoea (27 % and 33 %, respectively). 
The self-rated defecation pattern after FMT compared to the pre-existent defecation 
pattern (before the CDI episodes) had improved in 16 % at 3 weeks, and in 38 % at 
long-term follow-up (Table 4).  
 
Table 4. Gastro-intestinal complaints post-FMT 
 
Abbreviations  
FMT: fecal microbiota transplantation, LTFU: Long-term follow-up, n/a: not applicable,  
rCDI: recurrent Clostridioides difficile infection  
†   A questionnaire is filled in by the patient or treating physician at regular follow-up 3 to 4 weeks post-FMT  
‡   LTFU: long-term follow-up (median 42 weeks, range 19-143 weeks) 
 
No definitely or probably related serious adverse events were reported. Five (5/128, 
4 %) FMT (procedure)-related adverse events were observed (Table 5). Regurgitation 
of donor feces occurred in four patients shortly after duodenal infusion of the fecal 
suspension (Table 5). During the first three weeks after FMT, 23 % (26/115) of the 
patients were admitted to the hospital or had prolonged hospitalization, of which nine 
(8 %) for possibly FMT-related indications (Table 5). The most frequently observed 
infections after FMT were urinary tract infection (UTI) (8 %, 9/115) or pneumonia (5 %, 
6/115). The majority of patients suffering of these infections had known predisposing 
factors for UTI or pneumonia (Table 5). 
Gastro-intestinal complaint Day of FMT † 1-week post FMT † 3-weeks post FMT † LTFU ‡
Nausea (% yes) 20%  (19/94) 14%  (13/96) 11%  (11/97) 18%  (13/73)
Abdominal pain (% yes) 33%  (31/93) 28%  (27/97) 21%  (21/98) 21%  (15/71)
Diarrhoea (% yes) 52%  (48/93) 30%  (29/97) 27%  (26/97)  33%  (24/73)
Self-rated defecation pattern   
(post-FMT vs before CDI episode) 
   Improved          
   Similar 













16%  (13/80) 




38%  (25/65) 
46%  (30/65) 
15%  (10/65)








COPD: chronic obstructive pulmonary disease, CVA: cerebro vascular accident, GI: gastrointestinal, GvHD: graft versus host 
disease, PCR: polymerase chain reaction, RSV: respiratory syncytial virus, SCT: stem cell transplantation.  
† Four patients (80 %, 4/5) developing a pneumonia had a medical history of either COPD, asthma or lung fibrosis.  
‡ Four patients (44 %, 4/9) had known predisposing factors for UTI (medical history of pyelonephritis, diabetes type II and 
benign prostate hypertrophy, Sachse urethrotomy or Bricker bladder).  




SAE None 0% (0/128)
AE Procedure related AE’s 
   »  Regurgitation, no aspiration, patient successfully treated 
   »  Sore throat after placing duodenal tube
4% (5/128) 
–   4 
–   1
Possibly related 
to FMT
SAE Hospitalization within 3 weeks post-FMT due to: 
   »  Lower respiratory tract infection (causing pathogen unknown) † 
   »  Urinary tract infection (causing pathogen unknown) ‡ 
   »  Diarrhoea (non-CDI) 
8% (9/115) 
–   5 
–   3 
–   1
AE Gastro-intestinal (see Table 4) 
Infections 
   »  Urinary tract infection (causing pathogen unknown) ‡ 
   »  Urinary and lower respiratory tract infection† 
Other 
   »  Fever 
   »  Possible flare IBD (ulcerative colitis), uncertain if it was pre-existent
11 - 52% 
 
–   5 
–   1 
 
–   1 
–   1
Unrelated to 
FMT
SAE Hospitalization (or prolonged hospitalization) within 3 weeks post-FMT 
 
   »  Lower respiratory tract infection (COPD exacerbation due to Moraxella catarrhalis 
and RSV infection) 
   »  CDI relapse 
   »  Related to pre-existent comorbidity (elective surgery dialysis shunt, complications 
knee prosthesis, perforated diverticulitis, hyponatremia with tongue carcinoma, 
GvHD after allogenic stem cell transplantation (already existing), diarrhoea due to 
chemotherapy) 
   »  Death within 3 weeks post-FMT due to comorbidity (tongue carcinoma/hypo-
natremia, sepsis due to pneumonia, comorbidity GvHD lung after allo-SCT) 
   »  Infection with Yersinia pseudotuberculosis post-FMT, donor suspension tested 
negative (with both PCR and culture (cold enrichment-broth) 
   »  Perforated diverticulitis, in retrospect already present before FMT (upper GI 
delivery) 
   »  CVA
15% (17/115) 
 
–   2 
 
–   3 




–   3 
 
–   1 
 
–   1 
 
–   1
AE Infections 
Otitis, infection of toe, phlegmon groin
 
–   3
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Discussion  
During the four years since its establishment, the NDFB has evaluated over 175 FMT 
requests and provided standardized FMT to almost 130 patients affected by rCDI. A high 
cure rate of nearly 90% at two months after FMT and a sustained cure rate over 70% at 
42 weeks post-FMT was observed.  
The cure rate of FMT facilitated by the NDFB appears high compared to the 76% cure 
rate reported in a recent meta-analysis of single FMTs for rCDI [4]. This may be explained 
by the stringent criteria for diagnosis and treatment applied by our FMT expert panel [13]. 
This expert panel discusses the indication for FMT and provides advice during treatment 
and follow-up of the patients. We rejected a quarter of FMT requests, mainly because the 
diarrhoea was attributed to another cause that coincided with C. difficile carriership. Thus, 
consultation might prevent inappropriate use of FMT and increases the clinical benefits 
and cost-effectiveness. Our observation is similar to a previous report from an FMT-expert 
centre, which showed that 25% of patients referred for FMT did not have confirmed rCDI 
[18]. In particular, new onset or persistent activity of IBD appears to be a diagnostic pitfall 
[18, 19]. In addition, non-responsiveness to anti-CDI antibiotics seems to point to an alter-
native diagnosis rather than therapy-refractory CDI in most patients. In fact, only four of 
our 129 patients were deemed to suffer from therapy-refractory by the expert-panel. 
A subgroup of rCDI patients remains vulnerable for CDI after FMT, as 9% (10/107) of 
initially cured patients developed a late CDI recurrence. Of this group, 80% had used 
antibiotics preceding the recurrence, in contrast to only 39% of patients with an early 
relapse. This indicates that antibiotic use after FMT should be limited as much as poss-
ible for a prolonged period. It also emphasizes that a long follow-up after FMT is 
mandatory to assess the long-term efficacy of FMT. The majority (61 %) of early relapses 
was not preceded by antibiotics, indicating that other factors also contribute to FMT 
failures, such as an immunocompetence. Other studies have identified Charlson 
comorbidity index [20], the severity of CDI [21, 22], previous (CDI) hospita lisation [22, 23], 
inpatient status [22], surgery [23], female sex [23] and older age [24] to predict recurrence 
after FMT. We did not recognize donor-related factors contributing to FMT outcome, 
confirming previous reports [25-27]. The majority of patients with post-FMT CDI were 
cured with antibiotic treatment, suggesting that this should be considered a different 
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entity compared to the antibiotic resistant episodes prior to FMT. This could be explained 
as an FMT mediated gut microbiota reset, which renders patient less susceptible to rCDI 
after treatment with antibiotics alone.  
In our experience, duodenal delivery of donor feces was highly effective and certainly 
not inferior to delivery by colonoscopy, although this report was not designed as a study to 
compare routes of delivery. Duodenal FMT has a small risk of regurgitation. To prevent this, 
we currently advise slow infusion of the fecal suspension in the duodenum (10 cc/min), 
room temperature of the suspension to avoid cold shock, and colonoscopic delivery in 
case of possible bowel dysmotility. After introduction of these precautions, regurgitation 
was no longer recognized. We did not observe FMT-related serious adverse events. Several 
patients developed a UTI (9/115) or pneumonia (6/115) after FMT. This might be explained 
by existing predisposing factors in most patients, although a relation with FMT cannot 
be fully excluded. Interestingly, it has been suggested that the incidence of UTI could 
decline after FMT due to a reduced abundance of Enterobacterales in the gut [28]. About 
21 %-33 % of patients suffered from abdominal complaints at follow-up. This is in line 
with a previous report, in which no FMT-attributable factors could be identi fied [29]. 
Remarka bly, at long-term follow-up, the self-rated defecation pattern im proved (38%), or 
had stayed unchanged (46 %) in most of our patients, compared to the period before the 
first CDI episode, suggesting that gastro-intestinal symptoms after FMT could be related 
to post-infectious complaints and pre-existent comorbidity. Post-infectious irritable bowel 
complaints after CDI were also reported in 4 to 25 % of patients not given FMT [30]. 
We observed a low two months mortality rate of 3 % (3/120) after FMT, which is 
lower than the 30-day mortality rate of primary CDI in the Netherlands (9 % overall 
mortality) [31]. The mortality of 12 % at long-term follow-up (median 42 weeks) is lower 
than observed in two other FMT cohorts (20 % at weeks 30 and 48 post-FMT) [32, 33].  
A strength of our evaluation report is the structural follow-up of donors and patients 
of a complete stool bank cohort, with use of standardised questionnaires and over a long 
period of time post-FMT. Several studies report on retrospective analyses of only specific 
patient groups treated with stool bank FMT-suspensions without structural long-term 
follow-up. In one of the largest retrospective studies, 307 of 528 (39 %) rCDI patients 
were successfully contacted, a sustained cure of 76% at 34 months follow-up was 
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observed [33]. Our high sustained cure rate is confirms this observation. A limitation of 
our report is that 26 % patients were lost to long-term follow-up, and late recurrent CDI 
may be overestimated as these were actively reported to the NDFB by the local 
physicians. This is supported by the fact that no unreported recurrences were detected 
with the follow-up questionnaires. Another limitation, also related to the setting of a 
national stool bank, is the lack of nation-wide uniform microbiological testing, which 
may have influenced the process of consultation and the outcome of the treatment. 
The risk of infectious complications after FMT depends on appropriate donor screen-
ing. This may even be more important for severely immunocompromised patients, as 
suggested by the cases where transfer of MDRO by FMT in neutropenic patients resulted 
in sepsis and death [34]. Only 2% of potential donors were eventually eligible after 
extensive selection and screening. This is comparable to the donor qualification rate of 
3% of a large US stool bank [8]. Others reported higher donor acceptance rates of 10-
31% [35-37]. Unfortunately, donor exclusion criteria and screening-protocols are hetero-
geneous and often incomplete [38], underlining the need for standardization of donor 
screening. After initial donor acceptance, a quarter of our donors were excluded at the 
first quarantine screening. In addition, over half of the active donors stopped donating 
after six months for logistic reasons or persistent colonization by a potential pathogen. 
A high dropout rate was also observed in Canada; four of five approved donors were 
excluded during the quarantine period due to travel or acute gastro-enteritis [39]. This 
demonstrates the need for a quarantine period and targeted screening on indication 
before fecal suspensions can be used safely. Although the identification of potential 
pathogens such as MDRO, norovirus, or rotavirus in asymptomatic, active donors is rare, 
the NDFB performs complete micro biological screening of the dedicated fecal 
suspension when the recipient is severely immunocompromised. In the future, donor 
selection will be even more challenging if specific donor characteristics are required 
for FMT treatment for indications such as ulcerative colitis or hepatic encephalopathy 
[25]. In this regard, the finding that fecal suspensions with a shelf life of two years at -
80°C are safe and evenly efficacious for treatment of rCDI is encouraging.  
In conclusion, the use of strict donor selection criteria, standardized processing and 
storage of FMT suspensions, and consultation by a multidisciplinary FMT-expert team, 
as provided by a professional stool bank, results in safe and efficacious application of 
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FMT for rCDI. With the increasing number of reports pointing to potential beneficial 
effects of FMT in patients with a variety of gastrointestinal and extra-intestinal disorders, 
a growing demand of FMT can be expected in the near future. Initially, experimental 
studies will have to be performed in a controlled setting. However, for routine clinical 
practice, standardised preparation, quality control and careful and long-term monitoring 
of outcomes and adverse events, stool banks are required. We encourage FMT-centres 
and stool banks to utilize a multidisciplinary FMT-experts team to fill a currently existing 
gap, and ensure a safe and controlled application of FMT. 
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Supplementary material  
Table S1. Donor selection and screening 
 
Donor screening by questionnaire, when donors pass the questionnaire, laboratory screening of feces will follow. Feces is first 
screened for the presence of Dientamoeba fragilis and Blastocystis sp. When negative, other pathogens are investigated, after 
which screening of serum is performed. If a donor is suitable for donation, before every donation a questionnaire about the 
recent health status should be filled in.  
a Or 60 years when no colon cancer is detected during the national colon cancer screening programme.  
b In case of rescreening, only repeat when prior sero-negative, to detect seroconversion and subsequent potential transmission 
via feces.  
c In case of rescreening only when travelled outside Europe.  
d In case of rescreening only when travelled to Middle and South America, Africa or Asia.  
Exclusion criteria by questionnaire:  
Age < 18 or ≥ 55a, BMI < 18.5 or > 25 [40, 41], high risk fecal- and or blood transmittable diseases, recent antibiotic 
use (<6 months) [42, 43], gastrointestinal complaints (for example diarrhoea, obstipation or irritable bowel like 
symptoms) [44-46], recent travel to endemic areas of gastrointestinal pathogens, (first degree relative with) inflammatory bowel 
disease [47], known systemic infection, liver diseases like hepatic encephalopathy or Non Alcoholic Fatty Liver Disease [5, 48], 
History of cancer, including GI malignancy or polyposis [49], first degree relative with a GI malignancy < 60 years or family 
history of genetically-driven cancer, metabolic syndrome [50], substantial comorbidity, chronic medication use [51], 
autism [52-54], auto-immune disorders [55], neurological/neurodegenerative disease [56, 57], atopic diseases [58]
Laboratory screening serum  
 
Hepatitis A (IgM + IgG)b 
Hepatitis B (HBsAg + anti-Hbcore) 
Hepatitis C (anti-HCV) 
Hepatitis E (IgM + IgG)b 
HIV (anti-HIV, type 1 and 2) 
Lues; Treponema pallidum (Ig) 
Cytomegalovirus (IgM + IgG)b 
Epstein Barr Virus (IgM + IgG)b 
HTLVc 
Strongyloïdes (IgG1/IgG4)d 
Laboratory screening feces 
 
Clostridioides difficile (PCR) 
Helicobacter pylori (antigen test) 
Bacterial gastro-enteritis: (PCR): Salmonella spp. Campylobacter spp.,  
Campylobacter jejuni, C. coli, Shigella spp., Yersinia enterocolitica and Y. pseudotuberculosis, 
Aeromonas spp., Plesiomonas shigelloides, and Shiga Toxin producing E.coli  
Antibiotic resistant bacteria (culture); ESBL and/or carbapenemase producing bacteria, 
aminoglycoside AND quinolone resistant Enterobacterales, vancomycin resistant 
Enterococci and methicillin resistant Staphylococcus aureus 
Viral pathogens (PCR): Norovirus serotype I+II, Astrovirus, Sapovirus, Rotavirus, 
Adenovirus 40/41, Adenovirus non-40/41, Enterovirus, Parechovirus,  
Parasites (PCR): Giardia lamblia, Entamoeba histolytica, Cryptosporidium parvum and 
C. hominis, Microsporidium spp, Cystoisospora belli, Cyclospora cayetanensis. Strongyloïdes d 
Microscopy for ova, cysts and larvae [59]: for example: Blastocystis sp.
Questionnaire recent health status: One day before donation of feces 
Stool frequency/pattern, general health, use of antibiotics, travel history, sexual behaviour
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Table S2. FMT success rate individual donors 
 
*   Number of patients with an early relapse/late recurrence who received a faecal suspension of a specific donor/ total number 
of faecal suspensions of that donor used. 
Donor Early relapse rate  (CDI <2 months post-FMT)*
Late recurrence rate  
(CDI >2 months post-FMT)*
1. 11.8% (2/17) 5.9% (1/17)
2. 0% (0/3) 0% (1/3)
3. 0% (0/4) 0% (0/4)
4. 25% (1/4) 0% (0/4)
5. 16% (4/25) 16% (4/25)
6. 0% (0/22) 13.6% (3/22)
7. 11.1% (2/18) 0% (0/18)
8 0% (0/3) 0% (0/3)
9. 0% (0/4) 0% (0/4)
10. 9.1% (2/22) 4.5% (1/22)
11. 0% (0/4) 0% (0/4)
12. 66.7% (2/3) 0% (0/3)




Number of patients at risk for CDI after FMT:  
 
Figure S1. Kaplan Meier curve of Clostridioides difficile infection (FMT failure, early 
relapse or late recurrence)-free survival post-FMT of patients receiving (red line) 
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Number of patients at risk for CDI after FMT:  
 
Figure S2. Kaplan Meier curve of Clostridioides difficile infection (FMT failure, early 
relapse or late recurrence)-free survival post-FMT of immunocompetent (blue line) 
versus moderately (red line) or severely (green line) immunocompromised patients. 
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Human transmission of 
Blastocystis by Fecal Microbiota 
Transplantation  
without development of gastrointestinal symptoms 
in recipients
Chapter 
Chapter 7. Human transmission of Blastocystis 
by Fecal Microbiota Transplantation without develop -
ment of gastrointestinal symptoms in recipients 
Abstract  
Background: Patients with multiple recurrent Clostridioides difficile infections 
(rCDI) are treated with fecal microbiota transplantation (FMT) provided by 
healthy donors. Blastocystis colonization of donors is considered an exclusion 
criterion, whereas its pathogenicity is still under debate.  
Methods: The introduction of molecular screening for Blastocystis sp. at our 
stool bank identified two donors with prior negative microscopy but positive 
PCR. Potential transmission of Blastocystis sp. to patients was assessed on 16 
fecal patient samples, pre- and post-FMT, by PCR and subtype (ST) analysis. 
In addition, clinical outcome for treatment of rCDI (n=31), as well as develop -
ment of gastrointestinal symptoms was assessed. 
Results: There was one donor carried Blastocystis ST1, the other contained 
ST3. All patients tested negative for Blastocystis prior to FMT. With a median 
diagnosis at 20.5 days after FMT, 8 of 16 (50 %) patients developed intestinal 
colonization with Blastocystis, with identical ST-sequences as their respective 
donors. Blastocystis containing fecal suspensions were used to treat 31 rCDI 
patients, with a FMT success rate of 84 %. This success rate was not statis-
tically different from patients transferred with Blastocystis sp. negative donor 
feces (93 %, 76/82). Patients transferred with Blastocystis sp. positive donor 
feces did not report any significant difference in bowel complaints in the first 
week, after 3 weeks and the months following FMT. 
Conclusions: We demonstrated the first transmission of Blastocystis ST1 and 
ST3 from donor to patients by FMT. This did not result in gastrointestinal 
symptomatology or have any significant effect on rCDI treatment outcome.
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Blastocystis is a genus of common unicellular intestinal parasite in humans and 
animals which belongs to the stramenopiles, one of the eight major phylogenetic 
groups of eukaryotes. It is a diverse genus comprising of 17 characterized lineages, the 
so-called subtypes (ST1 – ST17), of which nine have been reported to occur in the 
human gastrointestinal tract  [1, 2]. Blastocystis sp. carriage is very common but varies 
globally from 0.5 % in Japan, to 100 % in Senegal and 30-50 % in Europe  [3 -6].  
The pathogenicity of Blastocystis sp. is uncertain, and in general it is considered an inno -
cent parasite  [7]. The presumed entero-pathogenicity is based on anecdotal case reports 
and retrospective reviews and is mainly tested in animal models  [8, 9]. The symptoms attri -
buted to this organism include nausea, anorexia, abdominal pain, flatu lence and acute or 
chronic diarrhea  [8]. However, outbreaks have never been reported and a human challenge 
model has not been applied. An association of Blastocystis sp. with irritable bowel 
syndrome (IBS) was suggested  [10, 11], but could not be confirmed in two large cohort 
studies  [4, 12]. Interestingly, Blastocystis sp. is found to be less prevalent in patients with 
inflammatory bowel disease (IBD), a disorder which is associated with a reduced diversity 
of the gut microbiota  [4, 13, 14], and asymptomatic Blastocystis sp. carriers tend to have 
a more diverse microbiota  [4, 15-20]. These observations could indi cate that the presence of 
Blastocystis sp. may reflect a more healthy and diverse state of the gut micro biota.  
Patients with multiple recurrent Clostridioides difficile infection (rCDI) are treated with 
fecal microbiota transplantation (FMT) prepared with feces of healthy donors. 
Carriership of Blastocystis sp. by healthy donors is considered an exclusion criterion for 
donation by several stool banks, including the NDFB  [21 -26], resulting in considerable 
exclusion of donors (30-50 %). It is questionable whether this is justified. Therefore, 
Key points 
Transmission of Blastocystis by Fecal Microbiota Transplantation from colonized 
donors occurred in 50 % of treated patients. Transfer did not result in develop -
ment of gastrointestinal symptoms or affect the outcome of the FMT treatment 
in patients with recurrent Clostridioides difficile infections. 
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knowledge about potential side effects and treatment success of co-transplantation 
of Blastocystis sp. with FMT is warranted. This study reports the co-transmission of 
Blastocystis sp. from donor to patient, and the influence on the outcome and health of 
rCDI patients receiving FMT.  
Methods  
Donors and donor fecal suspensions for FMT 
The Netherlands Donor Feces Bank (NDFB) is located within the Department of 
Medical Microbiology at the Leiden University Medical Center (LUMC) and started 
with treatment of patients with multiple rCDI with FMTs in 2016 [21]. All donors of the 
NDFB are healthy individuals between the age of 18 and 50, with normal weight (BMI 
18.5 – 25) and no relevant medical history or medication use. All donors are extensively 
screened and rescreened for disorders associated with a perturbed microbiota and 
potential transmissible infectious diseases  [21].  
The NDFB uses standardized procedures for collection, preparation and storage of 
donor fecal suspensions as described earlier  [21]. In short, donors deliver stool at the 
NDFB within two hours after defecation. Sixty grams of donor feces is used to prepare 
one fecal suspension. The feces was homogenized with sterile saline with use of mortar 
and pestle, sieved, centrifuged until an end volume of 200ml (containing 10 % glycerol). 
Two cc of the final fecal suspension, and two grams of original donor stool are sepa -
rately aliquoted and stored as quality control. The fecal suspensions are stored within 
six hours following defecation. Storage is accommodated by a certified centralized bio -
banking facility in a dedicated -80 °C freezer with connected alarm notification and 
biobanking information and management system (BIMS SampleNavigator®).  
Patient selection and treatment  
Requests for FMT in rCDI patients are carefully evaluated by the working group of 
the NDFB. Upon approval, the NDFB facilitates FMT by providing ready-to-use fecal 
suspensions for treatment at the local hospital as previously described  [21]. Patients are 
preferably pretreated with vancomycin (125-250mg QID) for a minimum of four days, 
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followed by two liters of macrogol solution (bowel lavage) one day prior to FMT. The 
thawed fecal suspension is slowly infused through a duodenal tube, or via colon-
oscopy in selected patients.  
Follow-up  
Routine follow-up of patients consists of a standardized questionnaire three weeks 
post-FMT filled out by their local, treating physician and a telephonic interview performed 
by a member of the NDFB working group two months post-FMT. For this study an addi -
tio nal telephonic interview was performed between in January 2019, five to 33 months 
post-FMT. In addition, treating physicians were asked to contact the NDFB in case of any 
adverse events or treatment failures. Success of FMT was defined as reso lu tion of CDI 
symptoms without relapse of CDI within two months. A relapse of CDI was defined as 
the development of diarrhea for at least two consecutive days within two months following 
FMT, either in combination with positive free feces toxin test or PCR (proven relapse), or 
clinical suspicion for CDI (probable). A CDI episode occurring at a later timepoint than two 
months post-FMT was regarded as a new CDI episode, as pro po sed by the European 
Society of Clinical Microbiology and Infectious Diseases (ESCMID)  C. difficile treatment 
guideline  [27]. The development of gastro-intesti nal and other adverse events was also 
assessed, including nausea, vomiting, burping, abdominal pain, diarrhea not caused by 
rCDI, obstipation, hospital admittance, antibiotic use, and we included an open field for 
other complaints. In addition, participants were asked to evaluate their defecation pattern 
post-FMT compared to pre-FMT (improved, similar or deteriorated). 
Stool samples of patients were collected before and approximately three weeks after 
FMT. Stool samples were preserved until use at -80°C. Patients provided informed 
consent for collection of stool samples and outcome data of FMT for research purposes, 
which was approved by the Medical Ethics Committee at the Leiden University Medical 
Center (P15.145).  
Blastocystis sp. diagnostics and typing 
Stool samples of the donors were routinely screened for Blastocystis sp. presence by 
direct microscopy of the feces and Ridley-Allen sedimentation method  [28]. This 
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screening was performed on fresh donor stool (<2 hours after defecation). With the 
introduction of a specific Blastocystis PCR at our department in 2018, two donors were 
identified with negative microscopy but positive PCR for Blastocystis sp. In retrospect 
all donated fecal samples used to treat patients were tested for the presence of 
Blastocystis sp. with a specific PCR targeting approximately 360 bp of the small subunit 
ribosomal RNA gene (see Supplementary material). Positive samples were subtyped 
using sequence analysis as described previously  [29]. Furthermore, 16 available pre- and 
post-FMT fecal samples of the patients treated by these two respective donors were 
tested with Blastocystis sp. PCR and when positive subsequently subtyped. Blastocystis 
sp. PCR positive patients and donors were regarded as Blastocystis sp. colonized 
Statistics  
Statistical analysis was performed using SPSS 23.0 statistical software. To test for 
differences between the prevalence rate of relapses and gastrointestinal symptoms of 
Blastocystis sp. positive versus negative donors and patients a Chi-square test or Fischer 
exact in cases of n < 5, was performed. An odds ratio (OR) was calculated using logistic 
regression and presented with a 95 % confidence interval  [95 % CI]. For ordinal data 
a linear-by-linear association test was used. In addition, a Kaplan-Meier curve and log-
rank test to compare CDI free survival between patients receiving Blastocystis sp. 
positive or negative donor feces was performed. For statistical comparisons, a p- value 
below 0.05 was considered statically significant. 
Results  
Blastocystis sp. positive donors 
In the period between May 2016 and December 2018, 110 patients were treated with 
113 FMTs, using fecal suspensions of 10 donors. In two out of 10 donors, Blastocystis 
sp. testing revealed a negative stool microcopy but in retrospect a positive PCR, with 
Cycle quantification (Cq) value’s ranging from 18.95 to 25.13 (Table 1). Subtype analysis 
revealed one donor with Blastocystis subtype (ST) 1, and the other donor with ST3. The 
Blastocystis ST1 donor carried the Blastocystis for at least three donating months, and 
the second donor carried the Blastocystis ST3 for at least nine donating months. 
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Patients treated with Blastocystis sp. containing FMT suspensions 
Donor feces suspensions of Blastocystis sp. positive donors were used for rCDI 
 treatment of 31 patients; four patients were treated with donor feces containing 
Blastocystis ST1, 27 with Blastocystis ST3. From 16 of 31 patients, stool samples pre-FMT 
and post-FMT were available. All fecal samples of the patients prior to FMT tested 
Blastocystis sp. negative (Table 1). With a median of 20.5 days (5-53 days) post-FMT, 
8 of 16 (50 %) patients developed intestinal colonization with Blastocystis; 7 of 14 with 
ST3 and 1 of 2 with ST1 (Table 1). Patient DNA sequences of part of the Blastocystis 
small subunit rRNA region were 100 % identical to the sequences of their respective 
donors.  
Patient follow-up rCDI treatment 
Of the 113 FMT’s performed in 110 patients to cure rCDI, 31 FMTs were performed 
with feces from the Blastocystis sp. positive donors, 82 with Blastocystis sp. negative 
donor feces. Patients treated with Blastocystis sp. positive donor feces had a FMT 
success rate (cure without relapse < 2 months) of 84 % (26/31), whereas treatment 
with Blastocystis sp. negative donor feces had a success rate of 93 % (76/82). This 
difference in success rate was not significant (Table 2, Figure 1). Moreover, no signifi -
cant difference in the number of confirmed (three versus three) and probable CDI 
relapses (two versus three) was found (OR 1.5, 95 % CI  [0.14, 16.54], p- value 1). Of 
a total of 11 relapses of CDI, three were challenged by antibiotic treatment, whereas 
eight (five in Blastocystis positive and three in Blastocystis negative treated patients) 
developed a relapse without antibiotics as predisposing factor. The ST1 and ST3 
Blastocystis sp. positive donor fecal suspensions were used for treatment of four, and 
respectively 27 rCDI patients. Treatment with feces of the Blastocystis sp. ST1 donor 
resulted in a treatment success of 75 % (1/4), whereas the ST3 donor had a success 
rate of 85 % (4/27) (OR 0.522, 95 % CI  [0.04, 6.36], p- value = 0.525). In addition, no 
difference was found in relapse rate between patients with (12.5 %, 1/8) or without 
(0 %, 0/8) Blastocystis sp. colonization following FMT with a Blastocystis sp. containing 
donor suspension (OR 1.143, 95 % CI  [0.88, 1.49], p- value 1).  
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Table 2. Follow-up of rCDI FMT treatment success of patients transferred with 
Blastocystis sp. positive versus negative donor feces. 
 
Abbreviations: CDI, Clostridioides difficile infection, CI: confidence interval, FMT: fecal microbiota transplantation, OR: odds ratio. 
Percentages and final odds ratio with 95 % confidence intervals of the FMT treatment outcome between patients treated with 
Blastocystis sp. positive versus negative donor feces. A chi-square test or Fischer exact test in cases of n < 5, was performed. 
 
Nine (8.0 %, 9/113) patients experienced a new episode of CDI later than two 
months after FMT, with a median of four months (range 63 – 402 days) post-FMT. All 
new episodes could be attributed to initiation of antibiotic treatment shortly before 
development of CDI symptoms. The frequency of development of a new initial episode 
of CDI was not statistically different in patients transferred with Blastocystis sp. positive 
feces (9.7 %, 3/31) versus Blastocystis sp. negative (7.3 %, 6/82), Table 2, Figure 1. 
Moreover, no statistically significant difference in development of a new initial CDI 
episode was found between ST1 (0 %, 0/4) and ST3 (11.1 % 3/27) transferred patients 
(OR 0.889, 95 % CI  [0.78, 1.02], p- value 1), or between patients that were demonstrable 
Blastocystis colonized post-FMT using Blastocystis containing donor feces (12.5 %, 1/8) 
versus demonstrable Blastocystis negative post-FMT (0 % 0/8) (OR 1.143, 95 % CI  [0.88, 





Blastocystis sp.  
positive donor feces 
Blastocystis sp.  
negative donor feces 
Significance  
(OR [95% CI], p-value)
FMT success rate  83.9 % (26/31) 92.7 % (76/82) OR 0.411  [0.12, 1.46]         p-value 0.159
Relapses of CDI 16.1 % (5/31) 7.3 % (6/82) OR 2.436  [0.69, 8.65]         p-value 0.159
New CDI episode  
(> 2 months after FMT) 
9.7 % (3/31) 7.3 % (6/82) OR 1.357  [0.32, 5.80]  p-value 0.704
CDI event  
(relapse or new episode
25.8 % (8/31) 14.6 % (12/82) OR 2.029  [0.74, 5.88]        p-value 0.165
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Figure 1. Kaplan Meier curve of  C.  difficile infection (CDI) event free survival in 
patients post-FMT treated with Blastocystis sp. positive versus Blastocystis sp. 
negative fecal suspensions. 
CDI free survival is defined as survival without relapse (<2 months post-FMT) or new CDI infection 
(>2 months post-FMT) within two years (104 weeks) after FMT. Follow-up data exceeding 2 years, 
was censored at 104 weeks. Patients suffering from a new CDI event after 104 weeks were counted 
as no CDI even.  
Abbreviations: CDI: Clostridioides difficile infection, FMT: fecal microbiota transplantation 
Potential side-effects due to newly acquired Blastocystis sp. 
colonization following FMT  
Compared to patients treated with Blastocystis sp. negative donor feces, patients 
treated with Blastocystis sp. positive donor feces did not report significantly more bowel 
complaints (nausea, abdominal pain or diarrhea) after one week, three weeks or at 
long term follow up (median 35 weeks, range 10 – 143 weeks) (Table 3). Moreover, no 
difference in side-effects was observed in the subgroup of patients with demonstrable 
Blastocystis sp. colonization after FMT. Interestingly, a significant difference towards an 
improvement of the self-evaluated defecation pattern was observed at long-term 
follow-up in patients receiving Blastocystis sp. positive donor feces (Table 3).  
 




Healthy stool donors colonized with Blastocystis sp. are usually excluded from 
FMT donorship  [21 -26], though the enteropathogenicity of Blastocystis sp. remains 
debatable  [7]. Through a combination of PCR and subtyping techniques of donor, 
patient pre-FMT and post-FMT fecal samples, the first human to human transmission 
by FMT of Blastocystis sp. ST1 and ST3 was described. This transmission did not 
influence the success rate of the FMT to treat rCDI. More importantly, it did not result 
in gastrointestinal symptomatology of the recipients. 
Symptoms attributed to Blastocystis sp. infection described in anecdotal case reports, 
series and retrospective cohorts include nausea, anorexia, abdominal pain, flatulence 
and acute or chronic diarrhea  [8]. The high prevalence of Blastocystis sp. colonization 
in healthy individuals suggests Blastocystis sp. does not harm most hosts. As Blastocystis 
consists of 17 subtypes, initially the idea was raised that subtype correlated with 
pathogenicity  [30]. Numerous, globally performed studies comparing the subtypes of 
Blastocystis could not confirm such a consistent correlation and could not explain the 
pathogenicity in some patients  [30]. Currently, it is mostly acknowledged that Blastocystis 
sp. may colonize many hosts, but the infection’s potential depends on the interplay 
between the virulence of the parasite, number of infecting parasites present, duration of 
infection (acute versus chronic) and host factors like genetics, immune competence or 
gut microbiota composition  [3, 4, 20, 30, 31]. The two identified subtypes in this study, ST1 
and ST3, are the most commonly found subtypes in Europe and the Netherlands  [3]. In 
a Dutch study in which the stool samples of 442 patients were evaluated by routine 
parasitological examination, 107 (24 %) stool samples contained Blastocystis sp., of which 
40 % Blastocystis ST3 and 21 % Blastocystis ST1  [3]. The sustained colonization with 
Blastocystis ST1 and ST3 observed in 50 % (median 20.5 days) of Blastocystis transferred 
patients in this study, did not result in gastro-intestinal symptomatology, as determined 
by patient follow-up questionnaires. In contrast, these Blastocystis sp. transferred patients 
evaluated their defecation pattern significantly better post-FMT compared to patients 
receiving Blastocystis sp. negative donor feces.  
Unfortunately, a human challenge model to study the presumed entero patho -
genicity of Blastocystis sp. has not been described  [7]. In our study, the transfer of 
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Blastocystis sp. was accompanied by a healthy donor microbiota. This may not reflect 
the effects of Blastocystis sp. transfer from individuals with intestinal complaints or 
a disturbed microbiota to individuals with a healthy microbiota. Interestingly, Blastocystis 
sp. may not be able to maintain itself in a dysbiotic rCDI microbiota, since we found that 
none of the rCDI patients carried Blastocystis sp. pre-FMT. Low Blastocystis sp. coloni -
zation rates in diseased individuals were previously also reported in patients with active 
IBD or hepatic encephalopathy  [4, 13, 14, 32]. These diseased individuals and rCDI 
patients have a perturbed gut microbiota in common. Whether the association between 
a perturbed microbiota and low Blastocystis sp. colonization is a result from an absence 
of Blastocystis sp., or from the inability of Blastocystis to colonize and sustain in a dys -
biotic gut microbiota composition is an interesting question which merits further research.  
In this study the importance of performing appropriate Blastocystis sp. diagnostics 
is shown. The NDFB used microscopy on unfixed material, and Ridley-Allen sedimen -
tation to detect Blastocystis sp., in contrast to the more superior techniques using 
microscopy on two sodium acetate formalin (SAF) fixated stool samples or molecular 
detection of a single stool sample  [3]. Blastocystis sp. colonization of the donors or 
patients was, therefore, defined by positive PCR, irrespective of microscopic findings. 
Post-FMT stool samples with a positive Blastocystis sp. PCR were taken more than two 
weeks post-FMT. Together with the relative low Cq values (high load) found in these 
rCDI patients post-FMT suggests actual Blastocystis colonization instead of Blastocystis 
passage after FMT. 
There is no consensus among FMT centers and stool banks about Blastocystis sp. 
screening of donors, though published guidelines still recommend screening, especially 
for immunocompromised patients  [24]. Many centers do not screen for Blastocystis sp., 
and according to a recent systemic review only 14.5 % of 168 studies reported specific 
Blastocystis sp. screening  [33]. In addition, the method of screening for ova and parasites 
was often not stated  [21 -26]. Consequently, we assume that a substantial number of 
patients has received FMT treatment for rCDI or other diseases in experimental setting, 
with co-transplantation with Blastocystis sp.  
Our study is the first study that indicates that Blastocystis sp. transmission does not 
result in gastrointestinal symptoms of recipients. In the setting of rCDI, transmission 
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of Blastocystis ST1 and ST3 via FMT did not result in a significant decrease in efficacy 
of FMT, although there was a non-significant trend towards an increased rate of CDI 
events (both relapses and new episodes) in patients treated with Blastocystis sp. 
positive donors (8/31) versus Blastocystis sp. negative donors (12/82). Interestingly, this 
contrasts with expected outcomes as one could have extrapolated from recent 
metagenomic studies, in which Blastocystis sp. is correlated with a more diverse and 
healthy microbiota, a general prerequisite of a good donor  [4, 15-20]. In a large cohort 
of 1106 healthy Flemish individuals, Blastocystis sp. carriership was associated with 
higher microbial diversity, richness and composition. Tito et al, found that the most 
common subtypes in Europe, ST1, ST2, ST3 and ST4, were all associated with a higher 
diversity, though ST1 and ST3 (which were identified in our study) had a lower diversity 
increase than ST2 and ST4  [4]. For FMT treatment of rCDI, super donors have not been 
detected  [34, 35] and all donors display a high cure rate of around 85 %  [21]. The role of 
super-donors, could play a more significant role in possible future FMT indications 
other than rCDI, such as ulcerative colitis, metabolic syndrome, eradication of multi-
drug resistant organisms or hepatic encephalopathy  [4, 36, 37]. 
In this study only transfer of Blastocystis ST1 or ST3 was studied. To assess the 
contribution of Blastocystis sp. transfer to FMT success, it is important to include 
microbiota data of donors and patients, other subtypes of Blastocystis, and longer-term 
follow-up as colonization is described up to 6 – 10 years  [38]. An important limitation 
of this study is voluntary reporting by the treating physicians of late CDI relapses (after 
three weeks) or new CDI episodes (after two months) to the NDFB. However, 
physicians had a low threshold to contact the NDFB, since an excellent relationship 
was developed during the entire process of FMT request and treatment of the patient.  
In conclusion, to the best of our knowledge we demonstrate the first transmission 
of Blastocystis ST1 and ST3 from donor to recipient via FMT without development of 
gastrointestinal symptoms. This study is an important step towards a possible exempt 
of Blastocystis sp. (ST1 and ST3) as donor exclusion criterion in FMT.  
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Fecal microbiota transfer for 
multidrug resistant Gram-negatives; 
a clinical success combined 
with microbiological failure  
Chapter 
Chapter 8. Fecal microbiota transfer for multidrug 
resistant Gram-negatives; a clinical success 
combined with microbiological failure 
Abstract  
Combined fecal microbiota transfer (FMT) and antibiotic treatment pre -
vented recurrences of urinary tract infections with multidrug resistant (MDR) 
P. aeruginosa, but failed to eradicate intestinal colonization with MDR E. coli.  
Based on microbiota analysis, failure was not associated with distinct 
diminished microbiota diversity. 
Introduction  
Multidrug resistance (MDR) of Enterobacteriaceae is an increasing worldwide problem 
that challenges the treatment of common bacterial infections. MDR has been declared 
one of the greatest challenges to global public health today, and innovative strategies 
for decolonization of MDR bacteria are urgently needed to reduce the use of reserve 
antibiotics and prevent transmission  [1]. A few reports mention success with fecal 
microbiota transfer (FMT) to eliminate extended-spectrum β-lactamase (ESBL) pro -
ducing Enterobacteriaceae. Failures have not been reported. We present a 34-year old 
patient on peritoneal dialysis, treated with FMT to eradicate a Verona Integron-encoded 
Metallo-β-lactamase (VIM)-positive Pseudomonas aeruginosa causing recurrent urinary 
tract infections, which hampered planned kidney-pancreas transplantation. Microbiome 
analysis was performed prior to and after infusion of fecal microbiota.  
Case description  
A 34-year old male with type 1 diabetes mellitus was referred to our tertiary hospital 
because of diabetic nephropathy. Screening for combined kidney pancreas trans-
plant started. Two months after starting hemodialysis, he was admitted because of 
bacteremia and catheter related thrombophlebitis of the brachiocephalic vein by 
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Staphylococcus aureus, which was treated with flucloxacillin for 6 weeks. Because the 
extensive thrombosis prohibited shunt or catheter placement, he was converted to peri-
toneal dialysis (PD). During admission, a transurethral catheter was placed because 
of neurogenic bladder dysfunction. Shortly after discharge he returned to our hospital 
with a febrile catheter-related urinary tract infection (UTI) and was treated empirically 
with ceftazidim. Urinary cultures were positive with a blaVIM carbapenemase produ -
cing P. aeruginosa, resistant to carbapenems, cephalosporins, quinolones, aminoglyco -
sides and fosfomycin, only susceptible to colistin with a MIC of 4mg/L. The same 
P. aeruginosa was isolated from a rectal swab and the PD-catheter exit site. The patient 
received colistin intravenously (IV) for 2 weeks and the urinary and PD catheter were 
replaced. In the following months, the patient suffered from recurrent febrile UTIs due 
to the MDR P. aeruginosa (details on antibiotic use shown in Figure 1). Because of the 
high likelihood of recurrence of UTI caused by this MDR organism for which the only 
antibiotic was nephrotoxic, kidney transplantation was considered contraindicated and 
the patient was removed from the waiting list. During colistin treatment of the third 
episode, a plan for decolonization was developed. The transurethral catheter was 
removed and intermittent catheterization with twice weekly prophylactic intravesical 
high dose gentamicin instilments was started. Repeated negative cultures of urine, PD 
catheter-skin interface, skin, ears and throat excluded chronic prostatitis or coloniza -
tion at other sites than the gut. No oral selective digestive decontamination was given. 
After consultation with our ethics committee, informed consent was obtained from the 
patient for treatment with fecal microbiota. Six weeks after the last IV course of colistin, 
the infusion of FMT was performed.  
Material and methods  
Donor feces infusion was performed using the support of the National Donor Feces 
Bank (http://www.ndfb.nl/) according to the FECAL trial protocol with minor modifica -
tions  [2]. In summary, donor feces was obtained from an unrelated healthy volunteer. 
Donor serum and feces were extensively screened for fecal and blood transmitted 
diseases including MDR bacteria. 75 gram of feces was homogenized with saline, and 
sieved (300μm mesh) to remove undigested food fragments. Within 8 hours after 
defecation of the donor, 300ml fecal suspension was infused in the duodenum of the 
patient through a nasoduodenal tube, after full colon lavage. Stool samples were 
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collected prior to infusion, after 1 week, 2 weeks, 1 month, 2 months and 3 months 
and screened for MDR presence using selective enrichment media, as described 
 pre viously  [3]. A portion of the feces was stored within 4 hours after delivery at -80°C for 
microbiome research. To assess the relatedness of bacterial strains, Amplified Frag ment 
Length Polymorphism (AFLP) technique was performed as described previously  [4]. 
Microbiota analysis  
Bacterial DNA was isolated from the fecal samples using the ZR Fecal DNA MiniPrep 
kit (Zymo Research). Library preparation and amplification of the V4 hyper variable 
region 16S rRNA gene was performed using NEXTflex 16S V4 Ampliconseq kit v2.0. 
High-throughput sequencing was executed at ServiceXS (Leiden, the Netherlands) on 
the Illumina Hiseq 2500 platform (Illumina, San Diego, USA) in rapid run mode paired-
end 250 base pairs read length. Raw sequences were processed and analysed using the 
open-source bioinformatics pipeline QIIME 1.9.1 (http://qiime.org/), the Operational 
Taxonomic Unit were picked using the open-reference protocol. Subsequently, micro -
biota profiles were reported at phylum level and visualized using the visualization tool 
Krona  [5]. 
Results  
No adverse event occurred during or after the infusion of microbiota, other than 
loose stools for 3 days. The stool culture taken prior to FMT was negative for the MDR 
P. aeruginosa, but did contain an ESBL producing Escherichia coli, susceptible to 
carbapenems, gentamicin, piperacillin/tazobactam and colistin. Subsequently 5 stool 
cultures up to 3 months of follow up remained negative for P. aeruginosa, however 
persisted in containing the ESBL producing E. coli. The E. coli post-FMT was identical to 
the E. coli found prior FMT, using AFLP. No infectious complications caused by 
P. aeruginosa were noted during 18 months of follow up. However, the patient was treated 
once with trimethoprim-sulfamethoxazole for cystitis caused by an ESBL positive E. coli 
8 months after FMT. Unfortunately, this strain was not available for AFLP analysis.  
16S analysis of the patient’s stool 19 and 1 days prior FMT revealed a diverse 
microbiota composition, i.e., high Shannon diversity index of 7.8 and 8.1 respectively. 
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No significant changes in microbiota diversity of the recipient were observed following 
the FMT (Figure 1). At phyla level a high similarity of donor and recipient microbiota 
was observed with respect to the Firmicutes and Bacteroidetes as the expected main 
phyla of the microbiota (Figure 1).  
 
 
Figure 1. Timeline of recurrent infections, antibiotic use, and microbiota diversity 
prior to and after fecal microbiota transfer.  
CA MSSA: catheter related bacteremia with methicillin sensitive Staphylococcus Areus. 
MDR: multidrug resistant. PD: peritoneal dialysis. FMT: fecal microbiotica transfer. 
Discussion  
A 34-year old patient on peritoneal dialysis and recurrent urinary tract infections 
with a VIM-positive P. aeruginosa was treated with infusion of fecal microbiota to 
eradicate P. aeruginosa from the intestinal tract. A clinical success was observed, since 
at a follow-up period of 18 months no recurrent infections by P. aeruginosa were 
 diagnosed. FMT may have contributed to clinical success but it cannot be excluded 
that MDR P. aeruginosa was already eradicated from the gut before FMT, as the 
P. aeruginosa could not be cultured the day before FMT.  
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A remarkable observation is the persistence of an ESBL positive E. coli after FMT. The 
E. coli was presumably acquired after eradication treatment for P. aeruginosa, since it had 
not been detected in earlier cultures. It is possible that the incomplete eradication of 
the MDR E. coli is the result of coexistence of donor and patient E. coli strains after FMT. 
A recent study showed this coexistence of donor and recipient strains, which persisted 
for at least 3 months after FMT for treatment of patients with metabolic syndrome  [6]. 
This suggests that novel strains, acquired via FMT, can colonize the gut without 
 replacing the indigenous strain population of the recipient.  
In contrast to the diminished microbiota of recurrent CDI patients, our patient had 
an intact microbiota diversity and composition at phylum level prior to FMT. Previous 
antibiotic treatment (Figure 1) had not resulted in a distinct disturbance of the 
intestinal flora. Only minor changes of the microbiota composition were observed after 
FMT with a slight increase of cyanobacteria and tenericutes. We suggest that 
diminished diversity appears not to play a role in MDR carriership as opposed to 
recurrent CDI  [7]. Therefore, one might question the efficacy of fecal transplantation in 
patients with a normal microbiota diversity. The disturbed microbiota and its recovery 
after FMT might explain the positive results of MDR eradication in patients with 
recurrent CDI  [8, 9]. Interestingly, a recent paper showed that infusion of fecal 
microbiota in patients with recurrent CDI decreased the number and diversity of anti-
microbial resistance genes, particularly by restoring dysbiosis and reducing the number 
of Proteobacteria  [10]. Furthermore, beneficial effect of microbiota transfer has been 
shown in mice colonized with vancomycin resistant Enterococcus (VRE)  [11]. Clearly, 
more research on FMT for eradication of colonization of different MDR bacterial 
species is required.  
A total of only eight case reports have been published, showing FMT resulted in 
intestinal decolonization of ESBL- and carbapenemase-producing Enterobacteriaceae, 
VRE, or methicillin-resistant Staphylococcus aureus  [12 -15]. Unfortunately, no infor ma -
tion has been provided on microbiota composition before and after transplantation. 
Five trials are currently underway regarding the use of FMT for MDR bacterial 
decolonization which should provide more insight on the role of the microbiota on 
colonisation with specific microorganisms  [12].  
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A limitation of our analysis is that the microbiota was determined by 16S analysis. 
Although very useful in bacterial taxonomic classification, it lacks the required 
resolution to track transmission of bacterial strains in the microbiota using single-
nucleotide variants in metagenomes  [6]. Therefore, it was not possible to compare the 
composition of the microbiota at strain level, allowing a comparison between the 
donor and patient P. aeruginosa strains. However, no VIM-gene was detected by PCR 
on DNA from three feces samples after FMT.  
In conclusion, combined FMT and antibiotic treatment prevented recurrence of UTI 
with MDR P. aeruginosa. Intestinal colonization with ESBL producing E. coli persisted 
in the presence of a microbiota with intact diversity, suggesting that eradication of 
E. coli requires perhaps other specific strain(s) of microbes. More detailed analysis 
such as metagenomics, could identify specific strains that add to decolonization and 
should be applied in current studies on FMT for intestinal eradication of different MDR 
bacterial species.  
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Chapter 9. Discussion 
Summary of main findings 
Part I: New insights in the epidemiology of Clostridioides difficile 
and multidrug resistant Gram negatives. 
Infections with  C.  difficile have long been considered as a nosocomial acquired 
diarrheal disease, transmitted primarily from symptomatic patients. However, trans-
mission of  C.  difficile spores to the hospital environment, health care workers and other 
patients is not only accommodated by infected patients, also asymptomatically 
colonized individuals shed these microorganisms  [1]. Recognition of asymptomatically 
colonized patients is essential in reducing nosocomial transmission. In Chapter 2 the 
performance of several diagnostic  C.  difficile tests in comparison to toxigenic culture as 
gold standard was evaluated in asymptomatically colonized patients at admission to 
three large hospitals in the Netherlands. In this study, 5.1 % of the patients attending 
a tertiary-care hospital were positive with  C.  difficile, and 3.1 % contained toxigenic
C.  difficile. In a setting of low endemicity of asymptomatically colonized individuals, 
all three assays (an enzyme-linked fluorescent assay (ELFA) targeting glutamate 
dehydro genase, and two molecular tests targeting the toxin(s) of  C.  difficile; a com -
mercial artus PCR which targets TcdA and TcdB, and an in-house PCR only targeting 
TcdB) can be applied as a first screening test to detect the presence of (toxin produc-
ing)  C.  difficile, as they display a very high negative predictive value. Similar to the 
diagnosis of patients with symptomatic  C.  difficile infection (CDI), the positive pre -
dictive values of the tests in a low endemicity setting were suboptimal. Discrepancy 
analysis demonstrated that the majority of the small number of false positive results 
could not be confirmed upon retesting. This illustrates that in a low prevalence setting 
a positive GDH or PCR result is not automatically based on an increased sensitivity of 
these assays as compared to the toxigenic culture as gold standard. 
Nosocomial transmission by asymptomatic carriers is also recognized for MDRO. 
Prevention of this transmission in hospitals is pursued by screening selected patient 
groups for carriership of MDRO. The approach varies per country and per micro-
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organism, as illustrated by the variety of national guidelines. In 2015, a novel plasmid 
mediated resistance mechanism of colistin, mcr-1 was discovered in animals and 
humans in China  [2]. Currently, ten mcr genes types (mcr-1 to mcr-10) have been 
detected in Enterobacterales isolates  [3]. Epidemiological data on the prevalence 
of faecal carriage of mcr-1 in healthy individuals were not available shortly after the 
discovery of this novel resistance plasmid. To assess the risk of mcr introduction from 
asymptomatic carriers into our academic tertiary care hospital, the prevalence of mcr 
in faecal samples obtained from patients attending our hospital was investigated in 
Chapter 3. Two of the 576 (0.35 %) patients tested positive for mcr-1, whereas no mcr-
2 was found. This suggests that mcr spread from the community into the hospital 
environment was low in the Netherlands but could not be excluded. The finding of 
a phenotypically colistin susceptible, mcr-1 plasmid containing E. coli underlined the 
importance of phenotypical confirmation after molecular screening. 
In contrast to healthy young individuals in the community, nursing home resi dents have 
multiple risk factors for colonization and infection with  C.  difficile and MDRO  [4-10], and 
are considered a reservoir for transmission  [11 -14]. Frequent contact between resi dents due 
to communal living, increased frequency of healthcare contact and pre sence of factors 
that facilitate MDRO spread such as incontinence provide additional oppor tu nities for 
transmission. The data presented in Chapter 4 show that a high abun dance of  C. difficile 
and MDRO risk factors was present in Irish and Dutch nursing home residents. 
Surprisingly, this did not result in a high prevalence of MDRO’s; 9 % and 11 % Extended 
Spectrum Beta Lactamase (ESBL)-producing E. coli in Ireland and the Nether lands 
respectively, and 0 % carbapenemase producing Entero bacterales (CPE), van co mycin 
resistant Enterococci (VRE) or  C. difficile in both countries. Using core-genome multi locus 
sequence typing (cgMLST) small-scale spread of MDROs between residents of the same 
ward in the Netherlands was demonstrated. However, cross-transmission of MDRO’s 
between three different wards in Ireland was observed by whole genome  sequencing. The 
differences between Ireland and The Netherlands may reflect differences in nursing home 
infrastructure, specifically communal areas and multi-bedded resident rooms in the Irish 
nursing home, which were not present in the Netherlands. 
In conclusion, though asymptomatic colonization of MDRO and  C.  difficile can be -




Part II: The initiation of the Netherlands Donor Feces Bank to 
facilitate quality assured faecal microbiota transplantation 
Faecal microbiota transplantation (FMT) has become an established treatment for 
rCDI and is extensively studied as new treatment option for many other indications. As 
result, stool banks focussing on standardisation, safety, quality assurance and cost 
effectivity become increasingly important  [15 -17]. Stool banks provide ready-to-use 
faecal suspensions to hospitals for treatment of patients. Chapter 5 describes the 
establishment of the Netherlands Donor Feces Bank (NDFB). It addresses the 
difficulties encountered with donor recruitment and screening, preparation of the 
faecal suspension and transfer of the faecal microbiota suspension. It also provides 
treatment data and follow-up of patients treated with donor faeces of the NDFB. In 
comparison with the experiences of others stool banks, the NDFB has a high cure rate 
of rCDI at two months of nearly 90 % and a sustained cure rate of over 70 % after 
a mean follow-up of 42 weeks (Chapter 6). This high success rate is most likely 
achieved by the efforts of our multidisciplinary FMT-expert panel. This expert panel 
discusses the indication for FMT for patients for whom an FMT is requested and 
provides advice during treatment and follow-up of the patients. This strategy results in 
efficacious, appropriate and safe use of FMT for treatment of rCDI.  
Healthy stool donors colonized with Blastocystis sp. are usually excluded from 
FMT donorship  [21 -26], resulting in considerable exclusion of donors (30-50 %). It is 
questionable whether this is justified as the entero-pathogenicity of Blastocystis sp. is 
debatable. The presumed pathogenicity is based on anecdotal case reports and 
retrospective reviews and a human challenge model has not been applied  [7]. Recent 
literature shows a lower prevalence of intestinal carriage of Blastocystis sp. in patients 
with disorders associated with a reduced diversity of the gut microbiota, such as 
inflammatory bowel disease or hepatic encephalopathy  [18 -21]. Metagenomic studies 
reveal furthermore that Blastocystis sp. correlates with a more diverse and healthier 
microbiota  [18, 22-27]. Through a combination of PCR and subtyping techniques of 
faecal samples of donors and patients (pre-FMT and post-FMT), the first human to 
human transmission by FMT of Blastocystis sp. ST1 and ST3 is described in Chapter 7. 
This transmission did not influence the success rate of the FMT to treat rCDI. More 
importantly, it did not result in gastrointestinal symptomatology of the recipients. This 
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study is an important step towards a possible exempt of Blastocystis sp. (ST1 and ST3) 
as donor exclusion criterion in FMT. 
In Chapter 8 the potential of FMT for eradication of MDRO was explored in 
a patient suffering of recurrent urinary tract infections with a carbapenemase produc-
ing Pseudomonas aeruginosa hampering planned kidney-pancreas transplantation. 
Antibiotic pre-treatment subsequently followed by FMT prevented recurrence of 
a urinary tract infection with this Verona integron-encoded metallo-β-lactamase (VIM) 
positive P. aeruginosa by eradication of intestinal colonization. Although the treatment 
was a clinical success, a partial microbiological failure was observed as intestinal 
colonization with an ESBL-producing Escherichia coli persisted. In contrast to the 
diminished microbiota of rCDI patients, microbiota analysis showed an intact 
microbiota diversity and composition at phylum level before FMT. This suggests 
co-colonization rather than replacement of indigenous strains and eradication of this 
MDRO E. coli requires perhaps other microbiota interventions. 
With the increasing number of reports pointing towards potential beneficial effects 
of FMT in patients with a variety of gastrointestinal and extra-intestinal disorders, 
a growing demand of FMT can be expected in the near future. Initially, experimental 
studies will have to be performed in a controlled setting, both in-vitro and in-vivo. Once 
proven effective, a standardised screening and manufacturing procedure, quality 
control and careful and long-term monitoring of outcomes and adverse events 
requires stool banks and registries. The experience of this thesis and the NDFB may 
help the establishment, utilization, standardization and maturation of stool banks 





Targeting the pathogen alone is often not sufficient 
for diagnosis and treatment of CDI 
Diagnosis of CDI 
To prevent inappropriate use of FMT and increase the clinical benefit and cost-
effectiveness, evaluation of FMT requests by a multidisciplinary team is extremely 
important. The NDFB FMT-expert team rejects a quarter of FMT requests, which is in 
the majority of cases (30/47, 64 %) because the diarrhoea was attributed to another 
cause that coincided with  C.  difficile carriership (Chapter 6). In the past,  C.  difficile was 
difficult to isolate and cultivate from other anaerobic and facultative members of the 
gut microbiota. Currently, many molecular tests are available to demonstrate the 
presence of  C.  difficile and cultivating is not routinely applied anymore. However, the 
new diagnostic challenge is to distinguish colonization from infection. Due to the 
possibility of asymptomatic colonization and diarrhoea due to another cause, 
presence of the bacterium in the faeces does not consequently indicate disease. 
ESCMID and the ECDC recommend a two-stage algorithm with a screening test with-
high sensitivity (nucleic acid amplification test (NAAT) or glutamate dehydrogenase 
enzyme immune assay (GDH EIA)) followed by a specific assay for free toxin 
detection in the stool (toxin EIA)  [28]. The presence of free toxins in faeces is con -
sidered as the best proof for active  C.  difficile disease  [29, 30].  
 
New developments in diagnosis of CDI 
In order to simplify this diagnostic approach and minimize multiple testing, alter-
natives have been explored. The NAATs have gained much popularity in recent years 
because of their ease of use and the ability for automation and standardization. 
We and others have found that the cycle quantification threshold (Cq) value can be 
a predictor of free toxin presence as measured with toxin EIA  [31 -34], clinical 
disease  [35, 36] or poor outcome  [33, 37, 38]. In addition, in a study reporting both PCR, 
as well as a predicted toxin result based on Cq-value, all patients with CDI related 
complications were predicted correctly. This strategy furthermore reduced the treat-
ment of toxin-negative patients  [39], and can augment a more timely diagnosis in the 
more severe CDI cases or clear carrier cases (for instance: Cq value < 25 = CDI, 
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Cq value > 33 = carrier). It is however, still not sufficiently specific to use PCR as stand-
alone tests for CDI diagnosis, with a grey area of intermediate high Cq value of 25-33 
in which clinical assessment, a toxin EIA or cell cytotoxicity neutralization assay 
(CCNA) is necessary. Attempts to enhance the sensitivity of tests able to detect free 
toxin in stool have been unsuccessful so far. An example is a next generation enzyme 
immune assay; the ultrasensitive single-molecule array (SIMOA) technology  [40]. This 
ultrasensitive assay is capable of separately detecting and quantifying  C.  difficile toxins 
A and B down to picogram-per-millilitre levels. This more sensitive way of detecting 
free toxin in stool, increases the sensitivity to 85.2-100 % compared to CCNA  [40 -43]. 
This highly sensitive toxin assay may however suffer from the same specificity problem 
(with a reported specificity of 79.3 %  [42]) as the highly sensitive molecular tests, which 
can lead to the erroneous identification of colonized individuals as diseased  [44]. 
Although a decreased specificity was not reported in all studies  [40, 41, 43, 45]. Pollock 
and colleagues showed that on individual patient level both PCR as SIMOA could not 
distinguish a patient with CDI from asymptomatic carriage  [46]. Only on population 
level  C.  difficile toxin concentrations measured by SIMOA but not with NAAT, were 
significantly higher in CDI patients than in colonized individuals  [46]. This is in agree-
ment with a study showing that the rate of asymptomatic  C.  difficile carriage was similar 
to the symptomatic positivity rate  [47]. These results suggest that part of the PCR and 
SIMOA positive samples in symptomatic patients are likely due to  C.  difficile 
colonization, and exclusive reliance on highly sensitive tests results in overdiagnosis, 
overtreatment and increased health care costs.  
 
Personalized CDI diagnostics 
A complicating factor in the discrimination between infection and carriership 
of  C.  difficile is that only the presence of free toxins in the faeces as measured with 
CCNA highly correlates with clinical  C.  difficile disease  [29, 48]. The CCNA test however, 
is only performed in reference laboratories and is too cumbersome for routine diag-
nostics. In contrast, the routinely applied toxin EIAs lack sufficient sensitivity with 
a pooled sensitivity of 83 %  [28]. In addition, due to frequent testing in a low prevalence 
setting, the high specificity of 98-99 % can result in a low positive predictive value (69-
81 % when the prevalence of CDI is 5 %)  [28]. How can we then differentiate between 
colonization and infection? A personal view on personalised diagnostics is visualised 




in the test-algorithm, such as host inflammatory markers, stool metabolites and micro -
biota analysis in addition to multiplex testing for additional pathogens and virulence 
characteristics of  C.  difficile (e.g. RT027)  [49]. The serum presence of the chemoattractant 
C-C motif ligand 5 (CCL5), which is expressed by many cells and actively recruits 
leucocytes to inflammatory sites, was associated with CDI as compared to patients with 
non-CDI diarrhoea  [50]. Moreover, severe CDI patients had higher serum levels of TNF-
α, procalcitonin, hepatocyte growth factor, IL-6 and/or IL-8 suggesting worse inflam -
mation  [50 -54], and a serum based biomarker panel could inform about CDI diagnosis, 
treatment response and mortality  [54]. Interestingly, CCL5, which marks acute intestinal 
inflammation and severe CDI, seemed also to be significantly associated with an 
increased survival  [51]. Assessment of local host responses, with faeces as proxy, may be 
a more sensitive disease indicator than the systemic response. Faecal levels of biomarker 
as TNF-α, CXCL-5 messenger (m)RNA, IL-8 mRNA and IL-8 protein, lactoferrin, calpro -
tectin and procalcitonin at initial presentation correlated with disease severity or 
persistent diarrhoea  [49, 55-59], and were more sensitive than clinical severity scores or 
organism burden in identifying patients at risk for treatment failure  [60].  
 
Diagnostics in relation to FMT indication 
Measurement of the humoral immunity against  C.  difficile can play a significant role 
in the detection of patients who will most likely benefit of immunity enhancing 
anti- C.  difficile therapy with bezlotoxumab, since a higher risk of recurrence of CDI is 
associated with low serum concentrations of antibodies directed against the toxins 
TcdA and TcdB  [61 -63]. High serum endogenous IgG antibodies on day 1 
against  C.  difficile toxin B but not toxin A, were associated with protection with rCDI 
after bezlotoxumab, although the effect was limited (25 % versus 35 % relapse)  [64]. 
Furthermore, biomarkers can play a significant role in the evaluation of FMT-
candidates, which has proven to be difficult especially in patients with inflammatory 
bowel disease (Chapter 6). The biomarker procalcitonin can assist in differentiating 
infection from colonization with  C.  difficile in ulcerative colitis (UC) patients, as serum 
procalcitonin was significantly elevated in UC patients responding to CDI treatment, 
in comparison to UC patients diagnosed with a UC flare in combination with  C.  difficile 
colonization  [65]. Moreover, it could support the identification of patients potentially 
benefitting of repeat FMTs, as faecal calprotectin concentrations just prior FMT were 
higher in rCDI patients that needed multiple FMT treatments  [66]. The composition of 
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the microbiota can also be used to predict the likelihood for CDI recurrence. Compared 
to non-recurrent CDI, patients with rCDI have a diminished bacterial diversity and 
species richness, and significant shifts of Escherichia/Shigella (Enterobacterales), 
Veillonella, Streptococci, Parabacteroides and Lachnospiraceae  [67, 68]. Interestingly no 
particular taxon seemed to be associated with the severity of CDI, likely reflecting the 
dominant role of host-related factors  [67]. Reconstitution of a healthy microbiota after 
FMT both defined by a high diversity or by an alteration in abundance of specific taxa 
or restoration of functions (e.g. bile acid conversion, short chain fatty acid production), 
showed to be an excellent predictor of clinical response after FMT  [69, 70]. A prediction 
model based on 16S analysis of faeces at day seven post-FMT (with freeze dried 
capsules), which included the abundances of members of the families Lachno spi -
raceae, Ruminococcaceae, Bacteroidaceae, Porphyromonadaceae and Enterobacteriaceae 
showed an accuracy of 100 % and 97 % in predicting recurrences of respectively 
training and test data (n=89)  [69]. In addition, a higher engraftment of donor strains 
(50 %) was observed in the responders  [69]. Alternatively, bacterial fermentation 
products can be measured as read-out of a successful FMT, as a combination of 
urinary p-cresyl sulphate and the faecal concentrations of lithocholic acid seven days 
post-FMT could predict FMT success with high accuracy  [71]. 
 
Figure 1. Personalised diagnostics for CDI 
The future potential of personalised CDI diagnostics for enhanced discrimination 
between  C.  difficile colonisation and infection, and improved prediction of disease severity 




Personalized treatment of rCDI 
Personalized diagnostics can optimize treatment and subsequently improve the 
outcome of CDI. For a subset of patients, targeting the pathogen  C.  difficile alone is 
proven to be insufficient for sustained cure  [72]. Depending on the above described 
diagnostic outcomes, the patient can be categorized as having different systems  failing. 
Each system failing requires a different treatment approach. Therefore, I would envision 
the following treatment strategy (Figure 2) based on the assumptions mentioned below: 
√ A diverse and healthy microbiota is important for resilience against disease, not only 
to CDI, but also to other intestinal and extra-intestinal diseases. The aim of CDI 
therapy should therefore be to restore the patients’ perturbed microbiota. 
√ Fidaxomicin replaces vancomycin, because of the severe impact of vancomycin on the 
indigenous microbiota  [73]. Fidaxomicin is proven to be evenly effective in resolving 
CDI and preserves the microbiota, thereby resulting in fewer relapses after treat -
ment  [74 -77]. In addition, although fidaxomicin is more costly than vancomycin or 
metronidazole, it was proven cost-effective due to averted mortality, utility loss, and 
costs of rehospitalisation and/or further treatments of rCDI  [78]. Although fidaxomicin 
is superior in gain of quality-adjusted life years, the cost-effectiveness differs between 
studies in various countries  [79, 80], and a definite conclusion is difficult to make. 
However, preliminary data from the new IDSA and ESCMID guidelines (2020-2021) 
show that fidaxomicin will probably become the first agent of choice for CDI treatment.  
√ Extended-pulsed fidaxomicin (taper therapy) is superior and more cost-effective 
than a regular scheme of fidaxomicin  [81, 82]. However, the presumed decreased 
compliance of the patients to follow the more difficult treatment regime does not 
justify the extended-pulsed approach for a first CDI episode, but could be given for 
patients with a recurrence.  
√ FMT is both more effective and less costly than any other antimicrobial therapy for 
CDI  [83 -86]. Because of the unstandardized nature of this treatment and potential 
(low) risk for transfer of unrecognized pathogens or disease traits, treatment with 
anti-CDI antibiotics is preferred before FMT is administered. Consequently, FMT 
should be considered as treatment for the first relapse of CDI (Figure 2). 
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√ Bezlotoxumab is a human monoclonal antibody against  C.  difficile toxin B. 
Especially patients with a higher risk for rCDI (age ≥65 years, history of previous CDI, 
com pro mised immunity, IBD, renal disease, severe CDI or CDI with ribotype 
027/078/244)may benefit of bezlotoxumab  [87 -89] to prevent relapses. When added 
to anti- C.  difficile antibiotics it enhances the resilience for CDI relapses in general 
with ~40-50 % (relapse rate with vancomycin versus vancomycin + bezlotoxumab 
was 8 % vs 17 % and 16 % vs 26 %), but can be higher in particular patient groups 
with enhanced risk of rCDI  [88, 90]. Its efficacy appears to be due to prevention 
rather than delayed onset, as sustained cure was observed of 69 patients cured at 
12 weeks after treatment  [91].  
√ The clinical relevance of the difference in absolute relapse reduction by bezlotoxu -
mab (~9-10 %) versus fidaxomicin (~10-16 %) can be questioned. Bezlotoxumab is 
mainly studied in vancomycin and metronidazole treated patients, and only in small 
groups of patients using fidaxomicin  [90, 92]. If both therapies are additive to 
each other remains therefore unknown although they certainly could be due to the 
 dif fe rent working mechanism  [75, 77]. The combination of fidaxomicin with 
 bezlo toxumab has been successfully applied in a few patients (n=10) with multiple 
rCDI for which FMT was contraindicated (personal communication prof. Maria 
Vehreschild and prof. Ed Kuijper).  
√ A recent exploratory genome-wide association study revealed three genetic variants 
located in the extended major histocompatibility complex (MHC) that were 
associated with a two to three fold reduction of  C.  difficile relapses in bezlotoxumab 
treated patients  [93]. Around 40 % of patients have these genetic variants. This 
suggest a host-driven, immunological mechanism in response to bezlotoxumab. If 
these alleles are confirmed in a validation study, a human genetic analysis can be 
used to personalise CDI treatment.  
√ Bezlotoxumab is considered less effective in patients with multiple recurrent CDI 
(≥ 2 episodes) but prospective studies are missing  [90, 92]. The LUMC Center 
for Infectious Diseases (LU-CID) and NDFB are therefore currently designing 
a randomized controlled trial to assess the efficacy of vancomycin + bezlotoxumab 





Figure 2. Personalised treatment for CDI  
The future potential of personalised CDI treatment based on the in the text-mentioned assum p -
tions. The blue circles on the left reflect the estimated percentage of patients that has the specific 
type of CDI (a first CDI episode is set at 100 %). The dark blue boxes give information on the 
indication, the green boxes inside about the proposed therapy. 
* In case a genetic variant of the major histocompatibility complex (MHC) is present (~40 % of 
patients); this predicts a two to three-fold reduction in CDI relapses with bezlotoxumab use in 
comparison to patients without these genetic variants. 
$  In case this personalized treatment is not followed, and metronidazole or vancomycin is given.  
£  Based on shared decision making between patient and physician. Patients with ‘Chronic CDI 
susceptibility’ have suffered from multiple (recurrent) episodes in the past, but do not meet the 
criteria of recurrent CDI (CDI relapse within two months after prior episode) with the present 
episode. 
Patients with high suscepti bi lity for CDI have suffered from multiple (recurrent) episodes in the past, 
but do not meet the criteria of recurrent CDI (CDI relapse within two months after prior episode) with 
the present episode. 
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Mechanism of action of faecal microbiota transplantation  
Mechanism of action of FMT to prevent relapses of 
Clostridioides difficile infection  
The mechanism of FMT is likely multifactorial. Reinstatement of a robust and 
diverse, functional microbiota is an essential mechanism for resilience against CDI 
relapses  [94]. FMT was found to restore both short chain fatty acid levels and bile acid 
metabolism (bile salt hydroxylation (BSH) as well as 7-α-dehydroxylation)  [95 -98]. In 
a mouse model, the bile acid converting Clostridium scindens (7-α-dehydroxylase) 
bacterium was inhibitory to  C.  difficile  [99]. The co-administration of other bacterial 
species from Lachnospiraceae and Porphyromonadaceae families enhanced the 
protective potency  [99]. An additional effect of 7-α-dehydroxylase producing bacteria, 
is the secretion of tryptophan derived antibiotics; 1-acetyl-β-carboline and turbomycin 
A  [100]. These antibiotics inhibit the cell division of  C.  difficile, and the activity of 
tryptophan is enhanced by secondary bile acids  [100]. However, reconstitution of the 
bile acid converting microorganisms with synthetized bacterial communities or live 
biotherapeutic products (LBPs) enhance the colonisation resistance to  C.  difficile but 
are not sufficient for complete prevention of acquiring CDI or sustained cure of CDI. 
To date, no synthetic bacterial community has achieved a success comparable 
to CDI antibiotics or FMT though recent interim analyses of some phase 3 
studies are promising. In a proof of principle phase I study with a fractionated and 
 encap su lated bacterial spores product (SER-109 with spores from approximately 50 
bacterial species), following standard of care, most patients (29/30) achieved clinical 
resolution  [101]. However, SER-109 failed to be of additional benefit compared to 
standard of care in a phase II study in rCDI patients (44 % relapse versus 53 % in 
placebo, n=89)  [102]. Recently, SERES claimed via twitter that SER-109 did met their 
phase III primary endpoint, showing a statistically significant 30 % absolute reduction 
in rCDI compared to placebo (relapse rate of 11 % versus 41 % in placebo)  [103]. 
A remarkable finding in both studies is the high rate of relapses that occurred in 
the control group. This could either be explained by study inclusion of patients 
with a high risk on rCDI or inclusion of patients colonised with  C.  difficile. Various 
studies with rational selected bacterial consortia or faeces microbiota derived 





The gut microbiota does not solely consist of bacteria but does contain various 
other microorganisms. Recently, it was shown that the presence of Candida albicans 
in the intestinal tract reduces the efficacy of FMT  [104]. In contrast, healthy donors 
and patients responding to FMT displayed a high relative abundance of Saccharomyces 
and Aspergillus  [104]. A recently completed pilot study of NDFB and CMAT (Center for 
Microbiome Analyses and Therapeutics) analysing the mycobiome of healthy indivi -
duals and patients either infected or colonised with  C.  difficile confirms this observation. 
A relatively high abundance of C. albicans in CDI patients, and more Saccharomyces 
and Aspergillus in non-CDI patients and healthy donors was observed (Zwittink, 
unpublished observation). 
In patients with severe and therapy refractory CDI, administration of FMT 
results in fast but sometimes temporary improvement of clinical symptoms 
within hours  [105-107]. The temporary improvement is sufficient to deescalate the 
clinical status, enabling a response to repeat FMTs  [106, 107]. In this short period, 
stable engraftment of a functional microbiota is unlikely and inhibition of intestinal 
inflammation is likely to play a significant role  [107]. The afunctional and un -
balanced patient’s inflammatory response could be reshaped by yet not fully 
understood mechanisms and compounds, as the microbiota impacts various 
immune pathways that aid in recovery from CDI colitis  [108, 109]. An interesting 
target is interleukin-33 (IL-33), an important guardian of the gut barrier during 
C.  difficile colitis that prevents CDI-associated mortality via activation of group 2 
innate lymphoid cells  [110]. Intestinal IL-33 expression is regulated by the microbiota, 
and FMT was proven to rescue the antibiotic-associated depletion of IL-33  [110]. 
Also regulatory T-cells play a critical role in the maintenance of immune homeo -
stasis and seem an interesting immunological target  [109]. FMT was shown to 
control inflammation and colitis via induction of regulatory T cells  [111, 112]. 
Regulatory T cells are activated by many different pathways and different bacteria, 
for instance via commensals activating IL-10 and/or TGF-β which recruit the 
regulatory T cells to the intestine  [111-114], via bacterial polysaccharide A that results 
in inhibition of IL-17 and thereby an increase in regulatory T-cells  [113], or via short-
chain fatty acids that promote the fitness and differentiation of regulatory T-
cells  [115, 116]. Whether FMT-directed immunosuppression aids also in the recovery 
of CDI colitis requires further investigation  [109].  
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In addition to direct amelioration of severe CDI symptoms by immunomodulation 
through faecal suspension, a direct impact of the FMT can also be achieved by 
bacteriophages  [117] or production of bacteriocins such as thuricin CD or nisin 
by the living bacterial fraction of the faecal suspension [118-120]. In addition, the 
toxin expression of  C.  difficile could be suppressed by carbohydrates present in the 
faecal suspension  [94, 121], or human donor metabolites such as alpha-defensins  [122]. 
The toxins could be rapidly neutralized, as bile acids reversibly bind to TcdB, causing 
a ‘balled up’ formation of the toxin which is no longer able to bind to the host’s cell 
surface receptors  [123].  
In conclusion, it is likely that not a single bacterium or bacterial community 
contribute to colonisation resistance and prevention of CDI relapses by FMT. Multiple 
microbiota communities and networks (including bacteria, viruses, eukaryotes etc.) 
exist that enhance resilience or protection to rCDI. In addition, by faecal microbiota 
transplantation a complete functional ecosystem is transplanted. The effect of FMT is 
the result of a complex interplay of microbiota networks, immune modulation and 
metabolites that not only influence the colonisation resistance to  C.  difficile but also 
affect host inflammation and bacterial toxin production. 
Mechanism of action of FMT for eradication of multidrug 
resistant organisms 
Intestinal colonization of MDRO, and general decolonization strategies 
Most infections with ESBL producing Enterobacterales are preceded by intestinal 
colonization  [14, 124], and prevention and eradication of these MDRO from the gut is 
therefore of interest. Spontaneous intestinal clearance of an ESBL containing micro-
organism varies per bacterial (sub)species and per ESBL enzyme. Duration of 
colonisation is on average longer in patients with comorbidity; 43 % remained ESBL 
positive after 1 year  [125]). Contrary, healthy individuals in the general population had 
a mean duration of ESBL colonisation of 4.2 months  [126] and 33 % remained MDRO 
positive for > 8 months  [127]. Individuals who travelled had a median duration of ESBL 
colonisation of 30 days, whereas only 14.3 % and 11.3 % remained colonized at 6 and 
12 months after return, respectively  [128]. Spontaneous clearance of certain E. coli 




associated with a longer duration of carriage in a long-term care facility residents, with 
a half-life of 13 months versus 2- to 3- months for other STs  [129]. Presence of the 
MDRO in the intestinal tract below the limit of detection in faeces can sometimes 
complicate study outcomes or interpretation. This phenomena is well known for 
detection of vancomycin resistant enterococci (VRE), as on average four to five rectal 
swabs, collected on separate days, are needed to detect > 90 %-95 % of new VRE 
carriers  [130, 131]. Especially in the first stages of colonisation, just after a transmission 
event, VRE detection using rectal or perianal swab can be less sensitive than faeces 
samples  [132, 133]. Difficulties with detection of MDRO in the intestinal tract due to low 
levels is also observed for Gram negatives  [134, 135]. A RCT that studied the 
decolonisation effects of a combination of colistin and neomycin versus placebo 
observed a significantly lower rectal carriage of ESBL in the non-absorbable antibiotic 
treated group at the end of treatment (32 % versus 77 %), but the effect was lost 7 days 
post-treatment  [134]. A negative result may therefore reflect suppression of the MDRO 
below the detection limit or temporary suppression rather than decolonisation. An 
ESCMID guidance document could not find sufficient evidence for a successful 
therapeutic decolonisation therapy, not with orally non-absorbable antibiotics or any 
other therapeutic approach  [136]. The current knowledge on this topic provided by 
randomized and observational studies suffers of much heterogeneity between tested 
populations, used decolonisation therapy, inconsistency in defining and reporting end 
points and small sample sizes  [136], and both large, well-designed RCT as innovative 
strategies are desperately needed.  
 
Colonisation resistance against (multi drug resistant) Enterobacterales  
Modifying the (failing) indigenous intestinal microbiota to prevent or treat gut 
colonisation with MDRO is an interesting therapeutic intervention, although specific 
targets are unknown. A healthy indigenous microbiota does not contain an abundance 
of Enterobacterales. This family of facultative anaerobic Gram-negative bacteria 
harbours many species capable of MDR carriership. Colonisation resistance against 
MDRO or Enterobacterales in general, is accomplished by a complex interplay 
between different species and functions of the host’s microbiota. In our recently 
submitted study on microbiota-associated risk factor for asymptomatic MDRO 
colonisation study in nursing home residents, several taxa belonging to Dorea, 
Atopobiaceae and Lachnospiraceae of the ND3007 group were consistently more 
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abundant in faeces samples of nursing home residents who were never colonised with 
an MDRO during a six month time period (submitted, Genome Medicine, Ducarmon 
et al). At a functional level, many species of the Firmicutes and Bacteroidetes, are 
capable of metabolizing food fibres to Short Chain Fatty Acids (SCFA’s)  [137]. Of these 
SCFAs, butyrate is essential in maintaining host health by providing energy for 
colonocytes, contributing to the acidification of the lumen, modulating the immune 
system (maturation and expansion of colonic regulatory T-cells) and affecting diverse 
metabolic routes in the body (e.g. in liver and brain)  [114, 116, 138-140]. During homeo -
stasis, butyrate-producing bacteria limit the availability of oxygen and nitrate in the 
colonic lumen through the intracellular butyrate sensor peroxisome proliferator-
activated receptor (PPAR-γ)  [141]. PPAR-γ represses the gene encoding inducible nitric 
oxide synthase (Nos2), resulting in a lowered nitrate production. Consequently, the 
bioavailability of electron acceptors is limited, which is normally used for anaerobic 
respiration and drives an expansion of facultative anaerobes  [141-143]. Microbiota 
induced PPAR-γ signalling also directs the colonocytes towards oxidative phos phory -
lation and β-oxidation of short and long chain fatty acids, resulting in high epithelial 
oxygen consumption  [141, 143]. The consequent epithelial hypoxia helps to main -
tain a microbial community dominated by obligate anaerobic bacteria  [143] or 
eukaryotes  [144]. A depletion of butyrate-producing Clostridia was shown to drive an 
aerobic luminal expansion of Salmonella species  [145]. Furthermore, SCFAs at an acidic 
pH were able to inhibit the replication of E. coli and Salmonella sp.  [146-149], and provide 
subsequent resistance against colonisation and infection of Salmonella following 
streptomycin treatment  [150]. The gut microbiota of nursing home residents carrying an 
ESBL producing Enterobacterales was indeed characterised by a lower abundance of 
SCFA producing bacteria  [151]. In addition to the above described mechanisms of the 
healthy microbiota in combat against a perturbed expansion of Enterobacterales, the 
healthy indigenous microbiota is also capable to inhibit acquisition of antibiotic 
resistance and horizontal gene transfer  [152]. In an in vitro model containing a human 
gut microcosm, the microbiota not only suppressed growth and colonisation of 
a newly introduced E. coli strain, but also prevented it from evolving antibiotic resistant 
upon exposure to ampicillin. The invading E. coli only acquired resistance in the 
absence of the resident microbial community, even though highly effective β-lactam 
resistance plasmids were present in the resident microbial communities  [152]. In 




bacterales in which conjugative transfer occurs at unprecedented rates, as shown 
by the high rate of conjugative horizontal gene transfer of a resistance plasmid of 
Salmonella enterica serovar Typhimurium to E. coli in a mouse colitis model  [153].  
 
Innovative prevention of multidrug resistant gut colonisation, and 
decolonisation strategies 
Prevention 
An important key to reduce spread of antimicrobial resistance is the prevention of 
MDRO colonisation in the gut. Restricting the use of (broad spectrum) antibiotics 
reduces the selection, colonisation and outgrowth of MDRO  [154]. This mechanism is 
well recognized and better known as antibiotic stewardship. Antibiotic stewardship 
programs are designed to restrict antibiotic overuse and misuse by educating physi -
cians on antibiotic selection, dosage, route of administration and duration of therapy. 
These programmes have proven their effectiveness and significantly reduce the 
incidence of colonisation and infections with MDROs and  C.  difficile  [155-157]. Accor -
dingly, the improved rational use of antibiotics also reduces sepsis  [158] and the over-
all mortality rates  [159]. It seems plausible that at least some of these effects 
are mediated by the preservation of a diverse and healthy microbiota. Antibiotic 
 stewardship programmes should therefore incorporate consideration for the impact of 
antimicrobial therapy onto the commensal microbiota  [160]. Disruption of the healthy 
microbiota is in line with use of broad-spectrum antibiotics, and CDI can be 
considered as surrogate indicator for a disturbed microbiota. However, other infectious 
complications or diseases associated with a perturbed microbiota may also arise on 
the short or long term. For example, the use of metronidazole was correlated with 
intestinal enterococcal domination and subsequent bacteraemia in hematopoietic 
stem cell transplant patients  [161]. In addition, early administration of broad-spectrum 
antibiotics in allogenic stem cell transplantation patients resulted not only in 
a decreased abundance of Clostridiales (especially cluster XIVa), but also in 
a significant higher transplant related mortality  [162]. A lower diversity of the intestinal 
microbiota at the time of neutrophil engraftment was associated with a higher 
mortality  [163]. The early administration of antibiotic therapy active against 
commensal organisms warrants the use of commensal sparing antibiotics and rapid 
restoration of the microbiota after cessation of antibiotic therapy. In patients with 
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rCDI, it was shown that FMT as microbiota restoring therapy (and not anti-CDI anti-
biotics) lowered the chance on developing a blood stream infection, and subsequent 
mortality  [164]. 
Therapy 
Once the indigenous microbiota failed to provide colonisation resistance against an 
MDRO and the gut has become colonised, targeting the microbiota could support 
decolonisation. This decolonisation strategy demonstrated its potential when it was 
observed that patients receiving an FMT for multiple recurrent CDI, had a significant 
reduction in the number and diversity of antimicrobial resistance genes after 
FMT  [165-167]. Moreover, not only resistance genes in the microbiota as determined with 
metagenomics, but also resistance of clinically relevant MDRO Gram negatives 
decreased after FMT. Data from the NDFB indicate that 50 % of pre-FMT MDRO 
colonised rCDI patients (ESBL producing or fluoroquinolone and aminoglycoside 
resistant Enterobacterales), lost the MDRO within three weeks after FMT (preliminary 
results NDFB and LU-CID, K.E Vendrik and E.M Terveer). This observation adds to 
various case-reports of patients colonized with ESBL or carbapenemase producing 
Enterobacterales (CRE) treated and often successfully decolonized by FMT  [168-182]. 
Chapter 8 describes such a case-report. We experienced that infusion of a healthy 
donor microbiota into the gut of a patient with normal microbiota diversity did not 
result in eradication of the ESBL-producing E. coli. Possibly specific microbial strains 
are required, or an improved donor engraftment by antibiotic pre-treatment (further 
described in paragraph “Optimal donor selection for FMT”). Seven larger case series 
display mixed results, but varied in study design, patient characteristics and outcome 
measurement. Of the patients colonised with ESBL, 20 % was decolonised one month 
after a single FMT, 40 % after two FMTs (n = 15)  [171]. Haematological patients (n=25) 
colonised with either ESBL or carbapenemase producing Enterobacterales (CPE) were 
decolonised in 60 % of cases one month after FMT  [168]. Of note, patients that received 
antibiotics within seven days after FMT achieved significantly less decolonisation 
(36 % versus 93 %). Of patients colonised with CRE, decolonisation rates varied from 
33 %, 50 % to 80 %, two weeks to four months after FMT  [169, 170, 180]. A recent 
retrospective analysis of CRE and/or VRE colonised patients (n=35) treated with FMT 
showed that 69 % was decolonised after one year. In addition, microbiota analysis prior 




decolonisation), as a higher initial level of Verrucomicrobia and Proteobacteria and 
lower species richness was observed in the non-responders  [183]. These case series 
should be interpreted with caution as they suffer from publication bias, and also have 
different study designs with varying pre-treatments, number and application routes of 
FMT and different follow-up periods. Besides, definitions of gut MDRO colonisation 
differed and various microbiological tests to detect MDRO in faeces were used. Only 
one RCT was performed in which 39 adults colonized with ESBL- or carbapenemase-
producing Enterobacterales were randomized to either no intervention or a 5-day 
course of non-absorbable antibiotics followed by FMT. Unfortunately, no statistically 
significant advantage of FMT was found, though the trial suffered from inclusion of 
insufficient number of patients  [184, 185]. Similarly, only small differences in the 
microbiota composition were observed in the patients after treatment with FMT. 
Relative to baseline, post-FMT microbiota was significantly enriched in Bifidobacterium 
species and Collinsella aerofaciens  [186].  
The eradication potential of various microbiota modifying agents can be studied via 
transplantation of a complete ecosystem of a healthy donor. However, in the long run, 
application of this ‘black box’ therapy is undesired, and several treatment components 
merit further research. These are for example “live biotherapeutic products (LBPs)”, 
bacteriocins or other microbial metabolites or bacteriolytic phages. Bacteriophages are 
highly specific for one bacterial (sub) species, providing a desirable asset in the refine 
modification of a host microbiota. A number of animal studies showed that 
bacteriophages can be used as treatment for infections caused by MDRO  [187], and 
also demonstrated potential as eradication strategy for colonisation of MDR Gram 
negatives (MDR Pseudomonas and MDR uropathogens) of the gut in nematodes and 
mice respectively  [188, 189]. The stability of bacteriophages during intestinal passage, 
their impact on the non-targeted human microbiota, potential side effects and the 
achievable effect size and duration merit further research  [185, 187]. An interesting treat-
ment approach is adding bacteriophages to sub-lethal dosages of a non-absorbable 
antibiotic leading to synergy  [190]. The ‘phage-antibiotic synergy’ is considered an 
enhanced phage production and accelerated lysis of infected cells, in response to the 
filamentation of bacterial cells upon exposure to the antibiotic  [190]. Other interesting 
components of FMT acting against MDRO are bacteriocins or (in combination with) 
live biotherapeutic products. A lantibiotic-producing commensal of the gastro -
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intestinal tract, Blautia producta, reduced and prevented VRE colonization in man and 
mice  [191]. Another interesting candidate demanding further research is Lactobacillus. 
Lactobacillus species in the faecal microbiota of hospitalised patients were associated 
with resistance to MDRO acquisition during admission  [192]. Additionally, mice treated 
with a combination of 1010 CFU L. plantarum and L. acidophilus were able to eradicate 
MDR enteroaggregative E. coli from the gut  [193]. However, up till now probiotics, 
synthetic bacterial communities or live biotherapeutic products have failed to eradicate 
intestinal carriage of Gram negative MDROs in human randomized controlled trials. 
Amongst them, an attempt to eradicate MDROs in ICU patients with Lactobacillus 
rhamnosus  [194], a trial to eradicate MDR E. coli in long-term care facility residents using 
E. coli Nissle 1917 as probiotic  [195], and a combination of L. bulgaricus-L. rhamnosus-
fructo-oligosaccharides failed to eradicate MDR Gram-negative bacilli in hospitalized 
patients  [196]. A live biotherapeutic product of eight living bacterial strains could not 
eradicate ESBL Enterobacterales in outpatients  [197]. The concept of super donors have 
recently drawn attention in the development of live biotherapeutic products from these 
donors  [198]. The super donors have specific microbial traits and are thereby signifi -
cantly more capable in treating a specific disease than other donors. Studying these 
super donors might be crucial in understanding MDRO colonisation resistance and 
subsequent cure. The concept of super donors for MDRO eradication is currently 
investigated in a clinical trial by us and others (Davido of the Hôpital Universitaire 
Raymond-Poincaré in Paris in collaboration with NDFB and Vedanta). For these trials, 
an FMT donor is selected based on the capability of MDRO clearance in 80 % of the 
FMT-treated and MDRO colonised mice  [199]. Lastly, immunological approaches can 
be explored as option for MDRO eradication. Vaccination of pregnant cows with the 
inactivated cells of the globally disseminated and MDR E. coli sequence type 131 
resulted in highly specific anti E. coli ‘hyperimmune bovine colostrum’. This colostrum 
was able to disrupt the intestinal colonization of the ST131 E. coli in mice  [200].  
In conclusion, many therapeutic options are currently explored, but demonstrate 
high heterogeneity in set-up as well as outcome, and need harmonization. Further -
more, it appears that the concept of FMT for treatment of rCDI is not applicable for 
decolonization of MDROs. Metagenomic studies could provide answers on the effect 
of the decolonizing agents on the microbiota composition and dynamics, and should 




trials to assess the above described innovative therapeutic approaches, with assess-
ment of the optimal pre-treatment, for a larger panel of clinically relevant MDRO’s are 
needed in the future. These studies should also include sufficient long-term follow-up 
on microbiological and clinical outcomes which assess both adverse events as well as 
clinical relevance of the decolonization (e.g. reduced MDRO infections and sub -
sequent readmission, fewer long-term complications). Additionally, more fundamental 
research should be performed using in vitro gut microbiota models to study specific 
donors, specific microbiota species and networks essential for colonisation resistance 
for several clinically relevant MDRO’s. 
Optimal donor selection for FMT  
Donors and super donors 
A perturbed microbiota has been observed in a large variety of disorders, and FMT 
as microbiota modulating therapy, is increasingly used in trials not only for intestinal 
but also for extra-intestinal diseases. The presumed mechanism of action of FMT for 
other diseases is however likely different than for rCDI and could vary per treatment 
indication. Though it is generally considered that FMT restores the functionality of 
a perturbed gut microbiota by engraftment of donor strains, the precise mechanism 
is probably more complex than a simple replacement of bacterial species. Bacterial 
networks, metabolites, archaea, viruses, fungi and other eukaryotic microorganisms 
also influence the composition and function of the microbiota. Corresponding with 
the variation in gut microbiota composition between healthy individuals (e.g. 
donors), variability exists in the faecal suspensions used for FMT treatment. Donors 
of faecal suspensions with a significantly higher success-rate are referred to as super 
donors. Super donors for rCDI treatment do not appear to exist as no donor related 
factors attributing to the FMT success could be identified by us (Chapter 6) and 
others  [198, 201, 202]. Patients with multiple, recurrent CDI have a perturbed and 
diminished microbiota diversity  [203]. Replenishing this severely reduced diversity with 
any healthy donor microbiota results in prompt resolution. For other diseases, 
such as ulcerative colitis super donors do seem to exist  [204], but the evidence is 
sparse. Studying these super donors might be crucial in understanding complex 
disease pathology and subsequent cure  [198]. The question is how to find these super 
donors?  
EXPLORING THE ROLE OF THE MICROBIOTA IN DEFENCE AGAINST CLOSTRIDIOIDES DIFFICILE  
AND MULTIDRUG RESISTANT GRAM-NEGATIVES
216
With respect to donor selection, it is very unlikely that one super donor can cure all 
microbiota related illnesses  [205]. Like our society, a healthy microbiota is diverse. 
However, this encompasses not only a diverse community within the host, but also 
between the microbiota’s of different hosts. In diseases with a perturbed microbiota, 
the specific failing network should be restored, and optimal donors could vary per 
microbiota related disease. For instance a donor for FMT to boost the immune 
response in patients that show progressive cancer while on checkpoint inhibitors 
[206, 207] could be very different than the donor needed to abolish the overactive 
immune system in patients that suffer of grade III/IV toxicity during checkpoint 
inhibitors  [208, 209].  
 
Replenish the beneficial bacteria 
Different strategies exist for rational donor selection, depending on the specific 
disease intended to cure with FMT. A patient can have a decreased load of beneficial 
bacteria which can be replenished by healthy donor strains (Figure 3). Replenishment 
is based on supplementation of unique taxonomic or functional deficiencies present 
in the diseased microbiota  [210]. A very successful open-label trial among patients with 
cirrhosis with recurrent hepatic encephalopathy randomized to receive either standard 
of care or FMT (with antibiotic pre-treatment), performed rational donor selection. 
Using microbiome data of hepatic encephalopathy patients and healthy controls 
a machine learning technique was performed to identify a single donor with the 
highest relative abundance of Lachospiraceae and Ruminococceae. FMTs derived from 
the faeces of this donor significantly reduced hospitalizations, improved the cognition 
and perturbed microbiota over more than 12 months  [211, 212]. If this effect was indeed 
due to the selected ‘super-donor’ is questioned  [213], since the relative abundance of 
Lachospiraceae and Ruminococceae was not significantly different before and after FMT 
in the FMT-treated patients  [213]. A metaproteomic and metabolomic analysis added 
to the metagenomic data should provide more insights in the functional changes of 
the group of Lachospiraceae and Ruminococceae.  
An example for which taxonomic selection would be rational is Ulcerative Colitis 
(UC). The short chain fatty acid; butyrate is important in alleviating inflammatory 
bowel diseases (IBD) such as UC  [214]. A meta-analysis showed a consistent lack of 




be a donor with an overabundance of these gut bacteria. This super donor effect was 
indeed observed in an RCT with FMT for treatment of UC, using five faecal donors. The 
majority (78 %) of patients who achieved remission received faecal suspensions 
prepared from one single donor. The other donors were not more efficacious than 
placebo  [204]. The super donor contained the highest load of butyrate producing 
bacteria. Though, in a study combining microbiota data of three RCT’s for UC, an 
abundance of butyrate producing bacteria of the donor was not associated with 
patient response  [210]. In addition, host factors are also important in the response to 
FMT treatment for UC. Younger age, moderate disease severity and endoscopic mayo 
scores predicted achievement of clinical remission of FMT in patients with active 
UC  [216]. This reflects the multifactorial aetiology and treatment of this disease and the 
challenges of donor selection in the real world. A critical note is that abundance or 
shortness of a certain group of bacteria in correlation with a specific disease may be 
an oversimplification. The mucosa associated microbiome and host immune factors 
may play a more prominent role.  
 
Replacement of the undesired bacteria 
A disease could also be mediated by the presence or overabundance of one or 
more harmful bacteria for which competitor donor strains can be selected (Figure 3). 
The most straightforward competitors are bacteria that directly inhibit the undesired 
strain (direct competition), for instance bacteria that produce bacteriocins. An example 
is the lantibiotic-producing commensal, Blautia producta, which demonstrated a 
reduction and prevention of VRE colonization in man and mice  [191]. Competitors of 
undesired bacteria can be identified by another mechanism of colonisation resistance; 
competitive exclusion. Bacteria occupying the same nutritional or environmental 
niche can be selected from literature. For instance, Bacteroides thetaiotaomicron is 
a direct competitor of food (carbohydrates) for Citrobacter rodentium, a gastro-enteritis 
pathogen in mice  [217]. Selection of a donor-mouse containing (high rates of) B. 
thetaiotaomicron to treat a C. rodentium infection would therefore make sense. A second 
illustrative example involves a subgroup of non-alcoholic fatty liver disease (NAFLD) 
patients, who suffer of auto brewery or gut fermentation syndrome. After a carbo -
hydrate-rich meal, the microbiota of these patients is capable of ethanol production, 
resulting in an impaired mitochondrial function and subsequent liver injury  [218-220]. 
Though the pathogenesis of this disease is still unknown, several members of the 
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microbiota like Candida species, Saccharomyces, Enterococcus faecium or Klebsiella pneu-
moniae have been identified as potential ethanol hyperproducers  [221]. Yuan and 
colleagues show that a high-alcohol-producing K. pneumoniae (HiAlc-Kpn-strain) was 
present in 60 % of individuals with NAFLD in a Chinese cohort, only 6 % of the healthy 
controls was colonised with this Klebsiella  [218]. Transfer of the intestinal microbiota 
from a NASH patient containing HiAlc-Kpn-strain, as well as the HiAlc-Kpn-strain 
alone into mice, introduced detectable blood alcohol and steatohepatitis. Selective 
removal of the HiAlc-Kpn-strain (using a bacteriophage) before FMT prevented 
NAFLD in the recipient mice  [218]. Removing this pathology-causing bacterium could 
thus lead to clinical improvement  [218]. Unfortunately, our laboratory could not repro -
duce these findings of a hyper ethanol producing K. pneumoniae in faeces samples of 
a suspected patient with an auto-brewery syndrome and the Chinese researchers did 
not provide their strains for further analysis. In patients with auto-brewery syndrome, 
not only replenishment with healthy microbes but also replace ment of the detrimental 
bacterium is needed. In patients with metabolic syndrome it was already shown this is 
 






Proposed methods for optimal donor selection  
Option 1: Use of existing data from clinical microbiota association studies  
Several approaches can be employed to select optimal donors (Figure 3). De first 
and most simple technique is selection of donors with a known desired microbiota 
composition. There are two requirements; First, the microbiota of the donors must be 
profiled. Metagenomic analysis is preferred, as this provides insight on functional and 
strain-level associations  [223]. Second, the microbiota characteristics associated with 
disease must be known from epidemiological studies or/and animal experiments.  
The NDFB is currently designing a granted FMT pilot study for Parkinson’s disease 
and considers rational donor selection. In this trial the safety and feasibility of FMT in 
Parkinson’s disease patients is assessed. Parkinson’s disease is a neurodegenerative 
disease characterized by neuron degeneration in the central, enteric and peripheral 
autonomous nervous system. Several mechanisms by which FMT could modulate 
Parkinson’s disease exist. An important factor in the aetiology of Parkinson’s is the 
aggregation of the protein alpha-synuclein  [224]. The hypothesis is that under influence 
of the microbiota, a neurotropic substance, possibly alpha-synuclein, is formed in the 
gut and transported to the enteric nervous system and brain, via the vagus 
nerve  [225, 226]. Key microorganisms or functions are not yet defined, although the 
microbiota of Parkinson’s patients is in general more pro-inflammatory oriented, with 
LPS-producing Proteobacteria, and contains less anti-inflammatory butyrate-produc-
ing bacteria  [227, 228]. The frequently observed obstipation in these patients could 
however bias the microbiota interpretation, and one could question whether rational 
donor selection to alter the natural course of disease is appropriate at the moment. 
Alternatively, the microbiota also seems to play a role in the bioavailability of the 
primary therapy of Parkinson’s disease; levodopa  [229, 230]. Bacterial decarboxylases 
(tdc gene) are identified that restrict local (intestinal) and blood levels of levodopa by 
not always straightforward, as donor strains rather co-colonize than replace similar 
patient strains  [222]. Faecal donors should be screened and excluded when containing 
(an overabundance of) the undesired bacteria, in addition to positive selection for 
bacteria known to out-compete the harmful taxa  [210]. 
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conversion to dopamine, which cannot pass the blood-brain barrier  [230]. Rational 
donor selection could therefore be performed with the hypothesis; “FMT from a donor 
with low amounts of tdc genes present in the microbiota will reverse the levodopa 
resistance by replacement and/or out-competition of tdc containing patient strains.” 
The patient will then again respond to levodopa therapy and patients will experience 
less side-effects (e.g. dyskinesia) due to the stabilised levodopa bioavailability and 
drug dosing  [229]. If this hypothesis holds, the replacement of bacteria carrying tdc 
genes will be most likely based on similar bacteria without the tdc gene. If such an 
effect is found, the next question is whether this replacement will be permanent under 
continuous exposure to levodopa, or if the patient needs maintenance or sequential 
FMTs.  
Option 2: Use of donor data obtained from in vitro, gut or animal microbiota 
models  
A second strategy involves data obtained from in vitro or in vivo microbiota models. 
In close collaboration with Vedanta Biosciences, in vitro experiments in mice were 
performed with faeces of NDFB donors. Antibiotic-pre-treated mice were densely 
colonized with either a carbapenemase-producing Klebsiella pneumoniae or vanco -
mycin resistant Enterococcus faecium. The mice were subsequently treated with faecal 
micro biota from various NDFB donors. Consistent with clinical findings, variability in 
FMT-mediated decolonization of resistant bacteria was observed. An FMT donor 
enriched in the microbiota capable to eradicate both MDRO’s best, as determined by 
complete MDRO clearance in 80 % of treated animals  [199], was selected for a clinical 
MDRO eradication trial in kidney transplant patients (trial currently performed, in 
collaboration with NDFB). Modulation of the immune response by FMT can also 
be tested in a mouse model. The microbiota plays an important role in the develop -
ment, training and maintaining of the immune system  [231], and the microbiota seems 
involved in many diseases with an imbalance of pro- and anti-inflammatory 
responses  [232]. Regulatory T-cells are important for the maintenance of intestinal self-
tolerance and will likely be important for therapeutically manipulation of IBD  [233]. 
Again, in close collaboration with Vedanta Biosciences, mice sensitive for IBD 
were colonized with faeces of NDFB donors. The donors which could enhance the 
regula tory T-cells in the IBD mice the most were selected for an RCT with FMT for UC 




Option 3: Use of patient-donor microbiota correlation networks 
Another donor selection strategy can be deployed if the microbiota characteristics 
for a particular disease are not available from human epidemiological studies or 
animal experiments, but microbiome data of an individual patient is available. The 
existing microbiome data can be mined to find bacteria that consistently show 
a negative association with a pathogen or other undesired bacteria. An important 
assumption with donor selection based on these bacterial networks is that the bacteria 
that negatively correlate are competitors of the undesired bacterium, rather than that 
they are both consequence of the underlying disease. The preferred donor should have 
high abundances of these putative competitors  [234]. We studied the microbiota 
composition of patients with  C.  difficile infection and compared the data with 
asymptomatically  C.  difficile carriers and healthy controls. The aim was to find special 
groups of bacteria responsible for progression of a carrier to a diseased state. It was 
found that the presence of Eubacterium hallii and Fusicatenibacter may indicate 
resistance against  C.  difficile colonization and infection, while Veillonella may indicate 
susceptibility  [235]. A second example is the role of the microbiota in atopic disease. 
By mining microbiome data of healthy three months old babies staying either healthy 
of becoming atopic at the age of 1 year (e.g. asthma, atopic dermatitis, food allergy) 
Boutin and colleagues showed that this approach can also lead to a potential 
drug  [236]. A machine learning approach revealed a consortium of commensals of the 
infant gut as candidates for a live biotherapeutic product that could be tested in the 
future for its potential to prevent the onset or progression of a variety of atopic 
diseases  [236]. A nine-component bacterial community consisting of the following 
genera was proposed; Blautia, Coprococcus (Anaerostipes/Eubacterium_E), Dorea (Tyzze -
rella), Faecalibacterium, Lachnospira, Oscillospira (Intestinimonas/Flavinifractor), Para bacte -
roides, Roseburia and Ruminococcus, and follow-up studies are planned. Although 
promising, one has to realise with these microbiota association studies that the 
functional capacity of bacterial genera, species and even strains can be vastly disparate. 
The cultivation and functional testing in vitro and in vivo (mouse and human) will be 
critical for the actual development of a proposed biotherapeutic product  
Option 4: Use of donor faeces metabolomics data  
A fourth strategy involves measuring metabolomics. One could rationally select 
a donor based on molecules (butyrate (SCFA) or secondary bile acids) present in 
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donor faeces that serve as proxy for a ‘healthy’ metabolic output of the donor micro -
biota as ecosystem. In patients suffering of multiple recurrent  C.  difficile infections, the 
metabolomics of bile acids in the faeces clearly differs from healthy donors. In the 
faeces of rCDI patients, secondary bile acids were absent, whereas primary acids were 
abundant  [237]. FMT promptly normalized the faecal bile acid composition to the 
healthy donor situation (low primary, high secondary bile acids)  [95, 237]. Restoring 
a disturbance of the capacity of 7α-dehydroxylation of bile acids of part of the 
microbiota, is not only important in the course of (r)CDI. Many other diseases are 
influenced by a disturbed bile acid metabolism like liver diseases including cirrhosis, 
and could therefore be subject of targeted therapy with FMT of a selected optimal 
donor  [211, 238]. A complicating factor is the difficulty of the read-out of the metabolic 
activity, which is complicated by several individual and environmental factors that 
influence the absorbance or conversion of the metabolite of interest. For instance the 
level of bile acids rises after meal  [239]. To overcome this bias, the capacity of bile acid 
conversion of the faecal slurry can alternatively be measured. Ideally the mechanisms 
of action of the metabolites within complex ecosystems, like the human gut 
microbiota, must be further explored with a multi-omics approach. The reported 
integrated use of compositional (metagenomics) and functional (metabolomics and 
metaproteomics) approaches should preferably be validated with an in vitro model to 
assess the effects of human donor faecal microbiota transplantation to the bile acid 
pathway. This enables a greater understanding of how variation in the gut microbiota 
influences host bile acid signatures, their associated functions and their implications 
for health  [240]. 
Optimizing the patient for FMT to facilitate engraftment 
An important step in FMT is to optimize the patient’s microbiota to facilitate 
 engraftment of donor strains (Figure 3). This can be performed with bowel lavage to 
reduce the patient’s bacterial load, although its effect has never been compared to 
placebo  [241]. In addition, the undesired strains could be diminished by a (semi-) 
targeted antibiotic pre-treatment, for example with polymyxin/neomycin for eradi -
cation of Gram negative MRDO’s as described in Chapter 8. Although both in our 
case-report as well as in a RCT, this combination was unable to eradicate MDROs 




mycin pre-treatment results in a significant engraftment of donor strains as well as 
a decline in the number and diversity of antibiotic resistance genes  [165, 242]. This 
decline does not necessarily mean eradication of MDRO’s, and the reduction could 
reflect solely the normalisation of the overabundance of Gammaproteobacteria after 
FMT in rCDI patients irrespective of vancomycin. On the other hand, the decline in 
antibiotic resistance genes could also be the result of enhanced engraftment of donor 
strains capable to compete with the patients’ MDRO. Therefore, in contrast to targeting 
the pathogen with pre-treatment, a more revolutionary idea is to target the indigenous 
microbiota and create a niche for the donor strains to colonize and compete. 
Vancomycin is a broad spectrum antibiotic and oral administration results in non-
absorbable high intestinal concentrations causing a dramatic decrease of Firmicutes 
and to a lesser extent Bacteroidetes, the two most important phyla of the indigenous 
microbiota  [73]. Preliminary data on engraftment of live biotherapeutic products 
in healthy volunteers show that prolonged engraftment is only successful when volun-
teers are pre-treated with vancomycin (preliminary data of VE303, Vedanta). 
Additionally, the spore-based microbiome therapeutic SER-287 reported that pre-treat-
ment with vancomycin resulted in a significantly higher engraftment and clinical 
response in patients with mild-to-moderate ulcerative colitis  [243]. Clinical remission 
was achieved at 8 weeks in 0 %, 13.3 %, 17.7 % and 40 % of patients receiving 
placebo/placebo, placebo/SER-287 weekly, vancomycin/SER-287 weekly and van -
comycin/SER-287 daily respectively  [243]. The superiority of vancomycin as pre-
 treatment enhancing engraftment could however not be confirmed in mice that 
received donor mice faeces through oral gavage  [244]. Surprisingly pre-treatment with 
poly myxin B resulted in the highest rate of viable donor bacteria in the recipient 
mice  [244]. Of all tested antibiotics, vancomycin, metronidazole and cefotaxime 
resulted in impaired engraftment efficiency  [244]. Lastly, in a proof of principle study 
on the concept of antibiotic pre-treatment targeting the recipient microbiota, 
amoxicillin-metronidazole-fosfomycin in combination with FMT (n=27) alleviated the 
intestinal perturbed microbiota caused by a loss of Bacteroidetes in UC patients better 
than FMT alone (n=4)  [245]. The optimal pre-treatment for bacterial engraftment is 
currently unknown, and likely varies for the underlying disease and possibly even 
differs between the specific microbiota modulating therapies (e.g. FMT or LBP).  
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The relation between Blastocystis species and 
a healthy microbiota 
Blastocystis is a genus of a common unicellular obligate anaerobic intestinal para -
site in humans and animals that belongs to the stramenopiles, 1 of the 8 major 
phylogenetic groups of eukaryotes. It is a diverse genus comprising 17 characterized 
lineages: the so-called subtypes (ST1 – ST17), of which 9 have been reported to occur 
in the human gastrointestinal tract  [246, 247]. Blastocystis sp. carriage is very common 
but varies globally, from 0.5 % in Japan to 100 % in Senegal and 30–50 % in 
Europe  [18, 248-250]. An interesting finding in our NDFB patient cohort (Chapter 7) 
was that none of the rCDI patients carried Blastocystis species  [251]. Low Blastocystis sp. 
colonization rates in diseased patients were previously also reported in IBD 
patients  [18 -20]. IBD and rCDI patients have a very disturbed microbiota in common. It 
is unknown if the association between a disturbed microbiota and low Blastocystis sp. 
colonization results from the inability of Blastocystis to survive in a disturbed environ-
ment. Homeostasis of the microbiota is associated with buty rate-producing bacteria, 
resulting in oxygen consumption by the colonocytes (for more information, see section 
“Colonisation resistance against (multidrug resistant) Enterobacterales”, this 
thesis)  [141, 143]. The subsequent epithelial hypoxia helps to maintain a microbial 
community dominated by obligate anaerobic bacteria  [143], or oxygen sensitive 
eukaryotes like Blastocystis species  [144]. The result of antibiotic related depletion of 
butyrate-producing bacteria can be observed in some perturbed microbiotas, such as 
rCDI and IBD, where a shift occurs from obligate anaerobic bacteria belonging to the 
phyla Firmicutes and Bacteriodetes to the facultative (an)aerobes of the phylum 
Proteobacteria  [242, 252]. The presence of Blastocystis in half of the patients after transfer 
of healthy donor faeces (FMT), could reflect reestablishment of a healthy microbiota 
after FMT. The second theory encompasses a top-down control of the microbiota by 
Blastocystis, the parasite itself influences the composition of the microbiota 
by predation or ecosystem management and thereby creates a more diverse 
microbiota  [27]. Evidence of the predatory capacity of Blastocystis on bacteria is shown 
by the capability of bacterial engulfment  [253] and the low frequency of the ameboid 
form in axenic cultures. In this case, the transfer of Blastocystis sp. by FMT could 
enhance the microbial diversity of the patient more than non-Blastocystis containing 




In general, the concept is increasing that Blastocystis is a marker for a healthy 
microbiota  [18, 22-27]. We showed that FMT containing Blastocystis ST1 or ST3 did 
not result in an altered treatment efficiency or gastrointestinal symptomatology 
(Chapter 7). Therefore, Blastocystis ST1 and ST3 should be deleted as donor exclusion 
criterion, although screening and long-term follow-up of the patients is preferred. 
Additionally, FMT trials for rCDI and other indications should allow Blastocystis positive 
donors and test whether this leads to a higher efficiency to cure disease with FMT. 
Quality assurance of faecal suspensions 
With the emergence of FMT as new treatment approach, stool banks are needed to 
provide ready-to-use donor faecal suspensions that are produced in a standardized 
way  [254]. A donor faecal suspension is however not a standardized drug that is 
produced in a factory, but a highly diverse and donor-specific microbiota in its 
broadest sense, also known as substance of human origin (SoHo; blood, tissues, cells 
and organs)  [255]. This implies that faecal suspensions and subsequently stool banks 
require (inter)national guidance of quality and safety measures, comparable of other 
SoHo therapies  [255]. Significant advantages of centralized donor screening and 
production of donor faecal suspensions are the possibilities to provide quality assu -
rance, standardisation of manufacturing and appropriate monitoring of unexpected 
adverse events. The current FMT product manufacturing protocols are for a large part 
based on expert opinion  [256, 257], and optimized for treatment of  C.  difficile. The FDA 
recently published “Regulatory considerations for FMT products”, in which it is stated 
that the stability and viability testing should be considered for FMT products used for 
clinical trials  [258]. In Europe, the Guide to the quality and safety of Tissues and Cells 
for human application (Tissue Guide) of the European Council includes a chapter 
about FMT, that is currently revised and may serve as a reference for quality assurance 
of FMT in Europe.  
 
Viability of anaerobic bacteria during processing and manufacturing 
Faecal suspensions for FMT are most often produced in ambient air (aerobic 
preparation). A recent in vitro study applied Propidium Mono Azide (PMA) to measure 
the viability of bacteria after aerobic and anaerobic processing. PMA is a fluorescent 
dye which selectively enters cells with a compromised cell membrane. Upon exposure 
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to light, PMA covalently binds to DNA in these cells or naked DNA, thus leaving only 
viable cells available for PCR amplification  [259]. An optimization of this method to 
apply on stool samples has been developed  [260]. The study of Papanicolas and 
colleagues showed that aerobic processing decimated the yield of delicate obligate 
anaerobic bacteria like Faecalibacterium sp., Eubacterium rectale, E. halli, Subdoligranulum 
sp., Anaerostipes, Megamonas, Bifidobacterium and Roseburia up to 12-fold  [259, 261]. 
Other taxa were found to be more oxygen resistant such as Bacteroides, Parabacteroides, 
Barnsiellaceae or Rikenallaceae  [261]. In the case of rCDI, this aerobic degradation has 
little or no impact on clinical efficacy as studies using anaerobically produced FMT 
suspensions do not report a significant increase in rCDI cure rate (cure rate of 
80 %)  [262-264]. For other indications such as IBD or hepatic encephalopathy, where 
the therapeutic component is poorly understood, variation of the number of living 
anaerobic bacteria could theoretically have significant effect on the clinical outcome. 
In the ulcerative colitis RCT of Moayyedi and colleagues a super donor with high 
levels of butyrate-producing bacteria was found  [204]. These butyrate producing 
bacteria often belong to the Firmicutes, a phylum disproportionally affected by 
oxygenic stress  [261, 265]. Manufacturing faecal suspensions in ambient air resulted in 
a more than 2.5-fold reduction in relative abundance of butyrate-producing bacteria. 
Consequently this impacted the level of the gene encoding a terminal enzyme in the 
dominant pathway of butyrate biosynthesis (butyryl-CoA:acetate CoA-transferase 
gene), and subsequent post-fermentation of butyrate levels was reduced with 
approximately 50 %  [259]. In contrast to oxygen exposure, lag time (time between 
defecation and processing) and freeze-thaw steps didn’t seem to alter the living 
microbiota much, both in absolute amount as well as the composition  [259, 261, 266]. 
Altogether the loss of butyrate-producing, and obligate anaerobes combined with the 
relative overabundance of oxygen tolerant bacteria could potentially transform 
a healthy donor microbiota into faecal suspensions containing a microbiota profile 
more closely resembling those of the patients. 
 
Viability of anaerobic bacteria during storage 
Two RCTs and one meta-analysis showed non-inferiority and comparable cure rates 
for the treatment of rCDI with fresh or frozen faecal suspensions (stored at -80°C for 
up to 30 days)  [267-269]. Use of a frozen faecal suspension allows storage at -80°C for 




donor faecal suspension. This lowers the risk of transferring transmissible diseases by 
bypassing the window of detection phase of some transmissible infections (e.g. HIV, 
Hepatitis C). Having well-screened donor faecal suspensions in storage will allow 
a more rapid and safe transplantation when needed, bypassing the logistical 
difficulties of preparing a fresh FMT suspension. In addition, it allows extended screen-
ing and selection of preferred donors and specific faecal suspensions that are required 
for FMT for non-CDI indications. To prepare frozen suspensions, a cryoprotectant 
should be added prior to freezing. In general, the cryoprotectant glycerol is used in 
a final concentration of 10 to 15 %. Cryopreservation is a process of preservation of the 
biological and structural functions of tissues or cells when cooling to sub-zero 
temperatures  [270]. Viability of six representative groups of faecal bacteria after six 
months of storage at -80°C in normal saline with 10 % glycerol did not differ from 
baseline, whereas viability was reduced in suspensions stored with saline alone. 
Especially, the aerobes, total coliforms and lactobacilli were significantly reduced by 
>1 log in the faecal suspension stored without glycerol  [263]. In addition, the authors 
conclude that the protective effect of glycerol outweighs the presumed detrimental 
osmotic effect of glycerol on living cells. Long-term storage should be at -80°C or 
lower to prevent sample degradation. High cure rates have been reported with frozen 
FMT suspension stored up to two years -80°C  [16, 262, 263, 266, 271-275]. In fact, both the 
NDFB and OpenBiome concluded that storage duration did not impact the clinical 
effectiveness of FMT for rCDI patients (Chapter 6,  [276]). Whether a shelf-life of two 
years is also applicable for other diseases remains to be investigated, as in vitro studies 
suggest long-term storage does seem to impact some bacteria more than others. To 
test to what extent donor microbiota communities are affected by the manufacturing 
and storage procedures at the NDFB, a culturing pilot study was performed by the 
NDFB in close collaboration with Vedanta Biosciences. Donor faeces was collected 
and divided in two aliquots, one placed in an anaerobic chamber, the other processed 
aerobically and frozen within 30 minutes. Both aliquots were serial diluted and 
inoculated onto eight different selective and non-selective media. PCR and Sanger 
sequencing was performed on 1288 picked colonies. A general 10-fold loss in 
cultivability of anaerobic bacteria was found during processing in combination with 
storage at -80°C and subsequent thawing. Bacillus species, and Anaerostipes hadrus 
were identified  [277]. In a study that subjected fresh and frozen faecal microbiota 
suspensions to stress conditions that bacteria may undergo after transplantation in the 
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human gut with FMT, the results showed that the abundance of Bacteroidetes 
decreased with longer storage times  [278], in particular when stored beyond 15 months 
of storage at -80°C (with glycerol). In contrast, Firmicutes showed good resistance to 
a harsh DNA extraction protocol, including Proteinase K treatment (solubilizes solid 
human tissues, disrupts biofilms), DNAse treatment next to a chaotrophic agent 
(guanidine hydrochloride; disrupts human cells and also has affinity for Gram negative 
bacteria). More specifically, Operational Taxonomic Units (OTUs) of butyrate 
 produ cing bacterial species, showed relatively little changes of relative abundance 
when frozen samples were compared to fresh samples  [278]. The question remains if 
this pre-treatment of the faecal suspensions represents the in vivo conditions after 
transplantation. However, an in vivo mice experiment showed similar results. In this 
study, the viability was assessed using 16S rRNA analysis after PMA pre-treatment in 
fresh faeces compared to faeces stored at -20°C. The viability of frozen faeces was 
comparable with fresh faeces  [279], but after transplantation in mice, some bacterial 
taxa were attenuated in enteric colonization ability when stored frozen. Bacteroidetes, 
next to Actinobacteria and Deferribacteres showed less resilience or colonization 
ability after freezing at -20°C for more than 1 month  [279]. A second mice study used 
a complementing technique to test the viability of transplanted microbiota by labelling 
the gut microbiota in vivo of donor mice with a fluorescent marker. After FMT of the 
fluorescent donor microbiota, the recipient mice received a second fluorescent marker 
with another colour. The viable (metabolic active) portion of the donor microbiota 
incorporates both markers and can readily be distinguished from dead donor bacteria. 
16S rRNA analysis indicated that several bacterial genera were enriched, including 
Gammaproteobacteria, Clostridium XIVb and Butyricicoccus. Although FMT in this study 
is probably less efficient because the donor microbiota was administered by gavage 
and therefore did not bypass the acid stomach, the viability of donor Clostridium XIVb 
and Butyricicoccus strains is encouraging, since these are generally considered to be 
beneficial to the host  [138]. 
 
Proposed quality control for viability and stability of faecal suspension 
microbiota 
Some of the studies show a substantial donor variation in the viable component of 
faecal suspensions affected during manufacturing and storage  [138, 259, 278, 279]. This 




a different vulnerability of the microbiota to stressors as oxygen exposure or freezing. 
The composition and function of a healthy individual’s microbiota is in general stable, 
and resilient to most perturbations (low intra-donor variability)  [280]. However, minor 
changes in environmental factors such as diet, medicine use, season, travel or house-
hold contact can have large effects on the microbiota  [281-283]. The potential 
differences in intra- and inter-donor stability and viability during processing indicate 
the need for viability assays performed as quality control. Promising as relatively quick 
and less expensive screening tool for viability of the microbiota of a faecal suspension 
is a combination of staining (for instance a classical Live/Dead stain (based on 
 fluorescein diacetate (FDA) and propidium iodide (PI), which stain viable cells and 
dead cells, respectively) and flow cytometry. It has the potential of facilitating the 
analysis of complex ecosystems through visualizing the changes in the dynamics of 
bacterial communities  [284]. This can be combined with periodic deeper microbiota 
assessment with a subset of different methodologies to provide more detailed 
information. Analysing the microbiota of sequential faecal samples with a combination 
of culturomics, 16S analysis and flow cytometry showed that the various methods were 
additive to each other  [205]. In addition, culturomics showed the relevance of using 
sequential samples as many bacteria were found irregularly as the faecal microbiota 
may, to some extent, change daily  [205, 285]. In the end, investigating the functional 
microbiota, for instance by means of the pool of genes is the most important, as the 
functional traits of the microbiota should be maintained, and are not necessarily 
provided by the same organisms  [286]. Further research should focus on the best 
strategy for quality control of faecal suspensions for FMT treatment. Most likely this 
will involve multiple of the above-mentioned techniques once every 6 months to 1 year, 
in addition to a more frequent performed basic microbiology viability and stability 
check which encompasses culturing of several indicator anaerobes. Careful clinical 
follow-up is the ultimate quality control and should be organised by stool banks to 
establish the safety of their protocols. 
Future of stool banking 
Stool banks were initiated to implement safe and cost effective FMT. Gradually, 
stool banks became expertise centres with experts in the fields of microbiology, 
gastroenterology, infectious diseases, biobanking, data science, microbiome research 
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and pharmacy. This may result in multidisciplinary trials addressing the effects of 
microbiota modulating therapies in a wide range of disorders. Stool banks also enable 
fundamental research addressing both pathogenesis, functional microbiota networks, 
and mechanism of action to develop new treatment concepts.  
An interesting new application of the experience and expertise of stool banks is the 
banking of faeces for auto-transplantation. In case of an expected and undesired 
major change of the gut microbiota such as patients undergoing a stem cell trans-
plantation, a stool bank can facilitate with storage of pre-event faeces. A second inter-
esting application is the banking of faeces of patients that respond well to anti-cancer 
therapy. The NDFB will participate in an RCT phase Ib trial in metastatic melanoma 
patients refractory to immune checkpoint inhibitors (ICI) receiving either an FMT of an 
ICI responder or non-responder patient (prof. J Haanen, Oncology LUMC and AvL). 
The NDFB will in this case not provide faecal suspensions of healthy donors but 
collaborates with the knowledge on microbiota modulating therapies (e.g. patient-
donor selection and screening, manufacture of faecal suspensions, biobanking an 
preservation of the microbiota, selection and pre-treatment of patient, FMT treatment 
itself and follow-up of the patients. The rationale for this trial is that pre-clinical data 
indicates that the gut microbiota controls the immune response and subsequent 
response to ICI. The use of antibiotics within the first 3 months prior to initiation of ICI 
has been demonstrated to negatively influence the treatment response  [206, 287, 288]. 
Tumour bearing mice demonstrate that FMT of responder-patients can improve the 
anti-tumour immune response, and when combined with ICI can improve out -
come  [206, 207]. 
Banking faecal microbiota suspensions for FMT is a new research field and is 
constantly evolving and developing. Already in the beginning, FMT was recognised to 
have great potential to cure microbiota related diseases. The strength of this treatment 
is the transplantation of a complete ecosystem. Nevertheless, the weakness of this 
therapy also lies in transplanting a complete, but uncontrolled, unstandardized and 
not fully understood ecosystem. An undesired pathogen or disease trait could be co-
transplanted. To limit risks, standardisation of working processes of stool banks was 
established and standard operating procedures were formulated addressing; the 




donor faeces and storage and distribution of frozen faecal suspensions, together with 
selection, treatment and follow-up of patients both on institutional and national as 
international level (Chapter 5)  [241, 257]. Recommendations are regularly updated and 
adapted to new situations, such as the recent new advices to screen donors for the 
presence of enteropathogenic E. coli, MDROs and SARS-CoV-2  [289, 290]. The risk of 
infectious complications after FMT depends in part on appropriate donor screening. 
This may even be more important for severely immunocompromised patients, as 
suggested by the cases where transfer of MDRO by FMT in neutropenic patients 
resulted in sepsis and death  [291]. Following these cases and the subsequent FDA 
warning, the NDFB evaluated their screening protocol, with periodic screening every 
three months and targeted rescreening after foreign country visits. Although 25 % of 
active donors became MDRO positive at some point during their donation activities, 
the current NDFB screening protocol did not result in approval of MDRO-positive faecal 
suspensions for FMT treatment (K.E.W. Vendrik et al., Lancet Infectious diseases, in 
press). However, although the residual risk of transmission of MDROs appears accept-
able for most patients, this risk appears not acceptable for severely immunocompromised 
patients based on the above-mentioned cases. Therefore, the NDFB performs direct 
screening of suspensions used for immunocompromised patients  [292]. These studies are 
a step towards a more evidence-based way of donor screening, and stool banking. 
Setting up a national or even international registry both for donor and patient follow-up 
data would lift FMT as quality-assured treatment strategy to the next level. 
 
Future of microbiota modulating therapies 
In recent years FMT has been implemented worldwide as effective rescue 
therapy for patients with multiple recurrent CDI, with cure rates of approximately 
85 %  [83, 293-295]. Transplanting faecal microbiota of a healthy donor with the aim to 
restore a patient’s perturbed microbiota appears also promising for several other 
disorders, such as ulcerative colitis, hepatic encephalopathy and a subset of 
inflammatory bowel syndrome patients  [211, 296-299]. Furthermore, many of the 
previously discussed indications are interesting and merit further research. It is 
 illustrative that while writing this discussion, more new indications and appli -
cations pop-up as potential target for microbiota modulating therapy, such as FMT 
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for immune modulation of patients suffering of severe COVID-19  [300], or patients 
with systemic sclerosis  [301] and patients with alcohol use disorder  [302].  
Faecal suspensions for FMT contain a highly diverse microbial ecosystem. Because 
of the unstandardized nature of this treatment, and potential risk of transfer of 
unrecognized pathogens or disease traits, a more controlled and standardised treat-
ment is desired in the future. Most newly developed microbiota modulating therapies 
involve synthetic bacteria or bacterial communities (live biotherapeutic products). In 
the future well-regulated and characterized live biotherapeutic products are preferred 
over probiotics which are not regulated and can be sold without quality check as food 
additive. Most probiotic companies do not characterize the microorganisms or assess 
the presence of AMR and virulence genes. Recently the scientific community was 
startled by the finding that the probiotic E. coli Nissle 1917 contained colibactin 
encoded by a pks island  [303]. Colibactin is tumorigenic in murine models and more 
prevalent in patients with colorectal cancer compared to healthy controls  [304]. In 
the past, an unexpected increased mortality caused by the probiotic Ecologic 641 
(a mixture of Lactobacillus, Lactococcus and Bifidobacteriae) was reported in patients 
with acute pancreatitis participating in the PROPATRIA study  [305]. This was explained 
by the finding that the disrupted intestinal barrier of the patients with concomitant 
organ failure, in combination with the probiotic strains, resulted in increased bacterial 
translocation and enterocyte damage, with subsequent mortality in 16 % versus 6 % in 
the placebo group  [306]. This illustrates that selecting an unbalanced mix of several 
“beneficial” strains, without complete understanding of the function, effects and their 
interaction with and within the host is not without risks. In a landmark paper on treat-
ment and prevention of antibiotic induced perturbation of the microbiota, it was 
shown that a commercially available 11-species probiotic markedly delayed indigenous 
gut mucosal reconstitution after antibiotic exposure  [307]. Compared to spontaneous 
post-antibiotic recovery, the microbiome reconstitution (both in composition as well 
as in transcriptome) was not only delayed, but also remained incomplete by the end 
of the intervention period (day 28) or five months after probiotics cessation. An auto-
FMT induced rapid and near-complete recovery within eight days  [307].  
Many host-microbiota interactions pertaining with human health and disease 




by the gut microbiota or the host, or given as encapsulated therapy. By bypassing 
the transfer of live bacteria (e.g. in a bacterial mix or FMT), but instead provide meta -
bolites, some of the caveats of current microbiota modulating therapy can be  overcome, 
such as transfer of opportunistic pathogens or unwanted effects on unrelated 
conditions, or the individual variation in colonization resistance and engraftment of 
donor strains  [308]. Microbiota associated metabolites of interest are short- or long-chain 
fatty acids, bile acids, vitamins or polysaccharides. This therapy aims at impacting their 
downstream signalling pathways when relevant to pathogenesis of disease. Microbial 
molecules of therapeutic potential are not limited to secreted metabolites, but may also 
include cellular components, such as membrane proteins  [117] or even sterilised 
bacteria  [309, 310].  
During the establishment of the NDFB in 2015, it was believed that other microbiota 
modulating therapies (for example live biotherapeutic products) would have replaced 
FMT for rCDI within five to ten years. To date, not a single microbiota drug has 
shown significant and relevant treatment outcomes for rCDI  [101]. Rebuilding a well 
characterised synthetic microbiota community with the capability of resilience 
to  C.  difficile infection and relapse is much more difficult than previously thought. Once 
such strategies are of proven benefit in the future, this may result in effective and safe 
new drugs to cure and prevent rCDI and replace FMT as treatment approach. At 
present, transplanting a healthy faecal microbiota with the aim to restore a patient’s 
perturbed microbiota remains the standard therapy for patients with multiple recurrent 
CDI, and is promising and performed in research setting for many other diseases. For 
development of more sophisticated precision microbiota therapeutics, FMT will pave 
the way by providing mechanistic insights in the effects of the transplanted microbiota 
on a specific disease. In the future, preferably an arsenal of several precision 
microbiota therapeutics would stand to our disposal which should be administered on 
a tailored basis as a personalised microbiota modification treatment.
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Nederlandse samenvatting 
Antibiotica hebben de mensheid een ongekende slagkracht tegen bacteriële infecties 
geboden. Hierdoor veranderde het beloop van vele infectieziekten, en worden jaarlijks 
miljoenen levens gered. De opkomst van antibiotica is misschien wel één van de meest 
belangrijke ontwikkelingen geweest die onze huidige hoogwaardige geneeskunde 
mogelijk heeft gemaakt. Zonder antibiotica is een open-hart operatie of beenmergtrans-
plantatie bijvoorbeeld een stuk risicovoller, zo niet onmogelijk. De andere kant van 
de medaille is een verstoring en verarming van de menselijke bacteriële darm -
flora (darmmicrobiota), en het ontstaan van bacteriën met anti micro biële resistentie. 
Een verstoring in de microbiota resulteert in een verhoogde vatbaar heid voor een 
 darminfectie met Clostridioides difficle en mogelijk voor diverse Westerse, levensstijl-
geassocieerde ziekten zoals suikerziekte, kanker of inflammatoire darm ziekten 
(colitis ulcerosa). De Wereldgezondheidsorganisatie (WHO) verklaarde anti microbiële 
resistentie als één van de grootste uitdagingen voor de volksgezondheid van dit tijdperk, 
omdat het een goede behandeling van veelvoorkomende bacteriële infecties 
belemmerd. Naast multiresistente Neisseria gonorrhoea en Candida auris worden 
multiresistente Gram-negatieve bacteriën (carbapenem resistente Entero bacterales) 
en  C.  difficile door het Centers for Disease Control and Prevention (CDC) als meest 
urgente bedreigingen bestempeld. 
 C.  difficile en multiresistente Gram-negatieve bacteriën (BRMO: bijzonder resistente 
micro-organismen) gedijen goed in een samenleving waar breedspectrum antibiotica 
frequent gegeven wordt. Voor beide micro-organismen speelt dragerschap in het 
maag-darmkanaal een belangrijke rol in de ontstaanswijze van infectie, oftewel 
pathogenese. Een aanzienlijk deel van gezonde mensen (2-10 %) is asymptomatisch 
drager van  C.  difficile en/of een BRMO, maar bij slechts een beperkt gedeelte leidt dit 
tot ziekte. Bij gezonde asymptomatische dragers onderdrukt een complex samen -
spel van de darmmicrobiota, door competitie om voedsel en plaats, de uitgroei 
van  C.  difficile of BRMO. Dit mechanisme staat bekend als kolonisatie resistentie. Na 
antibioticagebruik kan de microbiota tijdelijk ernstig verstoord zijn, waardoor de 
kolonisatie resistentie afneemt en  C.  difficile kan uitgroeien tot grote hoeveelheden en 
toxines produceren die leiden tot een ontstekingsrespons met diarree en soms ernstige 
ontsteking van de darm (pseudomembraneuze colitis of zelfs toxisch megacolon). 
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Het doel van dit proefschrift is beter inzicht te verschaffen in de rol van de micro-
biota in verdediging tegen infecties met multiresistente Gram-negatieven en  C.  difficile. 
Het eerste deel beschrijft de epidemiologie (het vóórkomen), en de detectie van 
C.  difficile en BRMO dragerschap in verschillende populaties. Het tweede deel richt zich 
op de behandeling van dragerschap of infectie met deze micro-organismen, middels 
herstel van de verstoorde darmmicrobiota door transplantatie met gezonde 
donormicrobiota, oftewel fecale microbiota transplantatie (FMT). 
Deel I: Nieuwe inzichten in de epidemiologie van Clostridioides 
difficile en multiresistente Gram-negatieve bacteriën 
Lang werd gedacht dat infecties met  C.  difficile verworven werden in het ziekenhuis 
door (nosocomiale) overdracht via symptomatische patiënten. Recent verschenen er 
enkele publicaties waarin werd beschreven dat de overdracht van  C.  difficile naar de 
ziekenhuisomgeving, gezondheidsmedewerkers en andere patiënten ook wordt 
gefaciliteerd door patiënten die  C.  difficile asymptomatisch met zich mee dragen. 
Herkenning van deze asymptomatische dragers is daarom essentieel om de omvang 
van  C.  difficile verspreiding te bepalen en mogelijk te verminderen. De laboratorium -
technieken om asymptomatisch gekoloniseerde patiënten te herkennen, zijn onder-
zocht in hoofdstuk 2. In de feces van patiënten zonder klachten van diarree en 
afgenomen bij opname in één van drie grote ziekenhuizen in Nederland, werden drie 
verschillende diagnostische  C.  difficile testen vergeleken met de toxigene kweek als 
gouden standaard. De feces werd getest met een enzym-linked fluorescent assay 
(ELISA) gericht op glutamaat dehydrogenase (GDH) en twee moleculaire testen gericht 
op het toxine gen (de commerciële artus PCR gericht op toxine A en B, en een in-house 
PCR enkel gericht op toxine B). Uit deze studie bleek dat 5.1 % van de patiënten bij 
opname in het ziekenhuis een  C.  difficile bij zich droeg; 3.1 % was drager van een toxine 
producerende  C.  difficile. In deze laag endemische setting van  C.  difficile dragerschap 
kunnen alle drie de testen worden gebruikt als eerste screeningstest, gelet op de hoge 
negatief voorspellende waarde. Net als bij de diagnose van patiënten met een  C.  difficile 
infectie (CDI), is de positief voorspellende waarde bij lage prevalentie (weinig vóór-
komen) niet optimaal. Een discrepantieanalyse liet zien dat het merendeel van het 
relatief kleine aantal fout-positieve testen niet kon worden bevestigd na herhaling. Nu 
we weten dat  C.  difficile dragers goed gedetecteerd kunnen worden, rijst de vraag wat te 
EXPLORING THE ROLE OF THE MICROBIOTA IN DEFENCE AGAINST CLOSTRIDIOIDES DIFFICILE  
AND MULTIDRUG RESISTANT GRAM-NEGATIVES
256
doen met een positieve bevinding. Alhoewel dragers een bron voor verspreiding 
van  C.  difficile kunnen zijn, en in een Canadese studie het isoleren van dragers leidde tot 
een vermindering van in het ziekenhuis ontstane CDI, werd  dit voordeel in een 
Nederlandse studie (2016-2018) niet bevestigt. In Nederland worden  C.  difficile dragers 
niet actief opgespoord. Indien dragerschap wordt gevonden in patiënten met diarree 
door een andere oorzaak dan CDI zal de patiënt echter wel in isolatie worden gelegd.  
Ook voor BRMO’s speelt nosocomiale transmissie door asymptomatisch dragers 
een significante rol. Preventie van BRMO-transmissie binnen ziekenhuizen wordt 
nagestreefd door geselecteerde patiëntgroepen met een hoog risico op dragerschap te 
screenen en zo nodig te isoleren. Eind 2015 werd in China een nieuw soort colistine 
resistentie (mcr-1) bij Enterobacterales ontdekt in dier en mens. Colistine is een 
reserve-antibioticum dat ingezet kan worden ter behandeling van BRMO’s. Nieuw aan 
deze vorm van resistentie is dat het plasmide gemedieerd is. Dit betekent dat de 
overdracht van de resistentie tussen verschillende bacteriën veel gemakkelijker zal 
gaan. Momenteel zijn tien mcr-genen (mcr-1 tot mcr-10 ontdekt in verschillende 
Enterobacterales. Om het risico van introductie van mcr door asymptomatisch dragers 
in ons academisch ziekenhuis in kaart te brengen, werd in hoofdstuk 3 de prevalentie 
van dragerschap bepaald van patiënten die opgenomen werden in ons ziekenhuis. 
Twee van de 576 (0.35 %) patiënten werden positief getest op mcr-1. Mcr-2 werd niet 
gevonden. Ten tijde van het uitvoeren van deze studie waren epidemiologische 
gegevens over de prevalentie van dragerschap bij gezonde individuen niet beschikbaar, 
maar enkele recente onderzoeken van het RIVM bevestigden het lage percentage 
dragerschap (0.5 %) van mcr-1 positieve bacteriën bij gezonde mensen. De verspreiding 
van mcr vanuit de samenleving naar de ziekenhuisomgeving in Nederland is dus 
laag. In ons onderzoek werd een fenotypisch colistine gevoelige mcr-1 bevattende 
Escherichia coli gekweekt. De discrepantie tussen de fenotypische en moleculaire 
bepaling bleek te berusten op een defect mcr-1 gen (1329kb transposon in het mcr-1 
gen). Het resistentiegen kwam hierdoor niet tot uiting, waardoor de bacterie gevoelig 
bleef voor colistine. Dit onderstreept het belang van fenotypische bevestiging na 
moleculaire screening op een resistentietargetgen.  
Verpleeghuisbewoners hebben een aantal risicofactoren die kolonisatie en infectie 
met  C.  difficile en BRMO bevorderen. Veel bewoners komen veelvuldig in het zieken -
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huis of hebben andere zorgcontacten. Daarnaast is er vaak intensief contact tussen 
de medebewoners en zijn sommige bewoners fecaal incontinent, waardoor ver -
spreiding van BRMO’s wordt vergemakkelijkt. In hoofdstuk 4 wordt beschreven dat 
risicofactoren voor dragerschap en infectie frequent aanwezig zijn bij Nederlandse en 
Ierse  verpleeghuisbewoners, maar dit leidde niet tot een hoge prevalentie van BRMO’s; 
respectievelijk 9 % en 11 % van de Nederlandse en Ierse verpleeghuisbewoners 
was drager van een Extended Spectrum Beta Lactamase (ESBL) producerende E. coli. 
Geen van de patiënten had een carbapenemase producerende Enterobacterales, 
vancomycine resistente enterokok of  C.  difficile in de ontlasting. Met behulp van de 
DNA-typeringstechniek ‘core-genome multi locus sequence typing’ (cgMLST) werd 
kleinschalige verspreiding van BRMO’s tussen verpleeghuisbewoners van eenzelfde 
afdeling binnen het Nederlandse verpleeghuis, en tussen verschillende afdelingen in 
het Ierse verpleeghuis aangetoond. Dit verschil in transmissie van BRMO’s tussen 
beide landen zou een weerspiegeling kunnen zijn van verschillen in de werkwijze en 
de infrastructuur van de onderzochte verpleeghuizen in Ierland en Nederland, zoals 
bijvoorbeeld meerpersoonskamers en een andere invulling van de activiteiten in 
gemeenschappelijke ruimtes. 
De hoofstukken van deel I van dit proefschrift beschrijven dat asymptomatische 
kolonisatie van BRMO’s en  C.  difficile een reservoir kan vormen voor nosocomiale 
transmissie. De prevalentie ervan is in Nederland echter (nog) laag, en de huidige 
praktijk van detectie en preventie in Nederland lijkt dus effectief. 
Deel II: De oprichting van een Nederlandse Donor Feces Bank om 
microbiota transplantatie te faciliteren  
Het doel van feces microbiota transplantatie (FMT) als behandeling van terug -
kerende Clostridioides difficile infectie (rCDI) is het verbeteren van de microbiota 
samenstelling middels het inbrengen van gezonde donormicrobiota, waardoor de 
kolonisatie resistentie tegen  C.  difficile hersteld wordt. Hierdoor kan  C.  difficile niet 
opnieuw uitgroeien, toxinen produceren en de symptomen van een infectie veroor -
zaken. FMT is inmiddels in nationale en internationale richtlijnen als gevestigde 
behandeling voor mensen met rCDI opgenomen, en wordt ook veelvuldig onderzocht 
als behandeloptie voor andere ziekten. Fecesbanken die zich kunnen richten op zowel 
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de standaardisatie, veiligheid, kwaliteitswaarborging, beperking van kosten én doel -
matigheid zijn hierdoor in toenemende mate van belang. Fecesbanken leveren kant-
en-klare fecessuspensies voor behandeling van rCDI patiënten in het eigen, lokale 
ziekenhuis. Hoofdstuk 5, ‘How to run a stool bank’ beschrijft de oprichting van de 
Nederlandse Donor Feces Bank (NDFB). Het geeft inzicht in de zeer strenge screening 
en selectieprocedure van donoren en de bereiding, opslag en toediening van fecessus-
pensies. De eerste patiëntengroep die met door NDFB uitgegeven fecessuspensies 
werd behandeld, is gevolgd om de kwaliteit van onze behandeling te evalueren. In 
vergelijking met andere fecesbanken of FMT-expert centra heeft de NDFB een relatief 
hoog rCDI genezingspercentage van bijna 90 % na twee maanden en van meer dan 
70 % na een gemiddelde follow-up van 42 weken (hoofdstuk 6). Dit hoge succes-
percentage wordt waarschijnlijk mede verklaard door de inspanningen van ons multi-
disciplinaire FMT-expertpanel. Dit expertpanel bestaat uit een arts-microbioloog, 
maag-darm-leverarts en internist gespecialiseerd in infectieziekten, en bespreekt de 
indicatie van de patiënt aangemeld voor FMT, en adviseert tijdens de behandeling en 
follow-up van de patiënten. Deze strategie resulteert in een effectief, veilig en doel -
matig gebruik van FMT voor de behandeling van rCDI.  
Bij donorscreening zijn nog een aantal niet opgeloste microbiologische vraag-
stukken. Gezonde donoren die bijvoorbeeld drager zijn van de parasiet Blastocystis 
worden uitgesloten van FMT-donorschap. Dit resulteert in exclusie van een aanzienlijk 
deel van gezonde donoren (30-50 %). Het is de vraag of dit gerechtvaardigd is omdat 
het ziekmakend vermogen (entero-pathogeniciteit) van Blastocystis niet overtuigend 
aangetoond is. De in het verleden veronderstelde entero-pathogeniciteit is gebaseerd 
op anekdotische casusbeschrijvingen en retrospectieve studies. Interessant is dat 
recente literatuur juist een lage prevalentie van intestinaal Blastocystis dragerschap laat 
zien bij diverse aandoeningen geassocieerd met een verminderde diversiteit van de 
darmmicrobiota, zoals inflammatoire (ontsteking) darmziekten of leverziekten 
(hepatische encefalopathie). Daarnaast lijkt de aanwezigheid van Blastocystis juist 
geassocieerd te zijn met het hebben van een diverse en gezonde darmmicrobiota. De 
donoren van de NDFB worden gescreend op Blastocystis middels microscopie en niet 
met de meer gevoelige PCR (polymerase chain reaction) techniek. Doordat twee 
donoren en hun fecessuspensies gebruikt voor fecestransplantatie achteraf Blastocystis 
PCR positief bleken te zijn, kon een eventuele overdracht van Blastocystis van donor 
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naar patiënt onderzoeken. Door een combinatie van DNA-technieken op ontlast-
ingsmonsters afgenomen van patiënten vóór en na de FMT en hun respectievelijke 
donor, beschrijven wij de eerste mens op mens transmissie van Blastocystis in hoofd-
stuk 7. De helft van de patiënten die Blastocystis positieve donorontlasting ontvangt, 
draagt deze drie weken nadien nog steeds. Deze transmissie had geen invloed op het 
succespercentage van FMT voor de behandeling van rCDI. Belangrijker bovendien is 
dat de overdracht niet resulteerde in gastro-intestinale symptomatologie bij de 
patiënten. Deze studie is een belangrijke stap op weg naar het loslaten van de uitsluit-
ing van Blastocystis bevattende donorfeces. 
FMT is in verschillende onderzoeken gebuikt om BRMO uit het maag-darmkanaal 
te verwijderen, maar de resultaten zijn nog niet heel bemoedigend. In hoofdstuk 8 
wordt het potentieel van FMT voor de eradicatie van BRMO-dragerschap onderzocht 
bij een patiënt die leed aan recidiverende urineweginfectie met een BRMO 
(carbapenemase producerende Pseudomonas aeruginosa). De patiënt kwam hierdoor 
niet in aanmerking voor een nier-pancreastransplantatie. Een FMT aansluitend op een 
antibiotica voorbehandeling voorkwam een recidief van de BRMO Pseudomonas 
urineweginfectie en werd de Pseudomonas niet meer aangetroffen in het maag-darm 
kanaal van de patiënt. Hoewel de behandeling een klinisch succes was, werd een 
gedeeltelijk microbiologisch falen waargenomen aangezien darmkolonisatie met een 
ESBL-producerende E. coli (ook een BRMO) wel persisteerde. In tegenstelling tot de 
zeer verstoorde darmmicrobiota bij rCDI patiënten, werd middels microbiota analyse 
(16S rRNA analyse) bij deze patiënt een vrijwel intacte diversiteit en samenstelling van 
de darmmicrobiota aangetroffen vóór transplantatie. Dit suggereert dat een intacte 
microbiota van de patiënt mogelijk minder vatbaar is voor vervanging van ongewenste 
bacteriën, en vereist eradicatie van de BRMO E. coli andere, complexere microbiota 
interventies. 
Met het toenemende aantal studies die wijzen op de mogelijk gunstige effecten 
van FMT bij patiënten met verschillende aandoeningen binnen en buiten het maag-
darm kanaal, wordt in de nabije toekomst een toenemende vraag naar zorgvuldig 
gescreende en goed gekarakteriseerde fecessuspensie verwacht. In het gehele proces 
van onderzoek, implementatie en vervolgens langdurige monitoren van de uit ein -
delijke uitkomsten zullen fecesbanken kunnen faciliteren. De ervaringen van dit proef -
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schrift kunnen bijdragen aan het opzetten, standaardiseren en verder ontwikkelen van 
 fecesbanken en onderzoeksinstituten van microbiota modificerende therapieën. 
Toekomst microbiota modificerende therapieën 
Bij de oprichting van de NDFB in 2015 werd algemeen aangenomen dat andere 
microbiota-modulerende therapieën (bijvoorbeeld next generation probiotics) FMT 
voor rCDI binnen vijf tot tien jaar zouden vervangen. Tot op heden is echter geen enkel 
microbiota-modulerend medicijn even effectief gebleken als FMT voor de behandeling 
van rCDI. Het samenstellen van een goed gekarakteriseerde bacteriële microbiota 
gemeenschap met het vermogen om de kolonisatie resistentie tegen  C.  difficile infectie 
te herstellen bij een patiënt, is veel moeilijker dan eerder werd aangenomen. Het lijkt 
erop dat de kracht van FMT bestaat uit de transplantatie van een compleet en werkend 
ecosysteem. Tegelijkertijd schuilt hierin ook het gevaar, namelijk het transplanteren van 
een compleet, maar ongecontroleerd, ongestandaardiseerd en niet volledig begrepen 
ecosysteem. Dit brengt theoretisch het risico mee op overdracht van een andere 
microbiota geassocieerde aandoening. Gelukkig blijken deze risico’s tot nu toe 
verwaarloosbaar, al kunnen de langetermijngevolgen nog niet compleet worden over-
zien. Op dit moment blijft FMT als ruwe diamant de gouden standaard. Voor de 
ontwikkeling van meer geavanceerde precisie-microbiota therapieën, zal FMT de weg 
plaveien door mechanistische inzichten te verschaffen in de effecten van de getrans-
planteerde donor microbiota op de specifieke ziekte. In de toekomst staat bij voorkeur 
een arsenaal van verschillende microbiota-precisie therapieën tot onze beschikking 
voor diverse ziekten, welke afhankelijk van de specifieke verstoring van de microbiota 
op maat kunnen worden toegediend als gepersonaliseerde behandeling. 
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